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ABSTRACT 
 
I. A1,3-Strain Enabled Retention of Chirality During Bis-Cyclization of β-Ketoamides: 
Asymmetric Synthesis and Bioactivity of Salinosporamide A and Derivatives  
II.  Optimization of an Organic Syntheses: Asymmetric Nucleophile-Catalyzed Aldol-
Lactonization of Aldehyde Acids. 
 (December 2010) 
Henry Nguyen, B. A.; M. S., Texas Woman’s University  
Chair of Advisory Committee: Dr. Daniel Romo 
 
The potential of human 20S proteasome inhibitors continues to be of interest for 
anticancer chemotherapy and the recent FDA approval of bortezomib (Velcade) 
validates the proteasome as a target for cancer chemotherapy.  Salinosporamide A, a 
marine unique bicycle [3.2.0] β-lactone-containing natural product, is not only a potent 
nanomolar inhibitor of the human proteasome but also active against bortezomib-
resistant multiple myeloma cells.  The racemic and asymmetric syntheses of 
salinosporamide A and derivatives were targeted.   
In this dissertation, we successfully accomplished the shortest route to date with 
only a 9-step total synthesis of (–)-salinosporamide A. The conciseness of this strategy 
arises from the key bis-cyclization of a β-keto tertiary amide, amenable to gram scale, 
constructs both the γ-lactam and the fused-β-lactone in one operation with high 
enantiopurity, which was enabled by A1,3-strain.  Several derivatives were synthesized 
 iv
and their inhibition activity toward chymotripsin-like, caspase-like, and trypsin-like of 
the human 20S proteasome was evaluated. 
This dissertation also included a successfully optimized Organic Syntheses 
procedure for asymmetric synthesis of (1S,5R)-6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-
[1,3]dioxolan]-7-one via the nucleophile-catalyzed aldol-lactonization. 
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CHAPTER I 
INTRODUCTION AND THE SYNTHESES OF A NOVEL PROTEASOME 
INHIBITOR SALINOSPORAMIDE A 
 
1.1. Introduction 
Inhibitors of the human 20S proteasome are of continued intense interest due to 
their potential as anticancer therapeutics and the recent FDA approval of bortezomib 
(Velcade) validates the proteasome as a target for cancer chemotherapy.1 
Salinosporamides A/B (1.1a-b), are unique bicyclo [3.2.0] β-lactone-containing natural 
products isolated by Fenical and coworkers2 from the marine actinomycete, Salinispora 
tropica. Salinosporamide A (salino A) is not only a potent nanomolar inhibitor of human 
proteasome, but also active against bortezomib-resistant multiple myeloma cells.3  
Salinosporamide A, which bears close structural similarities to the terrestrial 
metabolites, lactacystin-β-lactone (omuralide, 1.2) derived from the prodrug lactacystin 
(1.3),4  (Figure 1.1) is currently in Phase I human clinical studies for multiple myeloma 
having shown potential in mouse models toward several cancers when administered 
intravenously despite the potentially labile β-lactone.5  Salinosporamide A (1.1a), 
besides superior bioactivity to its congener omuralide (1.2) (35 times more potent IC50 
value)2 , its challenging structure comprised of five contiguous stereogenic centers has 
been targets for total6 and formal7 syntheses, structure activity relationship studies,8  
____________ 
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biosynthetic engineering,9 and crystallographic studies with the 20S proteasome.10 In 
this dissertation, we disclose our bioinspired racemic, asymmetric syntheses of 
salinosporamide A and derivatives.  Furthermore, the bioactivity of these derivatives was 
assayed against the chymotripsin-like, caspase-like, and trypsin-like activities of the 
human proteasome. The aim of this review as described in Chapter I is to provide an 
overview of these syntheses and to illustrate their potential applications in drug 
discovery.  This review will be restricted only to total syntheses of salinosporamide A. 
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Figure 1.1. Structures of Naturally Occuring Bicyclic-β-Lactone Proteasome Inhibitors 
 
1.2. Enantioselective Synthesis of (–)-Salinosporamide A (1.1a) 
   1.2.1. Corey’s Enantioselective Synthesis 
Only one year after its structure was published, Corey and co-workers reported 
the first enantioselective synthesis of salinosporamide A.6a (S)-Threonine methyl ester 
was N-acylated with 4-methoxybenzoyl chloride, followed by p-TsOH catalyzed 
cyclization to the corresponding oxazoline, which  allowed for diastereoselective 
alkylation with chloromethyl benzyl ether to to afford oxazoline 1.4.  Reduction of 1.4 
with NaBH3CN/AcOH afforded threonine derivative 1.5.  Transient TMS silylation of 
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1.5 was followed by acylation with acrolyl chloride and acidic work-up to give β-
hydroxy amide 1.6.  Subsequent Dess-Martin periodinane oxidation of the alcohol 1.6 
gave β-keto amide 1.7, which underwent an intramolecular Baylis-Hillman reaction, and 
subsequent cyclization using quinuclidine as the nucleophile led to a γ-lactam (dr 9:1) 
and silylation provided ether 1.8.  Tributyltin hydride mediated radical cyclization 
delivered a bicyclic compound followed by hydrogenolysis of benzylether, and oxidation 
gave aldehyde 1.9.  The remaining two stereogenic centers were established by 
diastereoselective addition of the organozinc reagent.  Cyclohexenyl zinc chloride (±)-
1.10 was reacted with aldehyde 1.9 to furnish the desired alcohol 1.11 with high 
stereoselectivity (dr 20:1).    Tamao-Fleming oxidation of the silylether 1.11 followed by 
oxidative PMB deprotection to give triol 1.12.  Finally, salinosporamide A 1.1a was 
obtained by saponification, lactone formation with BOPCl and chlorination in 13.7% 
overall yield and a longest linear sequence of 17 steps (Scheme 1.1). 
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Scheme 1.1. Corey’s Synthesis of (–)-1.1a from L-Threonine Methyl Ester 
 
 
  1.2.2. Danishefsky’s Enantioselective Synthesis of (–)-1.1a  
 Danishefsky’s Synthesis of (–)-1.1a6c commenced from strong facial bias of the 
pyroglutamate derivative 1.13 which directed the attack of vinyl cuprate from the α-face 
and subsequent diastereoselevtive alkylation at the C2 from its β-face to give lactam 
1.14 (dr 14:1).  Ozonolysis of the olefin and subsequent reduction with NaBH4 gave the 
corresponding primary alcohol which was then advanced to the carbonate ester, followed 
by N,O-acetal cleavage to afford 1.15.    Hydroxymethyl lactam 1.15 was converted to 
the imidate ester 1.16 following Jones oxidation, esterification, and treatment with 
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Meerwein’s reagent (Et3OBF4).  Treatment of this masked lactam 1.16 with LiHMDS 
led to exclusive enolate formation at the C4, which underwent intramolecular acylation 
with ethyl carbonate to delivered γ-lactone. Restoration of the lactam moiety under 
acidic conditions, followed by PMB protection and subsequent removal of the benzyl 
protecting group by hydrogenolysis afforded γ-lactone 1.17.   Nucleophilic γ-lactone 
ring opening with phenyl selenium anion gave a carboxylic acid which was benzylated 
to deliver diester 1.18. Subsequent selenide oxidation, elimination and Dess-Martin 
oxidation sequence gave aldehyde 1.19. It was set for a key acetal-mediated cationic 
cyclization.  Treament of 1.19 with phenylselenyl bromide and AgBF4 in the presence of 
benzyl alcolhol gave 1.20 with complete stereocontrol at C3.  After the benzyl ester was 
converted to aldehyde 1.21, it was then treated with cyclohexenyl zinc employing Corey 
protocol. The reaction proceeded with excellent diastereocontrol to afford amide 1.22 (dr 
20:1).  Oxidative cleavage of the PMB group and reductive debenzylation gave triol 
1.23.  Acid promoted cleavage of the t-butyl ester, followed by lactonization and 
chlorination to provide salinosporamide A 1.1a (Scheme 1.2).  
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Scheme 1.2. Danishefsky’s Synthesis of (–)-1.1a from Pyroglutamate Derivative 
 
      
  1.2.3. Nereus Enantioselective Synthesis of (–)-1.1a 
Nereus Pharmaceutials synthesis of (–)-1.1a6f started with an amide coupling 
between carboxylic acid 1.24 and oxazolidine 1.25.  The ketone functionality was then 
unveiled by the use of cerium trichloride to give β-keto ester 1.26.  The next step in their 
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synthesis was cyclization on to the ketone to give bicycle 1.27.  An osmium catalyzed 
oxidative cleavage sequence was then followed by conversion of the hemiacetal to the 
benzyl acetal 1.28.  Then a lithium borohydride reduction of the ester to the alcohol was 
followed by Ley oxidation to give aldehyde 1.29.  Attachment of the cyclohexenyl 
moiety was accomplished by an allylborylation with 1.10a to give alcohol 1.30.  The 
aldehyde was then unmasked with the use of acid and reduced to the primary alcohol 
which was then capped as its benzoyl ester 1.31.  The hemiaminal was then hydrolyzed 
with the use of 1,3-propanedithiol and acid.  The secondary hydroxyl was protected with 
TMS to give silyl ether 1.32.  The primary alcohol was then converted to the 
corresponding carboxylic acid via a two step protocol.  First, it was oxidized to the 
aldehyde by Dess-Martin periodinane, followed by Pinnick oxidation to carboxylic acid 
1.33.  The completion of the β-lactone was accomplished by first removal of the benzoyl 
group under basic conditions and then lactonization by using BOPCl yielding the desired 
β-lactone 1.34.  With the primary hydroxyl already deprotected, conversion to the alkyl 
chloride was the next step giving alcohol 1.35.  The stereochemistry of the side chain 
alcohol was then corrected by a two step process.  First, oxidation of the alcohol to the 
ketone with the Dess-Martin reagent gave ketone 1.36.  The ketone was then 
enzymatically reduced to give salino A (1.1a) (Scheme 1.3).   
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Scheme 1.3. Nereus Synthesis of (–)-1.1a from (R)-Serine 
 
 
 
 
 
 9
   1.2.4. Hatakeyama’s Enantioselective Synthesis of (–)-1.1a 
Hatakeyama’s synthesis of (–)-1.1a6h began with propargyl alcohol 1.37 by a 
palladium mediated addition to an acetal dehyde derivative to give ether 1.38.  The PMB 
protection group was removed with DDQ followed by selective acylation and fluoride 
mediated removal of the silyl group yielded diol 1.39.  Oxidative cleavage of the diol to 
the carboxylic acid and coupling with dimethyl 2-(4-methoxybenzylamino) malonate by 
way of the acid chloride gave amide 1.40.  With amide 1.40 in hand they were set to 
carry out their key reaction, next an indium catalyzed cyclization gave lactam 1.41.  An 
enzyme mediated selective hydrolysis of the acetate yielded the corresponding primary 
alcohol, which was then oxidized to aldhyde 1.42.  Next, cyclization of the aldehyde 
onto the alkene was accomplished by the action of phenyl selenium bromide in the 
presense of benzyl alcohol to capture the intermediate oxocarbenium ion to give acetal 
1.43.  The selenium was removed via radical reduction with n-tribuyl tin hydride to give 
diester 1.44.  Selective reduction of one of the ester moieties followed by oxidation with 
Dess-Martin periodinane gave aldehyde 1.45.  Coupling of the cyclohexenyl moiety was 
accomplished using Corey’s protocol to give alcohol 1.46.  The PMB group was then 
removed by CAN to give free lactam 1.47.  Next the benzyl group was removed using 
Birch conditions and the resulting lactol was reduced to triol 1.48 by sodium 
borohydride.  The completion of the synthesis was achieved by conversion of the ester to 
the acid and lactonization utilizing BOPCl and after conversion of the alcohol to chloride 
yielded salinosporamide A (Scheme 1.4).   
 
 10
Scheme 1.4. Hatakeyama’s Synthesis of (–)-1.1a  
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  1.2.5. Omura’s Enantioselective Synthesis of (–)-1.1a 
Omura’s synthesis of (–)-1.1a6i began with aldehyde 1.49 which underwent a 
Wittig reaction and subsequent deprotection to give diol 1.50.  Diol 1.50 was then 
converted to enantiomerically pure acetate by a lipase catalyzed acylation followed by 
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protection of the remaining hydroxyl group as its TBDPS ether to give acetate 1.51.  
This was then followed by hydroylysis of the acetate and protection of the hydroxyl as a 
MEM ether 1.52.  Deprotection of the silyl ether and transcarbamoylation and PMB 
protection of the amine gave carbamate 1.53.  The pendent alkene of carbamate 1.53 was 
then dihydroxylated utilizing osmium tetraoxide, followed by cleavage of the diol under 
the action of sodium periodate to give aldehyde 1.54.  The next step was the installation 
of the cyclohexenyl side chain, this was accomplished by an aldol reaction between 
cyclohexanone and aldehyde 1.54 using LDA as base. The aldol product was then 
converted in situ to its corresponding benzoyl ester 1.55 (Scheme 1.5).   
 
Scheme 1.5. Synthesis of Carbamate 1.55 
 
   
The next steps provided the necessary unsaturation in the cyclohexenyl side 
chain.  First reduction of the ketone to its corresponding alcohol and hydrolysis of the 
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benzoyl ester gave diol 1.56.  The alkene was then installed by first conversion to the 
sulfinate and then to the cyclic sulfate 1.57 by oxidation with ruthenium trichloride and 
sodium periodate.  The sulfate 1.57 was then eliminated under basic conditions which 
gave alcohol 1.58 after hydrolysis of the sulfate.  A second transcarbamoylation was 
then performed followed by Swern oxidation of the primary alcohol gave aldehyde 1.59.  
Methyl Grignard was then added to this aldehyde and the resulting alcohol was oxidized 
to the ketone followed by oxidative deprotection of the amine to give ketone 1.60.  
Acylation of the nitrogen with chloroacetylchloride followed by intramolecular aldol 
reaction gave bicycle 1.61.  This was followed by an intermolecular Reformatsky 
reaction with benzyloxy-acetaldehyde under the action of samarium diiodide which gave 
alcohol 1.62.  Lactam 1.63 was then formed by a two step elimination of the alcohol 
followed by 1,4-reduction with lithium triethylborohydride.  An additional nine steps 
yielded salinosporamide A (1.1a) (Scheme 1.6).   
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Scheme 1.6. Execution of Salinosporamide A (1.1a) Synthesis 
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chloroacetyl chloride
(63%)
N O
O
O
Cl
Me OH
H
OMEM
SmI2, LiCl
benzyloxyacetaldehyde
THF
(83%)
N O
O
O
Me OH
H
OMEM
BnO
HO
NH
O
BnO
Me OH OMEM
OH
H
9 steps
(17%)
1) NaH, THF/EtOH
2) (COCl)2, DMSO,
Et3N, CH2Cl2
(92%, 2 steps)
1) MeMgBr, THF
2) Dess-Martin, CH2Cl2
3) CAN, MeCN/H2O
(92%, 3 steps)
1) MsCl, Et3N
Me3N HCl, PhMe
2) NaOH, MeOH/H2O
3) LiEt3BH, THF
(62%)
(dr = 4.2:1)
1.1a
1.55 1.56
1.57
1.58
1.59
1.60 1.61 1.62
1.63  
    
  1.2.6. Romo’s Enantioselective Synthesis of (–)-1.1a 
In our early optimization studies, we determined that the diastereoselectivity was 
highly dependent on whether (S) or (R)-serine derived ketoacids were employed leading 
to different diastereoselectives, 1:2 vs 8:1 respectively.  The synthesis of (–)-1.1a6j 
(Scheme 1.7) began with reductive amination of commercially available (R)-O-benzyl 
serine 1.64 (99% ee) with p-anisaldehyde and subsequent esterification provided allyl 
ester (1.65, 98% ee).  Acylation of serine derivative 1.65 with unsymmetrical ketene 
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dimer (±)-1.66 under microwave conditions gave diastereomeric β-ketoamides 1.67/1.68 
(dr 1:1). At this stage of the synthesis, only the desired β-ketoamide (2R,4R)-1.67 with 
high diastereomeric purity was carried out to the next step since the absolute 
stereochemistry at the C2 will retain in the subsequent steps.  Separation of the 
diastereomers by MPLC provided the required (2R,4R)-1.67 ketoamide (dr 30:1, 98% ee, 
46%). Under acidic conditions, the undesired diastereomer (2S,4R)- 1.68  could be 
transformed to a 1:1 mixture of diastereomers via epimerization of the C2 but not the C4 
stereocenter  thus achieving an effective resolution of ketene dimer (±)-1.66 and greater 
material throughput. Pd(0)-mediated allyl deprotection of ester (2R,4R)-1.67 was also 
required to minimize epimerization of the C2 stereocenter and ultimately delivered keto 
acid 1.69 with negligible erosion of the diastereomeric purity. Treatment of keto acid 
1.69 with acid activating agent mesyl chloride, 4-pyrrolidino pyridine and toluene 
constructed the γ-lactam and β-lactone 1.70/1.71 in one step with minimum loss in 
optical purity (92% ee) and moderate diastereoselectivity 7:1 favoring relative 
stereochemistry found in natural product. Importantly, this transformation could be 
performed on gram scale with comparable diastereoselectivity and retention of 
enantiopurity (52% over 2 steps, dr 5:1, 90% ee). Completion of the salino A synthesis 
entailed benzyl deprotection through hydrogenolysis to provide alcohol 1.72 which  
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could be separated at this stage from the minor diastereomer produced during the bis-
cyclization process. Modified Moffatt oxidation and addition of the zinc reagent 1.10 
derived from the reaction of n-butyllithium with cyclohexenyl tributyltin and ZnCl2, 
following the procedure of Corey gave a mixture of C5, C6-diastereomeric alcohols (dr 
11:3:1:1) in 62% yield (2 steps, Procedure A ‘Proc. A’) and the desired diastereomer 
1.73 was the major adduct. Alternately, zinc reagent 1.74 could be prepared directly 
from commercially available 3-bromocyclohexene and activated zinc by the method of 
Knochel.  Treatment of this zincate 1.74 with the aldehyde intermediate simplified 
product purification since tin by-products were avoided (Proc. B). Most importantly, this 
protocol gave only two diasteomers (dr 4:1), improved the yield to 74% (2 steps). This 
procedure enabled isolation of a novel salino A diastereomer 1a’ (C5, C6-bis-epi-salino 
A) whose relative stereochemistry was verified by X-ray analysis. Finally, deprotection 
of PMB-protected lactam 1.73 led to salino A (1.1a). 
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Scheme 1.7. Romo’s Synthesis of (–)-1.1a from (R)-O-Benzyl Serine 
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1.67/1.68: R = allyl
(dr 1:1, 80%)MPLC
sepn.
(dr 20:1 1:1, 98%)
p-TsOH, EtOAc/MeOH (4:1), 45 oC
(2R, 4R)-1.67
CO2allyl
NHPMB
BnO
(+)-1.65 (98% ee)
1) p-anisaldehyde,
Et3N, MeOH; NaBH4, 0 oC
2) allyl alcohol, p-TsOH,100 ºC
(2 steps, 79%)
CO2H
NH2
BnO
(R)-OBn serine (1.64)
(99% ee)
ClCH2CH2Cl, pyridone
W, 50 oC ( 90%)
(±)-1.66
2
4
2
4
O
O
(CH2)2Cl
1.70 (92%ee)
N
O
H Me
O
O OBn
PMB
+
Cl
4-PPy, PhMe
5 10 oC
MsCl (1.5 equiv)
1.73/1.75: R = PMB
1.1a/1.76: R = H
1.72
N
O
H Me
O
O OH
PMB
N
O
H Me
O
O
OH
Cl
Cl
R
H2, Pd/C
THF, 23 °C
(75%)
CAN
MeOH/H2O
-10 oC (43%)
2) zincate, THF
1) EDCI, Cl2CHCO2H,
DMSO/PhMe, 23 oC
Proc.A: RZnCl (±)-1.10
( 62%, 2 steps, dr 11:3:1:1)
Proc.B: RZnBr (±)-1.74
74%, 2 steps, 1.73/1.75 (dr 4:1)
N
O
H
Me
O
O
BnO
PMB
Pd(PPh3)4
THF, morpholine
-5 oC, 70 min
1.69: R = H
Cl
1.71
N
O
H Me
O
O
OHCl
R
+
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1.3. Racemic Syntheses of (±)-Salinosporamide A 
  1.3.1. Pattenden’s Synthesis of (±)-1.1a  
The Pattenden group reported a first biosynthetically inspired approach towards 
racemic synthesis of salino A6g.  Pattenden’s synthesis of salinosporamide A began with 
known β-ketoester 1.77 (Scheme 1.8).  First the ketone was protected as its acetal and 
the ester was saponified to give acid 1.78.  Acid 1.78 was then coupled with dimethyl 
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amino malonate to give amide 1.79.  In order to complete the formation of the lactam 
ring, amide 1.79 was exposed to acidic conditions leading to lactam 1.80.  Next the 
tertiary hydroxyl was protected as its TMS ether and the nitrogen was protected with a 
PMB group to give diester 1.81.  Differentiation of the two esters was accomplished by 
selective reduction with lithium triethylborohydride to yield aldehyde 1.82.  The 
completion of the side chain was carried out by addition of cyclohex-2-enyl zinc 
bromide to aldehyde 1.82 to produce alcohol 1.83.  Removal of the protecting groups 
was accomplished by Lewis acid mediated deprotection of the benzyl ether, fluoride 
induced desilylation and oxidative cleavage of the PMB group gave triol 1.84.  The 
completion of the synthesis of salinosporamide A was carried out by cleavage of the 
methyl ester and β-lactonization with BOPCl and final conversion of the primary 
hydroxyl group to the corresponding chloride.   
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Scheme 1.8. Racemic Synthesis of (±)-Salinosporamide A  
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1.82
1.83
1.84
 
   1.3.2. Romo’s Synthesis of Salinosporamide A (±)-1.1a 
Our bioinspired racemic synthesis of salino A6e commenced from reductive 
amination of (S)-O-benzyl serine 1.85, followed by esterification to afford allyl ester 
1.86.   The β-ketoamide substrate 1.87/1.88 was obtained from coupling of ketene 
heterodimer 1.66 of acetyl chloride and commercially available 4-chlorobutanoyl 
chloride (13%) on multigram scale by the method of Saeur, and serine derivative 1.86. In 
this case, the bis-cyclization was employed both diastereomeric keto acid 1.89/1.90 
following allyl deprotection to give β-lactone (±)-1.70/1.71 in 25-35% yield (dr 2-3:1), 
however the relative stereochemistry of the major diastereomer corresponded to salino A 
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as confirmed by subsequent conversion to the natural product.  Bicyclic β-lactone (±)-
1.70 was processed to racemic salino A (1.1a) using an identical sequence to that 
described for enantioselective synthesis of (–)-1.1a.   
 
Scheme 1.9. Romo’s Synthesis of (±)-1.1a from (S)-O-Benzyl Serine 
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1.4. Conclusion 
 
 The discovery of salinosporamide A has been a milestone in synthetic organic 
chemistry in a number of ways that are reflected in its biological importance and the 
variety and methods of its synthesis.  Salinosporamide A drew attention due to its 
structural complexity and its potent biological activity.  A fair assessment of this is the 
number of syntheses that have been published in its short existence in the literature. 
 The first enantioselective synthesis was accomplished by Corey and co-workers.  
This route, in addition of setting the stage for syntheses to come, featured a Baylis-
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Hillman reaction in order to construct the lactam ring.  Another of the features of this 
synthesis is the use of a radical cyclization in order to construct what would become the 
C2 stereocenter.  Perhaps the most important feature of this synthesis, due to its use in 
others, is the addition of a cyclohex-2-enyl zinc reagent to C5 in high selectivity. 
 Following in the wake of the Corey synthesis, Danishefsky and co-workers also 
developed an enantioselective route to salinosporamide A.  Their synthesis featured the 
construction of a rigid bicylic intermediate which ultimately led to excellent control in 
the construction of one of their key intermediate, a benzylic acetal.  This bicyclic 
structure, similar to Corey’s intermediate, also gives excellent stereocontrol with respect 
to the addition of the cyclohex-2enyl zinc reagent ultimately leading to the construction 
of salinosporamide A. 
 Nereus Pharmaceuticals developed a route that differed from the previous 
enantioselective syntheses preceeding it.  The first difference is that instead of the 
addition of a cyclohex-2-e-nyl zinc reagent to install the side chain, they resorted to an 
allyl borylation.  This unfortunately resulted in the incorrect stereochemistry at the C5 
hydroxyl.  In order to correct this, they then employed a unique oxidation and enzymatic 
reduction in order to provide salinosporamide A. 
 Hatakeyama’s synthesis, while featuring an end game similar to those above, also 
contributed a unique reaction in their construction of Salinosporamide A.  Hatakeyama 
employed an indium catalyzed intramolecular cyclization of a diester on to an alkyne in 
order to construct their key lactam.  Their synthesis also featured a selective reduction of 
this geminal diester intermediate.   
 21
 Another method of attachment of the cyclohex-2-enyl fragment was put forth by 
Omura and co-workers.  Their method involved the aldol reaction between 
cyclohexanone and the oxazolidone aldehyde intermediate.  This was followed by a 
sequence which involved conversion to the cyclic sulfate and then elimination under 
basic conditions to give the cyclohex-2-yl side chain.  Their synthesis also featured an 
alternative method of attachment of the C2 side chain.  This involved a Reformatsky 
reaction in order to attach this necessary fragment.  
  Romo and colleagues developed the shortest route to date with only a 9-step 
sequence.  The highlight in his synthesis is the key bis-cyclization which constructs a C-
C and C-O bond simultaneously to form the bicyclic core γ-lactam-β-lactone.  Most 
importantly, in our enantioselective synthesis the application of A1,3–strain in 
ketoamides to retain the optical purity at the C2 during the bis-cyclization process.  The 
success in addition of zincate and Grignard reagent to the late stage aldehyde 
demonstrated the stability of the β-lactone and chloro substituent functionalities to the 
reaction conditions.  This feature in our synthesis suggested the high potential for 
evaluation of P1 derivatives for their unique inhibition profiles across all three subunits 
CT-L, T-L, and C-L sites.9c 
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CHAPTER II 
RACEMIC SYNTHESIS OF (±)-SALINOSPORAMIDE A, AND SIMPLIFIED 
DERIVATIVES* 
 
2.1. Introduction 
 As mentioned previously, salinosporamide A (1.1a) besides superior bioactivity 
to its congener omuralide (2.1) (35 times more potent the IC50 value)2, its challenging 
structure comprised of five contiguous stereogenic centers recently attracted intense 
interest from the synthetic chemists.  Besides salino A (1.1a) we were also attracted to 
cinnabaramide A (2.2)11, which showed more potent inhibition than omuralide (2.1), and 
we envisioned salinosporamide A as an ideal target for synthesis (Figure 2.1). 
 
Figure 2.1. Structures of Bicyclic-β-Lactone Proteasome Inhibitors 
 
Previously, our group reported a catalytic, asymmetric intramolecular, nucleophile 
-catalyzed  aldol-lactonization  (NCAL)  process  employing  aldehyde  acids that allows  
 
 
____________ 
*Reprinted with permission from American Chemical Society for “Concise Total 
Synthesis of (±)-Salinosporamide A, (±)-Cinnabaramide A, Derivatives via a Bis-
cyclization Process: Implications for a Biosynthetic Pathway?” by Ma, G.; Nguyen, H.; 
Romo, D. Org. Lett, 2007, 9, 2143.  
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access to carbocycle-fused-β-lactones12 and this process was recently extended to keto 
acid substrates.13 This methodology was initially inspired by omuralide (2.1) and initial 
studies of employing the NCAL reaction in aldehyde acids containing such an amide 
functionality by Dr. Seongho Oh encountered difficulties in preparing substrates 
required from coupling of α,α-disubstituted acids and N-alkylated-α-substituted amino 
acids.  The only accessible substrates were those derived from glycine 2.3a, 2.3b and the 
addition of an α-cyclopropane moiety simplified the couplings.  We were pleased to find 
that the intramolecular NCAL process does proceed with these substrates and provided 
the first bicyclic γ-lactam-fused-β-lactones 2.6a, 2.6b via the NCAL process (Scheme 
2.1).  This provided an entry to simplified omuralide derivatives.  
 
Scheme 2.1. Synthesis of Simplified Omuralide Derivatives 
 
 
2.2. Retrosynthetic Analysis of Salinosporamide A and Cinnabaramide A 
Building on our work with carbocyclic and heterocyclic fused-β-lactones, we 
envisioned a biomimetic synthesis of (±)-salinosporamide A6e that would allow a one-
step route to the bicyclic β-lactones 2.8 by simultaneous formation of the C-C and C-O 
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bonds from a keto acid precursor 2.9 via an intramolecular bis-cyclization process.  
Attachment of the cyclohexenyl moiety, or other side-chains, would be possible by 
addition of appropriate zinc reagents 2.714 to the aldehyde derived from benzyl ether 2.8, 
however the success of this process and subsequent manipulations were not guaranteed 
given the potential reactivity of β-lactone.  The keto acid substrate 2.9 could be derived 
from coupling of an amino acid 2.10 and a ketene dimer 2.11a, the latter serving as a 
suitable latent equivalent for a β-ketoester.15  One concern with this approach was the 
potential for enolization of the substrate β-ketoamide rendering the ketone non-
electrophilic. However, due to the known conformationally controlled acidity of β-
ketoamides due to A1,3 strain,16 such an approach appeared plausible (Scheme 2.2). 
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Scheme 2.2. Retrosynthetic Analysis of Salinosporamide A and Cinnabaramide A 
 
2.3. Initial Studies of Simplified C4-Unsubstituted Bicyclic β-Lactones 
We first targeted simple C4-unsubstituted substrates for the bis-cyclization. 
Ketene homodimers 2.13(a-d) were prepared by dimerization of acid chlorides 2.12 (a-
d), triethylamine and reflux in ether by the method of Sauer (Table 2.1).17 As expected, 
homodimers 2.13 (a-d) were obtained in moderate to good yields (43-65%) after silica 
gel purification. Homodimer 2.13d (entry 4, Table 2.1) which was chosen to test the 
mildness of the reaction sequences given the presence of the chloro-substituent in the 
required keto acid substrate leading to the most similar derivative to salinosporamide A 
(1.1a). 
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Table 2.1. Synthesis of Ketene Homodimers 
 
Entry R Dimer % yield 
1 CyCH2 O
O
CyCy
2.13a
60 
2 n-hexyl 65 
3 PhCH2 48  
4 Cl(CH2)2 43 
 
Subsequently employed (vide infra) heterodimers 2.11a toward salinosporamide 
A and derivatives from acid chloride 2.14 and acetyl chloride (Table 2.2) however 
provided the expected statistical mixtures and further reductions in yields were also 
noted during purification leading to low absolute yields (5-13% yield, 20-52% based on 
a statistical, theoretical yield of 25%).  The best yield was obtained from dimerization of 
4-chlorobutanoyl chloride and acetyl chloride (13%, entry 1, Table 2.2) due to similar 
reactivity of the corresponding ketenes with products ratio (~ 1:1:1:1).  Importantly, 
these dimerizations are readily run on multigram scale from inexpensive, commercially 
available acid chlorides and the desired heterodimers, despite low absolute yields, can be 
obtained in multigram quantities. 
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Table 2.2. Synthesis of Ketene Heterodimers 
 
Entry R Dimer % yield 
1 Cl(CH2)2 13 
2 Cl(CH2)3 10 
3 n-hexyl 5  
 
With racemic ketene homodimers 13a-e in hand, these were coupled with N-
PMB-glycine benzyl ester 2.18 by the method of Calter, which proceeded efficiently to 
provide keto acid substrates 21a-e following hydrogenolysis of the benzylester (Table 
2.3). Bis-cyclization of these ketoacids was achieved using conditions similar to those 
developed for carbocycles, with 4-pyrrolidinopyridine (4-PPY) as nucleophilic promoter 
at 23 ºC (not reported) and 0 ºC proceeded efficiently (70-93%) in most cases to give 
bicyclic-β-lactones 23a-e with moderate diastereoselectivity (2.2-4:1). Ketoacid 21c 
gave high diastereoselectivity (>19:1) but in reduced yield (54%; entry 3, Table 2.3), 
however monitoring this reaction by 1H NMR at 23 ºC indicated that the high selectivity 
was due to selective degradation of the minor diastereomer (not shown) with prolonged 
reaction times. The C2-unsubstituted ketoacid 21e gave only 25% yield (entry 5, Table 
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2.3) which may be due to facile enolization due to the absence of the C2-substitutent 
(R1), which likely leads to diminished rates of the initial aldol step. Importantly, 
ketoacid 21d bearing two primary chlorides thus mimicking the substrate required for 
the proposed salino A synthesis also proceeded efficiently (entry 4, Table 2.3). 
 
Table 2.3. Synthesis of Simplified, C4-Unsubstituted Bicyclic β-Lactones 
2.18
2.13a-e
PMBHN CO2Bn
O
O
R1
R1
2.20a-e: R2 = Bn
2.21a-e: R2 = H
N
O
R1
O
O
PMB OR2
R1
+ N
O
R1
O
PMB
R1
4
H
O
H2, Pd/C
THF
4-PPY
(1.5 equiv)
i-Pr2NEt, CH2Cl2
0 oC, 2 h
THF, 50 oC, 24h
N OH
N Br
n-Pr
OTf
(1.5 equiv)
2.23a-e
2.19
2.22
4
 
Entry % yield 
(2.21)a,b 
% yield 
(2.23)b 
β-lactone drc 
1 84  
(2.21a) 
93  
(2.23a) 
 2.2:1 
2 80  
(2.21b) 
90  
(2.23b) 
 2.2:1 
3 72  
(2.21c) 
85  
(2.23c) 
 2.5:1 (>19:1)d 
4 81  
(2.21d) 
70  
(2.23d) 
 4:1 
5  77  
(2.21e) 
25  
(2.23e) 
 - 
aYield is for 2 steps. bYields refer to isolated, purified (SiO2) product. cDetermined by 1H NMR analysis of 
crude reaction mixtures. dObserved diastereomeric ratio (dr) if reaction is allowed to proceed at 23 oC for 
36 h (54% yield). PMB = p-methoxybenzyl, 4-PPY = 4-pyrrolidinopyridine. 
 
 
N
O
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O
O
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N
O
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O
O
PMB
n-hexylH
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N
O
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O
PMB
CH2PhH
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N
O
Cl(H2C)2
O
O
PMB
(CH2)2ClH
2.23d
N
O
O
O
PMB
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The relative stereochemistry of the major diastereomeric β-lactone 2.23a was 
confirmed by X-ray analysis following cleavage of the PMB group (Scheme 2.3).  
Importantly, the relative stereochemistry corresponds to that found in salinosporamide. 
 
Scheme 2.3. X-ray Analysis of the C4-Unsubstited Bicyclic β-Lactone 
 
2.4. Synthesis of C4 Substituted Salinosporamide Derivatives  
Encouraged by the results with α-unsubstituted keto acid substrates (2.21a-e), we 
next studied more sterically demanding substrates derived from (R)-alanine. Ring 
opening of homodimer 2.13a with (R)-N-PMB-alanine methyl ester 2.25 gave a 1:1 
mixture of diastereomeric ketoamides 2.26 which were underwent saponification to 
diastereomeric keto acids 2.27 (Scheme 2.4). Pleasingly, bis-cyclization also proceeded 
with these substrates albeit in reduced yields (31%) to provide bicyclic β-lactone 2.28a 
and 2.28b (dr 1.6:1). The major diastereomer again possessed the relative 
stereochemistry found in the natural products as verified by X-ray analysis of the β-
lactone 2.29 following PMB-deprotection (Scheme 2.4). 
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Scheme 2.4. Synthesis of Sterically Hindered C4-Substituted Derivatives 
 
 
2.5. Racemic Synthesis of (±)-Salinosporamide A  
To validate the mildness of this strategy, Dr. Gil Ma successfully completed the 
synthesis of cinnabaramide A (2.2).6e In a similar strategy, we targeted salinosporamide 
A (1.1a) bearing the required chloro-substituent in the keto acid substrate.  The (S)-N-
PMB-serine methyl ester 2.30 (synthesized by Dr. Gil Ma) was coupled with 
heteroketene dimer (±)-2.11a, readily available in gram quantities from 
heterodimerization of acetyl chloride and commercially available 4-chlorobutanoyl 
chloride, to provide the amides 2.31a and 2.31b as a mixture of two diastereomers (1:1 
dr) in 84 % yield.  The saponification of the methyl ester 2.31a and 2.31b using LiOH, 
however gave undesired keto acid 2.32 due to deprotonation of Hα of the ketone 
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following intramolecular SN2 displacement of chloride to afford possible cyclopropane 
by-product 2.32 (Scheme 2.5). 
 
Scheme 2.5. Synthesis of Ketoacids 2.31a/2.31b 
 
  
Alternatively, hydrolysis of ester 2.31a and 2.31b using Me3SnOH18 which was 
employed successfully in preparation of the keto acid subtrate in synthesis of 
cinnabaramide A (2.2) also gave an irreproducible low yield of the desired keto acids 
2.33a and 2.33b plus unknown by-products (Scheme 2.6).  
 
Scheme 2.6. Sn-Mediated Hydrolysis of Ketoamides 2.31a/2.31b 
 
 
Due to sensitivity of the substrate under basic conditions during saponification, 
instead (S)-N-PMB serine allyl ester 2.34 was prepared by reductive amination of 
commercially available (S)-O-benzyl serine 2.10 with p-anisaldehyde followed by 
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esterification with allyl alcohol.  The (S)-serine allyl ester 2.34 was coupled with 
heterodimer (±)-2.11a to provide a keto amide mixture 2.35a/2.35b in 80% yield (dr 
1:1).  The keto acids 2.36a/2.36b were obtained from Pd-mediated allyl ester 
deprotection. Bis-cyclization provided β-lactones 2.37a/2.37b in 25-35% yield (dr 2:1) 
along with multiple by-products after some optimizations on reaction conditions (by-
products and optimized conditions for this reaction will be discussed in Chapter IV).  
Deprotection of the benzyl ether enabled enrichment of the major diastereomer alcohol 
2.38 to (dr 10:1) upon MPLC purification.  Parikh-Doering oxidation of the alcohol 2.38 
did not give the aldehyde but decomposition of β-lactone.  Finally, modified Moffatt19 
oxidation using 1-(1,3-dimethylaminopropyl)-3-ethyl carbodiimide hydro-chloride 
(EDCI)20 and dichloroacetic acid21 granted the corresponding aldehyde and recovered 
alcohol 2.38.  Subsequent addition of zinc reagent 2.8 applying Corey protocol gave 
predominantly two diastereomeric alcohols 2.39 (33% yield, dr 3.5:1, 2 steps) (Scheme 
2.7).  
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Scheme 2.7. Synthesis of Hydroxy-β-Lactone (±)-2.39 
allylO2C
N
PMB
O O
(CH2)2ClOBn
(±)-2.37a
(±)-2.38 (dr 10:1)
N
O
H Me
O
O OBn
PMB
N
O
H Me
O
O OH
PMB
N
O
H Me
O
O
OH
CO2allyl
NHPMB
BnO
2.34
PMB
(±)-2.37b
+
CO2H
NH2
BnO
1)p-anisaldehyde, NEt3, MeOH
25 °C, 12 h; NaBH4, MeOH, (83%)
2)p-TsOH, allyl alcohol
PhH, reflux 20h, (88%)
O
O
(CH2)2Cl
(±)-2.11a
2.10
N
O
H Me
O
O OBn
PMB
(dr 2:1)
minor
diast.+
Pyridone, THF
60 °C, 36 h (80%)
HO2C
N
PMB
O O
(CH2)2ClOBn
(1 mol%) Pd(PPh3)4
morpholine (3 equiv)
THF, 23 oC, 7 h
2.22 (2 equiv)
i-Pr2NEt (1 equiv)
PPY (4 equiv)
CH2Cl2 (0.02 M)
-10 °C, 6 h (25-35%)
H2, Pd/C, THF,
rt, 5 h
(62%)
1. EDCI, DMSO/PhMe,
Cl2CHCO2H, 23 oC, 2 h
2. , THF, -78 oC
(33%, 2 steps, dr 3.5:1)
ZnCl
2.36a/2.36b
Cl
Cl
Cl Cl
2.35a/2.35b
2.8
(±)-2.39
 
Final deprotection of the PMB group using ceric ammonium nitrate (CAN) 
enabled isolation of diastereomerically pure rac-salinosporamide A (48%) along with an 
isolated by-product ester 2.40 resulting from C5 free alcohol.   X-ray analysis of single 
structure correlated with the published data and the relative stereochemistry of the 
natural product (Scheme 2.8).  
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Scheme 2.8. Oxidative PMB Deprotection and Completion of the Synthesis of (±)-
Salino A (1.1a) 
 
 
2.6. Conclusion 
 We have succesfully developed concise synthetic routes to rac-salinosporamide 
A, and its simplified derivatives. This strategy is unique in enabling simultaneous 
construction of both the γ-lactam and fused-β-lactone found in these metabolites via a 
bis-cyclization process.  The β-lactone in these systems and the chloro-substituent in 
salinosporamide precursors has been shown to be tolerant to several transformations 
which contributes to the brevity of the sequence.22 The described bis-cyclization process 
points to a logical biosynthetic origin for these intriguing natural products and raises the 
interesting question of whether such a bis-cyclization might be involved in the 
biosynthesis of these natural products.23 Further optimization of this synthetic strategy 
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including the low yield for the oxidation of alcohol to the corresponding aldehyde, 
followed by attachment of the cyclohexenyl side-chain, and oxidative PMB 
deprotection.  Most importantly, the extension to an enantioselective strategy premised 
on A1,3-strain in keto acid precursors is a great challenge.  
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CHAPTER III 
A1,3-STRAIN ENABLED RETENTION OF CHIRALITY DURING BIS-
CYCLIZATION OF β-KETOAMIDES: ASYMMETRIC SYNTHESIS OF (–)-
SALINOSPORAMIDE A*  
 
3.1. Introduction 
Building on biosynthetic considerations and rac-synthesis of salinosporamide A 
(1.1a), the key step in our asymmetric synthesis6j is a diastereoselective, nucleophile-
promoted, bis-cyclization process that mandates preservation of optical purity of a 
potentially stereochemically labile β-keto acid substrate 3.2 imposed by A1,3 strain 
(Figure 3.1). This is crucial since the C4 stereocenter in β-keto acid 3.2 is lost during the 
bis-cyclization process, thus the integrity of the labile C2 stereocenter dictates the optical 
purity of β-lactone 3.1.  This strategy delivers the bicyclic β-lactone 3.1 in a single 
operation from acyclic precursors and the optical purity of the β-lactone reflects the 
diastereomeric purity of β-keto amide 3.2, derived from the acylation of serine 
derivatives and racemic ketene dimer 2.11a. 
 
 
 
____________ 
*Reprinted with permission from The Royal Society of Chemistry for “A1,3-Strain 
Enabled Retention of Chirality During Bis-Cyclization of β-Ketoamides: Total Synthesis 
of (-)-Salinosporamide A and (-)-Homoalinosporamide A” by Nguyen, H.; Ma, G.; 
Romo, D. Chem. Commun. 2010, 46, 4803. 
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Figure 3.1. Enantioselective Strategy to Salino A  
 
3.2. Enantioselective Syntheses of (–)-Salinosporamide A 
3.2.1. Preliminary Result: Synthesis of (+)-Salinosporamide A Employing (S)-O-      
Benzyl Serine 
Similar to the racemic synthesis of salinosporamide A, the enantioselective 
synthesis commenced from reductive amination of (S)-O-benzyl serine with p-
anisaldehyde followed by esterification with allyl alcohol to prepare N-PMB allyl ester 
(S)-2.34.  Given that known potential racemization of serine derivative, milder 
conditions were employed; however, HPLC methods to resolve (R)-2.34 and (S)-2.34 
were not successful after several attempts.  (S)-serine allyl ester 2.34 was coupled with 
racemic heterodimer (±)-2.11a for a shorter reaction time using microwave in order to 
afford keto amide 2.35a and 2.35b as a mixture of two diastereomers (dr 1:1, 90% yield) 
(Scheme 3.1).  
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Scheme 3.1.  Microwave Mediated Synthesis of β-Ketoamides 
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To access the enantioselective bis-cyclization reaction, separation of the two 
diastereomeric β-ketoamides employing MPLC using EtOAC/hexanes = 1:9 enabled 
enrichment of the higher Rf keto ester 2.35a to dr 16:1 (~ 92% ee resolution conditions 
were developed by chiral HPLC).  Since the absolute stereochemistry at the C2 was not 
determined, the higher Rf keto ester 2.35a was the substrate of choice for a Pd mediated 
allyl deprotection to provide keto acid 2.36a with erosion of diastereomeric ratio to 9:1.  
The bis-cyclization of the keto acids 2.36a, when 4-PPY was used without i-Pr2NEt, and 
modified Mukaiyama salt 2.22 improved the yield of β-lactones 2.37a/2.37b to 41% (dr 
3:1) favoring the one found in the natural product.  Most importantly, enatiopurity was 
conserved due to A1,3-strain as expected to provide β-lactone 2.37a (71% ee confirmed 
by chiral HPLC).  Subsequent conversions afforded salinosporamide A employing the 
synthetic strategy and same reaction conditions developed in the racemic synthesis as 
discussed in Chapter II.  Optical rotation of final product [α]23D = +42.6, c = 0.22, 
MeOH versus [α]25D = -72.9, c = 0.55, MeOH of natural product indicated that the 
enantiomer of naturally occurring salinosporamide A had been obtained in this sequence 
(Scheme 3.2). 
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Scheme 3.2.  Synthetic Execution of (+)-Salinosporamide A 
 
 
 
    
3.2.2. Preliminary Result: Synthesis of (–)-Salinosporamide A Employing (S)-O-      
Benzyl Serine 
Synthesis of (–)-salinosporamide A (1.1a) then utilized the lower Rf value β-
ketoamide (2R,4S)-2.35b (dr 18:1) which underwent allyl deprotection to provide keto 
acids (2R,4S)-2.36b with a reduction of dr 10:1.  Unexpectedly, the bis-cyclization of 
keto acid 2.36b gave β-lactones 2.37a/2.37b (40% yield, dr 0.8:1) favoring the undesired 
diastereomer 2.37b (scheme 3.3).   
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Scheme 3.3. Bis-Cyclization of β-Ketoacid 2.36b 
 
 
Subsequent conversions to the corresponding aldehyde via oxidation of alcohol 
after benzyl deprotection.  Side chain attachment and followed by oxidative PMB 
deprotection to give salinosporamide A ((–)-1.1a) employing the same conditions 
developed in the racemic synthesis (Chaper II).  Optical rotation of final product [α]23D = 
-32.1 corresponds to [α]25D = -72.9 (literature) which indicated that the natural product 
had been obtained in this sequence.     
To approach the asymmetric synthesis of γ-lactam fused β-lactone bicyclic core 
of (–)-salinosporamide A, ether ketoacid (2R,4S)-2.36b or (2R,4R)-3.4a could be desired 
subtrates (Scheme 3.4) since the C2 center would be retained during the bis-cyclization 
due to A1,3-strain. Although the C4 center is lost during the bis-cyclization, preliminary 
results showed diastereoselectivity highly depended on whether (R) or (S)-serine derived 
ketoacids were employed leading to different diastereoselectivity, 3:1 vs 0.8:1.  
Therefore, to address the diastereomeric selectivity of the bis-cyclization, we modified 
our synthetic strategy commencing from (R)-O-benzyl serine, and (2R,4R)-3.4a was our 
desired keto acid for the bis-cyclization (scheme 3.4). 
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Scheme 3.4.  Summary of β-ketoacid Derived from (R) and (S)-O-Benzyl Serine 
 
 3.2.3. Enantioselective Synthesis of (–)-Salinosporamide A Employing (R)-O-
Benzyl Serine 
As mentioned previously, a key step in our strategy is a diastereoselective, 
nucleophile-promoted, bis-cyclization of β-keto acid (2R,4R)-3.4a (Scheme 3.4). This 
process delivers the bicyclic-β-lactone 2.37a in a single operation from acyclic 
precursors and the optical purity of this β-lactone would reflect the diastereomeric and 
enatiomeric purity of β-ketoacid (2R,4R)-3.4a.  We were set to synthesize (R)-2.34 by 
reductive amination of (R)-O-benzyl serine 3.3 (99% ee) with p-anisaldehyde employing 
the procedure developed previously, and subsequent esterification to provide allyl ester 
(R)-2.34.  At this point, we extensively explored HPLC conditions in conjunction with 
commercially available chiral columns to resolve the racemic O-benzyl serine allyl ester 
(±)-2.34.  Fortunately, we found conditions which separated the two enantiomers 
showing that the enantiomeric excess of (R)-2.34 had dropped to 87% ee. It is known 
that challenges in racemization / epimerization are in the reductive amination step could 
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be due to imine isomerization24 between 3.5a and 3.5b isomers prior to reduction to the 
corresponding amine (scheme 3.5). 
 
Scheme 3.5. Challenges of Racemization in Reductive Amination Reactions 
1) i. p-anisaldehyde,
MeOH, MgSO4, Et3N
CO2H
NH2
BnO
(R)-O-Bn serine 3.3
( 99 % ee)
O2C
N OBn
MeO
O2C
N OBn
MeO
3.5a 3.5b
 
 
At the outset of our studies, we carefully explored reducing agents other than 
NaBH4 such as NaCNBH3, however a lower conversion was obtained (entry 1, Table 
3.1).  Therefore, NaBH4 was the reducing agent of choice for the optimized studies.  The 
outcome of entry 2 and 3 highlighted the importance of low temperature during the 
imine reduction stage to minimize racemization of the corresponding amine.  Finally, 
conditions were found to prepare O-benzyl serine allyl ester (R)-2.34 with minimal 
racemization in 79% yield (2 steps, 98% ee) (entry 5, Table 3.1). 
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Table 3.1. Optimization of N-PMB-(R)-Serine Allyl Ester Synthesis 
 
entry conditions (step 1) % yield (R)-2.34a,b % ee (R)-2.34
1 8h, 0 ºC then NaCNBH3, AcOH  
0 ºC – 23 ºC, 3 h 
low conversion – 
2 88h, 0 ºC then NaBH4, 0 ºC – 23 ºC, 1 h 70% 87% 
3 8h, 0 ºC then NaBH4, 0 ºC, 2 h 48% 98% 
4 8h, 0 ºC then NaBH4, 0 ºC, 5 h 60% 98% 
5 8h, 0 oC then NaBH4, 0 oC, 2 h; 
overnight in freezer (~ -10 oC)  
79% 98% 
aYield is for 2 steps. bYields refer to isolated, purified (SiO2) product.  
 
Acylation of serine derivative (R)-2.34 (98% ee) with heterodimer (±)-2.11a 
under microwave conditions (50 ºC, 1 h) in place of conventional heating (50 ºC, 48 h) 
gave diastereomeric β-ketoamides (2R,4R)-3.6a/(2S,4R)-3.6b (dr 1:1, 90%).  Most 
importantly, the microwave mediated coupling reaction could be run in 3-4g scale with 
only a slight reduction in yields (dr 1:1, 80%).  Separation by MPLC using a different 
solvent system (95% CH2Cl2/EtOAc) enabled the enrichment of the required β-keto 
amide (2R,4R)-3.6a (45%, 30:1 dr, 98% ee). To demonstrate the utility of our synthetic 
strategy, we investigated conditions to recycle the undesired ketoamide (2S,4R)-3.6b.  
Under basic conditions, ketoamide (2S,4R)-3.6b (dr 23:1) could be converted to a 
mixture of 3.6a/3.6b (78%, dr 1:1) along with  by-product  cyclopropyl ketoamide 3.7 
(19%) (entry 2, Table 3.2).  However, a more hindered base such as i-Pr2NEt did not 
efficiently epimerize C2 center after 48 h at 23 ºC (entry 3, Table 3.2).  Eventually, 
equilibrium under acidic conditions was obtained to avoid by-product 3.7, and the 
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undesired diastereomer (2S,4R)-3.6b could be transformed to a 1:1 mixture of 
diastereomers via epimerization of the C2 but not the C4 stereocenter (verified by chiral 
HPLC) thus achieving an effective resolution of ketene dimer (±)-2.11a and greater 
material throughput (entry 4, Table 3.2). 
 
Table 3.2. Epimerization of Undesired β-Ketoamide (2S,4R)-3.6b 
 
entry β-keto amides  
(dr 3.6b:3.6a) 
Conditions Reaction outcome 
3.6b/3.6aa 3.7a 
1 23:1 morpholine (6 equiv), CH2Cl2, 
23 ºC, 12 h 
49% (dr 1:1) 45% 
2 23:1 morpholine (6 equiv), CH2Cl2, 
-10 ºC, 48 h 
78% (dr 1:1)  19% 
3 20:1 i-Pr2NEt (6 equiv), CH2Cl2,  
23 ºC, 48 h 
dr 12:1 5% 
4 20:1 p-TsOH, EtOAc/MeOH (4:1), 
45 ºC, 48 h 
98% (dr 1:1) – 
aYields refer to isolated, purified (SiO2) product. 
 
Towards the required keto acid (2R,4R)-3.4a precursor for bis-cyclization, one 
hurdle needed to be overcome was the epimerization during deprotection of the enriched 
keto amide (2R,4R)-3.6a under mildly basic conditions as mentioned in preliminary 
studies of asymmetric synthesis.  Previously, 3.0 equiv of morpholine was used as a 
nucleophilic scavenger for the allylic cation.  To avoid epimerization, 1.2 equiv of 
morpholine was used instead of excess morpholine (entry 1 and 2).25  Another option 
was employing 1,3-dimethylbarbituric acid (entry 4) as the nucleophile in place of 
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morpholine, conditions developed for base-labile substrates, unfortunately a reduction in 
diastereomeric purity was also observed.26  Notably, ketoacid (2R,4R)-3.4a could be 
epimerized with silica gel; therefore, allyl deprotection conditions were desired that were 
column free.  Finally, a mild and brief exposure of β-ketoamide (2R,4R)-3.6a  (dr ~ 
32:1) to a Pd(0)-mediated deprotection provided keto acid (2R,4R)-3.4a  with similar 
diastereomeric purity, which was used in the next step without further purification (entry 
5, Table 3.3).  This condition was also applied successfully on gram scale synthesis 
(entry 6, Table 3.3).  
 
Table 3.3.  Pd-Meditated Allyl Deprotection Optimization 
 
entry β-keto amide 
(2R,4R)-3.6a (dr)a 
reaction conditions β-keto acid 
(2R,4R)-3.4a (dr)a 
1 30:1 morpholine (1.2 equiv), -5 ºC, 2 h 20:1 
2 30:1 morpholine (1.2 equiv), 0 ºC, 3 h 13:1 
3 26:1 Bu3SnH (2 equiv), 0 ºC, 2 h impure prod. 
4 26:1 1,3-dimethylbarbituric acid (3 equiv), 
0 ºC, 2 h  
16:1 
5 32:1 morpholine (1.2 equiv), -5 ºC, 1 h, 
0.5M 
30:1 
6b 30:1 morpholine (1.2 equiv), -5 ºC, 70 
min, 0.5M 
30:1 
aDetermined by 1H NMR analysis of crude reaction mixtures. bConditions for gram-scale synthesis. 
   
At the outset, it was unclear whether the A1,3-strain induced conformational bias 
in β-keto tertiary amides (~4 kcal mol-1) would be sufficient to avoid epimerization of 
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this center in the time frame and under the basic conditions of the bis-cyclization. I 
reasoned that an understanding of reaction mechanism of the bis-cyclization would give 
me the insight how to optimize this key reaction, thefore mechanistic studies (which will 
be discussed in Chaper IV) of the bis-cyclization were performed in parallel with 
asymmetric synthesis.   Applying bis-cyclization conditions that were recently developed 
in preliminary studies of the asymmetric synthesis of salino A (1.1a) to keto acid 
(2R,4R)-3.4a (dr 30 : 1, 98% ee) as expected led to similar yields and diastereoselectivity 
(40% yield, dr 2.5 : 1); however erosion of optical purity of adduct 2.37 was observed 
(85% ee) (Table 3.4, entry 1).  In this condition, 4-PPY was used as both base and 
nucleophile since diisopropylethylamine showed inefficient deprotonation at the C2 
stereocenter when epimerization reaction of the β-ketoamide (2S,4R)-3.6b was explored 
previously.  In our earlier report, although the modified Mukaiyama salt 2.22 used above 
to activate the acid in conjuction with dichloromethane are critical for aldehyde acid 
substrate to be obtained in high yield in NCAL reaction,12a and later was proven to 
facilitate the bis-cyclization of the ketoacid substrates,13 it took two steps to prepare.  
Application of recently developed optimized conditions that rendered the process more 
practical with the recognition of the importance of the counterion of the Mukaiyama 
reagent 2.22’ which required acetonitrile as solvent12b to ketoacid (2R,4R)-3.4a (dr 30 : 
1, 98% ee) gave comparable yields with 5% decrease in enantiomeric access (entry 2, 
Table 3.4).  The outcome of entries 1 and 2 showed that a less polar solvent could 
potentially slow down the epimerization of ketoacid (2R,4R)-3.4a.  Since modified 
Mukaiyama salt 2.22 was not soluble in toluene, which was used with acetonitrile in the 
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bis-cyclization of ketoacid (2R,4R)-3.4a (dr 30:1) surprisingly improved the 
diastereoselectivity to 7:1 and gave high enantiopurity (92% ee), however only a 25% 
yield and 42% recovered ketoacid 3.4a/3.4b.  The low conversion was probably due to 
solubility of the Mukaiyama salt 2.22 in toluene/acetonitrile (5:1) (entry 3, Table 3.4).  
The yield was improved with longer reaction times, and when more acetonitrile was 
used but resulted in lower diastereomeric and enantiomeric ratios (entry 4, Table 3.4). 
 
Table 3.4. Optimization of the Bis-Cyclization Reaction Conditions Employing 
Mukaiyama Salts as Activating Agents 
 
entry Bis-cyclization conditions 2.37a/ba,b 2.37a/b (dr, ee)c rec. 3.4a/bb 
1 4-PPY, 2.22, CH2Cl2, 3.5 h 41% dr 2.5:1, 85% ee - 
2 4-PPY, 2.22’, CH3CN, 3.5 h 40% dr 2:1, 80% ee - 
3 4-PPY, 2.22, PhMe/CH3CN 
(5:1), 2 h 
25% dr 7:1, 92% ee 42% 
4 4-PPY, 2.22, PhMe/CH3CN 
(3:1), 3.5 h 
46% dr 4:1, 85% ee - 
aYield is for 2 steps (deprotection and bis-cyclization). bYields refer to isolated, purified (SiO2) product. c 
% ee refers to (–)-2.37a. 
 
 
Encouraged by the outcome of the bis-cyclization in toluene, in that a less polar 
solvent might slow down epimerization at C2, we attempted to seek an alternative 
commercially available activating reagent, trifluoromethane sulfonic andhydride, the 
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reaction occured at -20 ºC with promising results of 37% yield, dr 7:1 and high 
enantioretention at C2 (92% ee) after 70 min.  As was expected longer reaction times 
lead to higher yields but erosion in enatiomeric and diastereomeric ratio.  Next, the bis-
cyclization was explored with the less reactive activating agents such as p-toluene 
sulfonyl chloride (TsCl), mesyl chloride (MsCl), and p-nitrosulfonyl chloride the 
reaction worked well with ether MsCl (Table 3.6) or TsCl (61% yield, 85% ee, entry 4, 
Table 3.5).  However, due to the ease of product purification MsCl was the activating 
agent of choice for our asymmetric synthesis. 
 
Table 3.5. Optimization of the Bis-Cyclization Reaction Conditions Employing 
Commercially Available Activating Agents 
 
entry bis-cyclization conditions 2.37a/b a,b 2.37a/b (dr, ee c) rec. SM b 
1 4-PPY, (CF3SO2)2O, PhMe, 70 
min, -20 ºC 
37% dr 7:1, 92% ee 31% 
2 4-PPY, (CF3SO2)2O, PhMe, 
 2 h, -20 ºC 
44% dr 5:1, 90% ee 29% 
3 4-PPY, TsCl, PhMe, 1.5 h, -10 
ºC to -5 ºC  
30% dr 7:1, 92% ee 37% 
4 4-PPY (3.5 equiv), TsCl, 
PhMe, 3.5 h, -10 ºC to -5 ºC
61% dr 4:1, 85% ee 11% 
5 4-PPY, 4-NO2PhSO2Cl, PhMe, 
-10 ºC to -5 ºC, 70 min 
40% dr 5:1, 90% ee 19% 
aYield is for 2 steps (deprotection and bis-cyclization). bYields refer to isolated, purified products. c%ee 
refers to 2.37a. 
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After patient and extensive optimization of the reaction conditions for the bis-
cyclization, we were pleasantly surprised to find that mesyl chloride at lower 
temperature and most importantly in a less polar solvent (toluene) led to a dramatic 
increase in both diastereoselectivity (7:1) and retained enantiopurity of bicyclic β-
lactone 3a (92% ee, 35% yield, 28% recovered keto acid, Table 3.6, entry 1). In addition, 
a yield of 60% was obtained with longer reaction times under these conditions; however 
this led to reduced diastereoselectivity and enantiopurity (dr 4:1, 88% ee, Table 3.6, 
entry 2). Importantly, this reaction could be performed on gram scale with comparable 
diastereoselectivity and retention of enantiopurity (52%, dr 5:1, 90% ee, Table 3.6, entry 
3). 
 
Table 3.6. Varying Conditions for the Bis-Cyclization/Gram-Scale Synthesis Employing 
MsCl 
 
entry time (h) % yielda,b % ee dr % recovered ketoacid 
1 1.5 35 92 7:1 28 
2 3.5 60 88 4:1 10 
3c 3.5 52 90 5:1 11 
aYield is for 2 steps (deprotection and bis-cyclization). bYields refer to isolated, purified β-lactones. cThis 
run was performed on gram scale. 
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Completion of the salino A synthesis entailed hydrogenolysis of the benzyl 
group, which facilitated isolation of alcohol (–)-2.38a in 75% yield. Modified Moffatt 
oxidation27 with 0.5 equiv of dicloroacetic acid granted the complete conversion to the 
corresponding aldehyde which was used in the subsequent step without further 
purification.  Addition of the zinc reagent 2.8 derived from the reaction of n-butyllithium 
with the prior prepared cyclohexenyl tributyltin and ZnCl2 following the procedure of 
Corey6a, to the aldehyde gave a mixture of C5, C6-diastereomeric alcohols (dr 11:3:1:1) 
in 62% yield (2 steps, Scheme 3.6).  
 
Scheme 3.6.  Elaboration of the Core β-Lactone (–)-2.38a to PMB (–)-Salinosporamide 
A 2.39. 
 
 
As mentioned previously in Chapter II, the reduced yield in oxidative PMB 
deprotection was due to the formation of an ester by-product 2.40 in the presence of the 
C5 free alcohol. These conditions were modified by addition of excess methanol or iso-
propanol in attempts to capture the benzylic cation intermediate.  Alternatively, 
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employing 2,3-dichloro-5,6-dicyanobenzoquinone also gave similar result.  Finally, 
mixture solvent MeOH/H2O slightly improved the yield of desired product (43%, dr ~ 
15:1) and reduced the formation of ester 2.40 to 11% (entry 3, Table 3.7).  Pure (–)-
salinosporamide A (1.1a) was then obtained via recrystallization (syn. [α]23D = -71.3, c = 
0.39, MeOH); lit. [α]25D = -72.9 (c = 0.55, MeOH).2 
 
Table 3.7. Optimization of Oxidative PMB Deprotection  
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entry PMB-lactam  
(dr 2.39:C5,C6 diasts.)
Conditions Reaction outcome 
salino A (–)-
1.1a 
ester 2.40 
1 12:3:1:1 CAN (5 equiv), 
CH3CN/H2O, -10 ºC, 2h  
34%  18% 
2 11.5:3:1:1 CAN (5 equiv), i-
PrOH/H2O, -10 ºC, 6h   
36% 19% 
3 11:3:1:1 CAN (5 equiv), 
MeOH/H2O, -10 ºC, 6h  
43%  11% 
 
3.3. Conclusion 
 In summary, we have developed a concise, 9-step enantioselective route to (–)-
salinosporamide A (92% ee, 3.2%) from (R)-O-benzyl serine (99% ee). The key bis-
cyclization of a β-ketoamide, amenable to gram scale, constructs both the γ-lactam and 
the fused-β-lactone in one operation with a high degree of stereoretention and moderate 
diastereoseletivity up to 7:1, which contributed to the brevity of the synthesis (Scheme 
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3.7). The ability to optimize the bis-cyclization in asymmetric fashion given readily 
epimerization at C2 center based on deep understanding and extensive studies of the 
mechanistic rational and how this system is operated are discussed in detail in Chaper V.  
Moreover, the ability of the described β-keto tertiary amide substrates to maintain 
stereochemical integrity by virtue of A1,3-strain raises the intriguing question of how 
such stereochemical integrity is maintained with β-keto secondary amides, known salino 
A precursors, prior to and during related biosynthetic cyclizations or if a dynamic kinetic 
resolution are operative.  
 
Scheme 3.7. Gram-Scale Synthesis toward Bicyclic Core β-Lactone. 
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CHAPTER IV 
MECHANISTIC STUDIES OF THE KEY BIS-CYCLIZATION AND FURTHER 
OPTIMIZATION TOWARDS SALINOSPORAMIDE A* 
 
4.1. Introduction 
Our racemic syntheses of cinnabaramide A and salinosporamide A demonstrated 
the viability of our synthetic approach in which the potentially labile β-lactone and 
primary chloride were stable through several final steps in the synthesis including 
organozinc additions to the aldehyde. However, our ultimate goal is to develop an 
efficient, enantioselective route to a versatile salino A core (i.e. β-lactone 37) amenable 
to the synthesis of derivatives.  As mentioned earlier, mechanistic studies were explored 
in parallel with asymmetric synthesis of salino A. In this chapter, we set out to identify 
reaction conditions that would minimize formation of observed by-products.  Most 
importantly, epimerization at the C2 stereocenter of the β-ketoacid 4.1 occurs during the 
biscyclization. Additionally, an optimized procedure for zincate generation by the 
method of Knochel was generally useful for C4 side chain addition toward the synthesis 
of salinosporamide A derivatives.28  
 
 
____________ 
*Reprinted with permission from American Chemical Society for “Bioinspired Total 
Synthesis and Human Proteasome Inhibitory Activity of (–)-Salinosporamide A, (–)-
Homoalinosporamide A and Derivatives Obtained via Organonucleophile Promoted Bis-
cyclization” by Nguyen, H.; Ma, G.; Gladysheva, T.; Framgen, T.; Romo, D. J. Org. 
Chem. 2010, ASAP. 
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4.2. Mechanistic Studies of the Key Bis-Cyclization 
Our working mechanism for this bis-cyclization invokes a nucleophile catalyzed 
aldol-lactonization process and follows from our previous studies with carbocyclic-fused 
β-lactones (Scheme 4.1).12,13 Activation of the carboxylic acid 4.2 followed by 
transacylation with 4-PPY to provide acyl ammonium 4.3, and deprotonation provides 
ammonium enolate 4.4. Equilibration to the reactive conformer 4.6 enables subsequent 
aldol reaction leading to aldolate 4.7. Lactonization, which may occur via a ‘SN2’ 
process,13,29 then delivers β-lactone 4.8. While a [2+2] cycloaddition mechanism via an 
intermediate ketene has not been excluded,30 evidence to date including reduced 
conversions upon varying nucleophilic promoters (vide infra) is suggestive of 
nucleophile involvement in the rate determining or prior step. Indirect evidence comes 
from previously reported highly enantioselective bis-cyclization routes to carbocycle-
fused β-lactones employing chiral nucleophiles.12a,13a 
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Scheme 4.1. Proposed Mechanism for the Bis-Cyclization with Two Diastereomeric 
Ketoacid Substrates 
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At the outset of our studies, we recognized that several energetically favored 
conformers dictated by A1,3-strain e.g. conformers 4.4 and 4.5, while unproductive for 
aldol-lactonization since the ketone is not proximal to the ammonium enolate,31 would 
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preserve the enantiopurity of the single stereocenter (C2). This would be possible since 
the α-proton is nearly in plane with the amide carbonyl (Scheme 4.1) in these 
conformations due to A1,3-strain.16 Furthermore, the energetically unfavorable conformer 
such as that represented by 4.6 is required to achieve bis-cyclization and, due to 
proximity and favorable formation of a 5-membered lactam ring, aldol reaction would be 
facile. What we did not anticipate was the impact of the C4 absolute stereochemistry on 
the diastereoselectivity of the bis-cyclization. In our early optimization studies, we 
determined that diastereoselectivity was highly dependent on whether (S) or (R)-serine 
derived keto acids were employed leading to different diastereoselectivities, 1:2 vs 8:1 
respectively. We suggest that the moderate diastereoselectivity observed for the bis-
cyclization is governed by developing torsional strain between the methyl group (C3) of 
the ketone and the C2 substituent (cf. 4.10, R    Me) during the initial aldol reaction, 
leading to the preferred relative stereochemistry following lactonization (cf. 4.8). Note 
that only a moderate preference for (cf. 4.6) over the alternative (cf. 4.10) is expected32  
and this is reflected in the observed diastereoselectivity for the bis-cyclization (dr 4-7:1, 
vide infra).  Regarding the C4 absolute stereochemistry dependence, this is likely a result 
of required conformations for deprotonation imposed by the N-C4 bond rotamer of the 
two diastereomeric, acyl ammonium species 4.3 and 4.9 leading to ammonium enolates 
4.6 and 4.10 and suggests the intriguing possibility of memory of chirality which we are 
currently studying in related systems. With acyl ammonium 4.3 derived from (R)-serine, 
deprotonation leads directly to a N-C4 conformer that can access reactive conformer 4.6 
leading to major diastereomer 4.8. Alternatively, deprotonation of the diastereomeric 
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acyl ammonium 4.9 derived from (S)-serine leads directly to reactive conformer 4.10 
that delivers the diastereomeric β-lactone 4.11.  
In most cases, the energy of activation for a chemical reaction is greater than that 
for a conformational equilibrium.33  If this had applied to our situation in which the 
energy needed for reactive conformer 4.6 and 4.10 to convert to product 4.8 and 4.11 
respectively are higher than the energy for interconversion between 4.6 and 4.10, 
diastereomeric ratio of the bis-cyclization of the two diastereomeric ketoacid would be 
similar (Figure 4.1).   
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Figure 4.1. Effect of Conformation on Product Distribution in a Curtin-Hammett 
Situation 
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In our case, we assumed a rapid bis-cyclization since enantiopurity could indeed 
be maintained in a non-Curtin-Hammett situation, if once the higher energy reactive 
conformation is achieved, bis-cyclization immediately takes place. The activation energy 
for the intramolecular aldol of the reactive conformers 4.6 and 4.10, followed by 
lactonization led to products 4.8 and 4.11 respectively might be lower than that for N- 
C4 bond rotation energy barrier between 4.6 and 4.10 (Figure 4.2).   
 
 
Figure 4.2. Effect of Conformation on Product Distribution in a Non-Curtin-Hammett 
Situation 
 
In early optimization studies of the bis-cyclization of ketoacid 2.36 directed 
toward salino A, we isolated and identified three by-products; enol lactone 4.12, 
cyclopropyl ketoamide 3.7, and unsaturated lactam 4.13 (Table 4.1). Only the former 
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two by-products were observed when both 4-PPY and Hünig’s base were employed and 
only low yields of β-lactones 2.37a, 2.37b were obtained (Table 4.1, entries 1 and 2). 
Enol lactone 4.12 is likely derived from intramolecular acylation of enol 4.14 of the β-
ketoamide with the activated ester (Scheme 4.2). Cyclopropyl ketoamide 1.42 may be 
derived from a condensation reaction of enol 4.14 leading to β-diketone 4.15, a retro-
Claisen process induced by 4-PPY via 4.16, and finally cyclization via enol 4.17 leading 
to the cyclopropane. We next studied the use of 4-PPY (7.0 equiv) as both base and 
nucleophilic promoter, which reduced the amount of by-products 3.7 and 4.12 with 
attendant dramatic increase in yield of β-lactone but formation of unsaturated γ-lactam 
4.13 (Table 4.1, entry 3). Consideration of possible mechanisms for formation of this by-
product suggested control experiments to determine if lactam 4.13 was derived from 
decomposition of β-lactones 2.37a, 2.37b via a decarboxylation pathway. Subjecting β-
lactones 2.37a, 2.37b to 4-PPY at 23 ºC indeed led to lactam 4.13 (31%) and 
interestingly recovered β-lactones 2.37a, 2.37b with improved diastereomeric ratio (dr 
5:1→9:1, Scheme 4.3). Decomposition was much slower at –10 → –5 ºC and was not 
observed if only Hünig’s base was added to β-lactones 2.37a, 2.37b. This suggests a 
differential rate of decomposition for the two diastereomers. This may be explained by a 
lower barrier syn-elimination (endothermic, late transition state) for β-lactone 2.37b due 
to a more accessible proton and release of torsional strain (R    Me) which is absent in 
diastereomeric β-lactone 2.37a. Finally, decarboxylation and protonation leads to the 
observed unsaturated γ-lactam 4.13. 
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Table 4.1. Optimization of the Bis-Cyclization Leading to Bicyclic-β-Lactone (±)-2.37 
 
 reaction conditionsa  
% yield  
2.37a/2.37bd 
 
% yield 3.7, 
4.12, 4.13e 
entry act. agentb 
(equiv) 
base 
(equiv) 
nuc.c
(equiv) 
solvent 
1 2.22 
(1.5 ) 
i-Pr2NEt 
(3.0) 
4-PPY 
(1.5) 
CH2Cl2 10 23 (3.7/4.12) 
2 2.22 
 (1.5) 
i-Pr2NEt 
(1.0) 
4-PPY 
(4.0) 
CH2Cl2 33 25 (3.7/4.12) 
3 2.22 
(1.5) 
- 4-PPY 
(7.0) 
CH2Cl2 42 19 (3.7/4.13) 
4 MsCl (1.5) - 4-PPY 
(3.5) 
PhMe 61 10f (rec. 2.36) 
5 MsCl (1.5) - DMAP 
(3.5) 
PhMe 54 8f (rec. 2.36) 
aAll reactions were performed at –5 → –10 oC except entry 1 which was run at 23 oC.  bCarboxylic acid 
activating agent. cNucleophilic promoter.  dYields are given for 2 steps (bis-cyclization/allyl deprotection) 
and refer to isolated, purified (SiO2) products. eBy-products were not easily separated and thus approximate 
yields are provided based on 1H NMR (500 MHz) integration. fRecovered  ketoacid 2.36. 
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Scheme 4.2. Proposed Mechanisms for the Formation of By-Products 3.7 and 4.12 
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Scheme 4.3. Differential Decomposition of β-Lactones 2.37a/2.37b Leading to 
Unsaturated γ-Lactam 4.13 
 
 
These studies highlighted the importance of 4-PPY as both nucleophilic promoter 
and base which required  minimizing reaction time to avoid decomposition of β-lactones 
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and C2-deprotonation to avoid these by-products and ultimately to maintain optical 
purity during the bis-cyclization process.  Dramatic improvements were therefore 
realized when alternative activating agents and most importantly a less polar solvent 
(e.g. toluene), which may slow C2-deprotonation, was employed. Use of MsCl in 
toluene avoided formation of all by-products and yields of the β-lactones 2.37a/2.37b 
increased to 61% (Table 4.1, entry 4). Use of the less nucleophilic 
dimethylaminopyridine (DMAP) also led to β-lactone 2.37a/2.37b but in slightly 
reduced yields 54% under similar conditions suggestive of nucleophile involvement in 
the rate-determining or prior step (Table 4.1, entry 5).  
The impact of the chlorine atom on the acidity of the C2-proton was investigated 
under the original bis-cyclization conditions with a dual purpose of studying inductive 
effects on conversion and by-product formation and demonstrating the versatility of this 
synthetic strategy for C2-derivative synthesis. Ketoamide substrate 4.18 was prepared 
from a β-ketothioester while keto amide 4.19 was prepared from heteroketenedimer 11b.  
Bis-cyclization of ketoacid derived from allyl ester 4.18 bearing a γ-siloxy group (Table 
4.2, entry 2) led to similar results as from ketoamide 2.35 bearing a γ-chloro substituent 
(salino core shown for comparison, Table 4.2, entry 1), however the δ-chloro ketoacid 
resulted from keto amide 4.19 led to a significant increase in yield (Table 4.2, entry 3). 
The yields obtained appear to correlate with the 1H NMR chemical shifts of the C2 
protons of β-ketoamides 2.35, 4.18 and 4.19 (Table 4.2, entry 1, 2 and 3).  Comparision 
with the salino A core (Table 4.2, entry 1) shows a Δδ of 0.4 between γ- and δ-
heteroatom substituted substrates, pointing to the inductive effects and attendant 
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increased acidity leading to by-product formation imposed by the heteroatoms.  
Inductive effects leading to reduced yields (70-85%) and greater by-product formation 
was also observed in simpler C4-unsubstituted substrates bearing α-phenyl and β-chloro 
C2 substituents (Table 2.3, entries 3 and 4) in comparison to other C2-alkyl substrates in 
that series (90-93% yield). 
 
Table 4.2. Variation of the C2-Side Chain: Inductive Effects on Efficiency of the Bis-
Cyclization Reaction 
 
entry R1 β-lactones % yield δ Ha, Hb 
1 (CH2)2Cl 2.37a/2.37b 40 3.92, 3.94 
2 (CH2)2OTBS 4.20a/4.20b 42 3.92, 3.95 
3 (CH2)3Cl 4.21a/4.21b 62 3.52, 3.57 
 
4.3. Further Optimization towards Salinosporamide A 
 As mentioned earlier, introduction of the C4-sidechain in our synthetic strategy 
relied on the method developed by Corey.6a One drawback from this protocol is that it 
requires a prior prepared tin reagent which is inefficient for a facile C4-sidechain 
addition to the aldehyde 4.22 (Scheme 4.4).  Alternately, zinc reagent (±)-4.23 could be 
prepared directly from commercially available 3-bromocyclohexene and activated zinc 
by the method of Knochel,34,6g which was then added to aldehyde 4.22 at –78 ºC and 
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allowed to warm up to –20 ºC afforded only two diasteomers (dr 4:1), and improved the 
yield (2 steps, 74% to 81%).  While side chain addition using zinc reagent 2.86a derived 
from the reaction of n-butyllithium, prior prepared cyclohexenyl tributyltin and ZnCl2 
following the procedure of Corey gave a mixture of C5,C6-diastereomeric alcohols (dr 
11:3:1:1) in 62% yield at –78 ºC (Scheme 4.4).   
 
Scheme 4.4. Optimization of C4 Side Chain Addition Employing Knochel’s Protocol 
 
 
We reasoned the moderate diastereoselectivity in the latter as a result of a cyclic 
chair-like transition state with syn addition. Product 2.39 resulted from the more 
favorable addition of the zincate (S)-4.23 to the aldehyde from the side opposite to the β-
lactone due to more steric hinderance of the β-lactone than the adjacent sp3 methyl. On 
the other hand, product 4.24 derived from the addition of the zincate (R)-4.23 to the 
same side of the β-lactone is less favored due to the steric hinderance of the β-lactone. 
Currently, we use 2 equiv of zincate (±)-4.23 in the reaction for complete conversion.  
Possibly, facial selectivity can be improved in favor the desired diastereomer if only 1 
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equiv of zincate is used. If racemization of the zincate is facile, dynamic kinetic 
resolution will facilitate the reaction with improved facial selectivity (Scheme 4.5).  
Zincate (R)-4.23 can be equilibrated to (S)-4.23 via 1,3-transposition of zinc atom 
(Scheme 4.6).  The former reaction of zincate addition to the aldehyde following Corey’s 
protocol, LiCl was formed in situ and could behave as Lewis acid which coordinated to 
the aldehyde resulting in an open transition state. A control experiment of C4 side chain 
addition was explored in which zincate (±)-4.23 was generated following method of 
Knochel and LiCl was added.  As expected, reaction proceeded at –78 ºC, and products 
were obtained as a mixture of four diasatereomers (dr 10:3:1:1). 
 
Scheme 4.5. Facial Selectivity of Zincate Addition to the Aldehyde 4.22 
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Scheme 4.6.  Proposed Mechanism for Racemization of Zincate 4.23 
 
 
With PMB lactam (–)-2.39/4.24 (dr 4:1) in hand, attempts further improvement 
to PMB deprotection were explored.  PMB deprotection using ceric ammonium nitrate 
(CAN) and CH3CN/H2O gave salino A (1.1a, 51%), (C5, C6-bis-epi-salino A) 4.26 
(12%) and isolation of the salino ester 2.40 (15%) along with a diastereomer oxazolidine 
4.25 (5%) due to less complications from fewer number of products to the previous 
result with four diastereomers at C5, C6.  The absolute stereochemistry at C5 according 
to PMB lactam 2.39 was tentatively assigned due to the diastereomeric ratio of 2.39/4.24 
as 4:1.  Most importantly, this procedure enabled isolation of a novel salino A 
diastereomer (C5, C6-bis-epi-salino A) 4.26 whose relative stereochemistry was verified 
by X-ray analysis (Scheme 4.7).   
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Scheme 4.7. Completion of Salino A Synthesis  
 
  
The by-product oxazolidine 4.25 could be derived from the intramolecular 
trapping of benzylic cation 4.27 with the C5 alcohol.  The oxazolidine 4.25 in the 
presence of excess CAN led to the formation of benzylic cation intermediate 4.28 which 
was then trapped by H2O to deliver the intermediate 4.29.  C-N bond cleavage, followed 
by rearomatization, removal of the proton and the final tautomerization of the amide to 
afford salino ester 2.40 (Scheme 4.8). 
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Scheme 4.8. Proposed Mechanism for the Formation of By-products 2.40 and 4.25 
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4.4. Conclusion  
Optimization studies of the key bis-cyclization are described that eventually 
allowed for gram scale synthesis of a versatile bicyclic β-lactone with a high degree of 
stereoretention despite the presence of a stereochemically labile β-ketoamide.   Isolation 
and characterization of by-products in the bis-cyclization provided information regarding 
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this process and various alternative reaction pathways.  Also, we successfully optimized 
a procedure for zincate formation by the method of Knochel which greatly simplified 
product purification since tin by-products were avoided. Most importantly, this protocol 
gave only two diasteomers (dr 4:1) leading to the isolation of a novel salinosporamide A 
diastereomer (C5, C6-bis-epi-salinosporamide A, 4.26).  Additionally, mild and stable 
zincate conditions improved the yield (74% to 81%), and avoided the use of toxic tin 
reagents.  The ability to generate zincates directly from its alkyl halide, and subsequent 
successful addition to the versatile aldehyde intermediate 4.22 further validated our 
synthetic strategy in variation of the C4-side chain.  
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CHAPTER V 
SYNTHESIS AND BIOACTIVITY OF SALINOSPORAMIDE  
DERIVATIVES*  
 
5.1. Introduction 
Previous structure-activity relationship (SAR) studies of omuralide (1.2) showed 
that the amide, β-lactone, and hydroxyl group are essential for biological activity.11b 
Recently SAR studies of salinosporamide A (1.1a) have been investigated.8 In these 
studies, a series of analogues were assayed for cytotoxicity, proteasome inhibition, and 
inhibition of NF-kB activation. These results indicated a dramatic reduction in potency 
in cell-based assays that accompanies the replacement of the chloroethyl group with 
unhalogenated substituents (Figure 5.1). Halogen exchange to Br, I and a cyclohexene 
ring epoxidation can be tolerated, while some stereochemical modification significantly 
reduces activity, for example; C2 epimer was 100 times less potent than salinosporamide 
A against chymotrypsin-like (CT-L) and trypsin-like (T-L) activities of the proteasome. 
Modifications to the cyclohexene ring gave various degrees of reduction in biological 
____________  
* Reprinted with permission from The Royal Society of Chemistry for “A1,3-Strain 
Enabled Retention of Chirality During Bis-Cyclization of β-Ketoamides: Total Synthesis 
of (-)-Salinosporamide A and (-)-Homoalinosporamide A” by Nguyen, H.; Ma, G.; 
Romo, D. Chem. Commun. 2010, 46, 4803. 
 
*Reprinted with permission from American Chemical Soceity for “Bioinspired Total 
Synthesis and Human Proteasome Inhibitory Activity of (–)-Salinosporamide A, (–)-
Homoalinosporamide A and Derivatives Obtained via Organonucleophile Promoted Bis-
cyclization” by Nguyen, H.; Ma, G.; Gladysheva, T.; Framgen, T.; Romo, D. J. Org. 
Chem. 2010, ASAP. 
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activity such as replacement with cyclohexyl results in 3 to 12 fold lower potency in 
most assays. Interestingly, epoxidation of the olefin to the (R,R) diastereomer is well 
tolerated in contrast to the (S,S) diastereomer which led to a 25-40 fold lower potency 
across the assays reported (Figure 5.1). 
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Figure 5.1. Summary of Omuralide and Salinosporamide A SAR Data 
 
5.2. Variation of C2-Side Chain 
   5.2.1. Synthesis of (–)-Homosalinosporamide A 
In our optimization studies described above, we altered the C2-side chain with 
the dual purpose of studying inductive effects (cf. Table 4.2, Chapter IV) and providing 
the one carbon homologated side-chain that could ultimately lead to (–)-
homosalinosporamide A (homosalino A, 5.1). Groll and co-workers have proposed that 
acylation of the proteasome by the β-lactone of salino A (1.1a) at the catalytic N-
terminus (Thr 1) is followed by cyclization of the incipient alcohol with the pendant 
chloroethyl group leading to the formation of a tetrahydrofuran (5.3), as verified by X-
ray analysis (Scheme 5.1). 10a Thus, we became interested in the synthesis of homosalino 
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A (5.1) to determine if a tetrahydropyran (cf. 5.4, n = 2) could be formed at the active 
site of the proteasome in analogy to the known formation of a tetrahydrofuran.   
 
Scheme 5.1. Mechanism of Inhibition of the Proteasome (CT Site) with Salino A (1.1a) 
and Proposed for Homosalino A 5.1 
 
 
In a similar manner as described in the asymmetric synthesis of salinosporamide 
A (Chapter III), the enantioselective synthesis of (–)-Homosalinosporamide A began 
with reductive amination of (R)-O-benzyl serine (3.3) (99% ee) with p-anisaldehyde and 
subsequent esterification with allyl alcohol provided allyl ester (R)-2.34 (98% ee) 
(Scheme 5.1).  Acylation of serine derivative (R)-2.34 with unsymmetrical ketene dimer 
(±)-2.11b employing optimized microwave conditions developed for asymmetric 
synthesis of salinosporamide A surprisingly lead only to 50% conversion.  Prolonged 
reation times or elevated temperatures (entry 2, Table 5.1) resulted in higher yield but 
lower enantiomeric access (88% ee). As discussed previously (Chapter IV), inductive 
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effects only impact the acidity of the C2 proton with attendant of δ-heteroatom 
substituted substrates.  As a result, the C4 stereocenter is more prone to epimerization 
under these reaction conditions.  The optimized reaction (entry 3, Table 5.1) gave a 
mixture of two diastereomers (2R,4R)-5.5a/(2S,4R)-5.5b (80% yield, dr 1:1) and 
recovered (R)-serine allyl ester (R)-2.34.   Subsequent MPLC separation of the β-keto 
amides (2R,4R)-5.5a/(2S,4R)-5.5b (dr 1:1) led to desired ketoamide (2R,4R)-5.5a (dr 
25:1) after two separations with  erosion of optical purity (98% to 94% ee). 
 
Table 5.1. Microwave Asssited Ketoamide Coupling of Ketene Heterodimer  and (R)-O-
Benzyl Serine Allyl Ester  
 
entry microwave conditions % yield (5.5a/5.5b) % ee (2R,4R)-5.5a 
1 50 
o
C, 120 min  ~ 50% conversion  -  
2 60 
o
C, 120 min  93%  88  
3 53 
o
C, 120 min  80%  94  
 
Pd(0)-mediated deprotection of allyl ester (2R,4R)-5.5a delivered keto acid 5.6a 
with similar diastereomeric purity (dr ~ 24:1). Utilization of the optimized bis-
cyclization conditions developed in the asymmetric synthesis of salinosporamide A with 
TsCl as an activating agent gave the bicyclic-β-lactones (–)-5.7a/5.7b in 60% yield (dr 
3.5:1, 2 steps) and recovered ketoacid 5.6a/5.6b (dr 1:1, 11%).  Hydrogenolysis of the 
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benzyl ethers 5.7a/5.7b (dr 3.5:1) facilitated very simple separation of the major 
diastereomer 5.8a (62 %, dr > 19:1) via flash chromatography compared to 
salinosporamide A substrate (separation by MPLC).  The enantiomeric excess of the 
desired alcohol (–)-5.8a was determined by chiral HPLC as 82% ee due to the moderate 
diastereromic ratio of ketoacid (2R,4R)-5.6a (dr ~ 24:1, 94% ee according to ketoamide 
5.5a) or epimerization had occurred at the C4 stereocenter.  However, the enantiopurity 
of the alcohol (–)-5.8a could be improved by recrystallization (CH2Cl2/Et2O), which 
removed the minor enantiomer since it had lower solubility and crystallized more readily 
leaving the major enantiomer in the mother liquor.  One recrystallization led to an 
enrichment of 89 % ee for the hydroxy-β-lactone (–)-5.8a (83% yield), which was 
followed by modified Moffat oxidation to deliver the aldehyde intermediate which was 
used in the next step without further purification.   Treatment of zinc reagent 2.8 using 
the method developed by Corey provived alcohol 5.9 in 61% yield (2 steps, dr 8:2:1:1).  
Final oxidative PMB deprotection with ceric ammonium nitrate (CAN) gave (–)-
homosalinosporamide A 5.1, which could be isolated diastereomerically pure in 41%. 
The structure and relative stereochemistry of 5.1 were confirmed by X-ray analysis 
(Scheme 5.2). 
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Scheme 5.2. Completion of (–)-Homosalinosporamide A 5.1 Synthesis 
 
       
    5.2.2. Synthesis toward Salino-Belactosin Chimera 
Recently, X-ray structures of the overlay of 20S proteasome/salino A and homo 
CBz-Bn-belactosin C showing active site residues and distances to key groups on salino 
and belactosin were reported by Groll and co-workers.10a  A chimeric structure of salino 
A and belactosin C 5.10, another proteasome inhibitor synthesized in our group,35 was 
targeted to probe the effect of replacing the THF forming chloroethyl group with the 
dipeptide found to be effective in the belactosin structures (Figure 5.2, 5.11).  
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Figure 5.2. Proposed Salino A and Belactosin C Chimera  
 
The synthesis of salino-belactosin chimera commenced from the preparation of 
the azido salino derivative 5.12, which was recently described by workers at Nereus 
derived from the action of azide on salino A.8a   In their synthesis, the conversion of 
clorosalino A (1.1a) to iodosalino A via Finkelstein reaction only gave 11% yield of 
product following isolation by HPLC.  In our hands similar results were observed, 
therefore a one pot transformation of salino A (1.1a) to azidosalino 5.12 was explored 
under various conditions.  Currently, the best reaction conditions (Table 5.3, entry 3) 
found to be in DMSO at 23 ºC for 48h provided azide 5.12 in 20%, along with recovered 
salino A (1.1a) (48%), and decomposition of β-lactone (24%). 
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Table 5.2. Azido Salinosporamide A Synthesis 
 
entry reaction conditions reaction outcome 
1 Acetone, 23 ºC, 48h Recovered SM (1.1a) 
2 Acetone, 58 ºC, 48h 20% (5.12), 35% rec. SM (1.1a), 28% by-product 
3 DMSO, 23 ºC, 48 h 20% (5.12), 48% rec.SM (1.1a), 24% by-product 
4 DMSO, 23 ºC, 60 h 26% (5.12), 37% rec. SM (1.1a), 32% by-product 
 
Subsequent reduction of azide 5.12 to amino salino A 5.13 employing a 
Staudinger reduction with Ph3P proved difficulties in term of separation due to the high 
polarity of primary amine in the presence of β-lactone 5.13 and triphenylphosphine 
(Ph3PO) by-product.  Alternatively, reduction of azide 5.12 applying Lindlar’s catalyst 
gave promising results (entry 3, Table 5.3).  A crude 1HNMR showed a mixture of 
products amino salino A 5.13, a dimer of product 5.15 and unreacted azide 5.12 as also 
confirmed by LC-MS analysis.  However, there was over reduction (entry 2, Table 5.3) 
when longer reaction times were applied. 
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Table 5.3. Studies of Azido Salino A Reduction 
H
N
O
H Me
O
O
OH
H2N
H
N
O
H Me
O
O
OH
N3
Conditions
5.12 5.13
 
entry reaction conditions reaction outcome 
1 PPh3, 23 ºC, THF/H2O, 5h Small peak observed by IR 
2 Lindlar catalyst, 23 ºC, THF, H2, 12h Product obtained with over reduction 
3 Lindlar catalyst, 23 ºC, THF, H2, 3h  Product used w/o further purification 
 
Attempts to purify amino salino A 5.13 resulted in loss of product 5.13.  
Therefore, reduction of azide 5.12 followed by coupling with peptide 5.14 using N-
hydroxybenzotriazole, 1-(1,3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 
(EDCI) at 23 ºC was explored.  Unfortunately, the reaction did not give the desired 
product but instead decomposition of the β-lactone under basic condition (entry 1, Table 
5.4).  Therefore, coupling reaction conditions were explored using succiimide ester 
5.14a, which however did not provide the desired product 5.11, surely dimerization of 
amino salino A 5.13 was detected by LC-MS (entry 2, Table 5.4). 
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Table 5.4. Attempt Synthesis of Salino A Belactosin Chimera  
 
entry reaction conditions reaction outcome 
1 HOBt, EDCI, i-Pr2NEt,CH2Cl2, 23 ºC, 6h No desired product by LC-MS 
2 
 THF/MeOH, 23 ºC
No desired product by LC-MS 
 
Alternatively, prior to PMB deprotection the mixture of alcohols was subjected 
to a Finkelstein reaction developed for natural product salino A derivatives.  
Unfortunately, the reaction only resulted in decomposition of the β-lactone to the 
unsaturated amides 5.16 (Scheme 5.3). 
 
Scheme 5.3.  Atempt Synthesis of PMB Azido Salino A 5.15. 
N
O
H Me
O
O
OH
Cl
PMB NaI, NaN3, DMSO,
23 oC, 24 h
N
O
H Me
O
O
OH
N3
PMB
N
O
OH
Cl
PMB
+
5.15 (0%) 5.16 (80%)2.39/ C5,C6-epi-diast.  
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Since PMB salino A is less stable than the natural product salinoA under the 
reaction conditions, the goal was to go back to the original strategy starting from salino 
A.  Given that amino salino A 5.13 was unstable at 23 ºC under the reaction condition, a 
one pot two step transformation was explored.  In this event, azido salino A 5.12 (1 mg 
scale) was subjected to Staudinger reduction conditions in the presence of NHS-ester 
5.14a gave promising result of potential salino-belactosin chimera 5.11 by LC-MS 
analysis (Scheme 5.4).  
  
Scheme 5.4. An One Pot Reduction /Amide Coupling of Azide 5.12 
 
5.3. Variation of the C4-Side-Chain of the Salino Core 
  X-ray analysis of salino A complexes with proteasome showed a large 
hydrophobic pocket accommodating the cyclohexenyl group of salino A terminating in a 
highly basic region (lysine residues) suggests that a larger hydrophobic group including 
those bearing a carboxyl group could be accessed to probe this feature of the binding 
pocket.10  Our synthetic strategy enables faciles variation of the C4-side chain by 
addition of organometallic reagents to the versatile aldehyde by addition of organozinc 
which has been applied successfully using Knochel protocol in the synthesis of salino A.   
Moreover, simple derivatives could be accessed by adddition of Grignard reagents to the 
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aldehyde intermediate following oxidation of the alcohol 5.18.  Oxidative PMB 
deprotection provided phenyl and dimethylphenyl salino derivatives 5.20 and 5.22, 
respectively (dr ~3:1, Scheme 5.5).  The structure of 5.20 was confirmed by X-ray 
analysis.  However, the addtion of isopropyl magnasium chloride was unsuccessful after 
several attempts, probably is due to steric effects of isopropyl and the aldehyde. 
 
Scheme 5.5. Varying the C4-Sidechain of Salino A. 
 
 
5.4. Biological Studies   
 The derivatives synthesized were analyzed for their ability to inhibit the 
chymotrypsin-like (CT-L), caspase-like (C-L), and trypsin-like (T-L) activities of the 
20S and 26S human proteasome in a luminogenic enzymatic assay (Table 5.5).  Both 
velcade (entry 6) and synthetic salino A (92% ee, entry 2) were included as controls and 
data obtained correlates well with previous analyses. As expected based on known 
structure-activity relationships,10,8 changes made to the C5-sidechain in general led to 
lower activity with drastic loss of activity observed for the rac-dimethylphenyl 
derivative 22. However, changes in the C2-sidechain are more tolerable as indicated by 
(–)-homosalino A (5.1, Table 5.5, entry 5) and indeed this derivative exhibited very 
similar activity to the natural product with the exception of inhibition of the trypsin-like 
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activity toward the 20S human proteasome (~3X decrease). 
 
Table 5.5.  IC50 Values for Inhibition of the 20S and 26S Proteasome by Salino A 
Derivatives in a Luminogenic Enzymatic Assaya 
Entry Compound  IC50  
  CT-L activity 
20S/26S (nM) 
C-L activity 
20S/26S (nM) 
T-L activity 
20S/26S (nM) 
1 rac-cinnabaramide A, 
(±)-2.1c 
2.8±0.6 
2.2±0.04 
125±12b 
230±24b 
260±29b 
412±83 
2 (-)-salino A (1.1a) (92% ee) 
0.8±0.08 
2.5±1.3 
111±22 
156±18 
39±7 
37±16 
3 rac-phenyl derivative 
(±)- 5.20 
29±0.7 
57±20 
788±50 
1585±633 
702±235 
589±120 
4 rac-diMePh (5.22) inact. b,c inact. b,c inact. b,c 
5 (-)-homosalino (5.1) (88% ee) 
0.7±0.04 
2.3±1.1 
144±12 
188±3 
118±28 
125±30 
6 velcade 2.6 ±0.7 7.4±1.9 
25±7 
72±17 
254±24 
680±150 
aIC50 values are the mean ± standard deviation of 4 or more experiments. bThe average of 2 experiments. 
cEssentially inactive at >99,000 nM. (CT-L: chymotrypsin-like activity; C-L: caspase-like activity; T-L: 
trypsin-like activity) 
 
 
5.5. Conclusion 
 Our synthetic strategy enables facile variation of the C4-side chain by addition of 
organometallic reagents to the versatile aldehyde by addition of organozinc which has 
been applied successfully using Knowchel protocol in the synthesis of salinosporamide 
A and extended to Grignard’s reagent for other C4 side chain derivatives.  Given the role 
of C4 side chain in recognizing the S1 specificity pocket of the proteasome, which 
largely imparts the CT-L, T-L and C-L sites with their substrate references, our synthetic 
strategy would quickly provide a wide range of derivatives which help reveal unique 
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inhibition profiles among subunits.  Regard the C2 side chain variation, in particular 
salino belactosin chimera 5.11 we should be able to synthesize this novel compound 
according our preliminary result. 
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CHAPTER VI 
OPTIMIZATION OF AN ORGANIC SYNTHESES PROCEDURE: 
ASYMMETRIC NUCLEOPHILE-CATALYZED ALDOL-LACTONIZATION 
WITH ALDEHYDE ACIDS* 
 
6.1. Introduction 
This procedure describes an organocatalytic, enantioselective method for the 
asymmetric synthesis of bicyclic β-lactones.  The intramolecular nucleophile-catalyzed 
aldol-lactonization (NCAL) process effectively merges catalytic, asymmetric carbocycle 
synthesis with β-lactone synthesis leading to unique bicyclic β-lactone.12  The demand 
for concise synthetic routes to optically active β-lactones continues to grow due to 
continued development of novel transformations of these heterocycles and a reappraisal 
of their utility as synthetic intermediates36 including natural product synthesis,37 their 
continued occurrence in natural products,38 their potent activity as enzyme inhibitors39 
and their utility as activity based probes.40 β-Lactones can be viewed as "activated aldol 
products" since they possess the structural features of aldol products yet they also have  
inherent reactivity due to ring strain (β-lactones, 22.8 kcal/mole; epoxides, 27.2 
kcal/mole, Scheme 6.1).41 
 
 ____________ 
*Reprinted with permission from Organic Syntheses for “Asymmetric Synthesis of 
(1S,5R)-6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one via the Nucleophile-
Catalyzed Aldol-Lactonization (NCAL)” by Nguyen, H.; Oh, S.; Henry-Riyad, H.; 
Sepulveda, D.; Romo, D. Org. Syn. 2010,88.  
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Scheme 6.1.  Comparison of Structure and Reactivity of β-Lactones to Aldol Adducts 
and Epoxides. 
 
 
The aldol motif, the β-hydroxy carbonyl motif, derived from polyketide 
biosynthesis, is common to many natural products, therefore asymmetric methods for 
their synthesis have been studied extensively. However, β-lactones arguably have 
greater utility over simple aldol products since they can undergo divergent nucleophilic 
cleavage processes occurring at either the acyl-oxygen (C2-O1) bond or the alkyl-oxygen 
(C4-O1) bond typically driven by release of ring strain.  As a result, β-lactones undergo a 
number of interesting and useful stereospecific transformations making them versatile 
intermediates for organic synthesis.36  Despite these facts, general methods for the direct 
synthesis of β-lactones in optically active form lag far behind those developed for 
epoxides and aldol adducts.  Furthermore, there is much unexploited synthetic potential 
of β-lactones as chiral synthetic intermediates.  Consequently, our group has been 
engaged in the development of efficient methods for the asymmetric synthesis of β-
lactones and their subsequent transformations with applications to natural product 
synthesis.42 Building on our initial reports of the NCAL process,12  we recently 
developed optimized conditions that render the process more practical with the 
recognition of the importance of the counterion of the Mukaiyama reagent.12b The utility 
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of the dioxolane bicyclic β-lactone 6.4 described in this Organic Syntheses procedure 
was demonstrated in the synthesis of cyclopentane diol 6.5,43 a useful intermediate in the 
synthesis of antiviral carbocyclic nucleosides including (-)-aristeromycin (6.6)12a and 
Merck IND intermediate anti-HIV CCR5 antagonists (6.7)44 (Scheme 6.2).  
 
Scheme 6.2. Utility of β-lactone 6.4 toward a Formal Synthesis of (-)-Aristeromycin and  
Merck IND Intermediate. 
 
 
6.2. Organic Syntheses Procedure for the Asymmetric Synthesis of the Bicyclic  
       β-Lactone  
To demonstrate the utility of the NCAL methodology, a gram-scale procedure for 
preparing optically active bicyclic β-lactone 6.4 has been developed and optimized to 
meet standard guidelines and requirements for an Organic Syntheses procedure.  This 
procedure contains a three step sequence with a total of five procedures which include 
one procedure for the preparation of Mukaiyama salt 6.8 (an acid activating agent), and 
one procedure for the synthesis of chiral catalyst O-TMS quinidine 6.9.  The synthesis of 
bicyclic β-lactone 6.4 commenced from commercially available cyclohexanone 6.10 
which was O-silylated with TMSCl to give silyl enol ether 6.11 followed by ozonolysis 
to provide aldehyde acid 6.12 which underwent our asymmetric NCAL reaction using 
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Mukaiyama reagent 6.8 and chiral nucleophile O-TMS quinidine (O-TMSQND) 6.9 to 
give optically active bicyclic β-lactone 6.4 (Scheme 6.3).  
  
Scheme 6.3. Synthesis of Optically Active Bicyclic β-Lactone 6.4 via Asymmetric 
NCAL Reaction 
 
 
Ideally, an Organic Syntheses procedure is designed for a large-scale synthesis, 
easy to handle with minimum column chromatography, and reproducible results which 
can be followed by a chemist with only fundamental laboratory experience.  Moreover, 
the target molecule / building block is broadly interesting.  Finally, safety is also a great 
concern when large scale reactions are carried out.   
 
   6.2.1. Synthesis of (1,4-dioxaspiro[4.5]dec-7-en-8-yloxy)trimethylsilane 
Originally, the synthesis of silyl enol ether 6.11 on small scale was derived from 
cyclohexanone 6.10, LDA and TMSCl.12a   This protocol was modified to be applicable 
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for the gram scale synthesis using cyclohexanone 6.10 (25g), TMSCl, triethylamine and 
N,N-dimethyl formamide.  This procedure was optimized to ensure reproducibility with 
quantitative yield (Scheme 6.4).  Notably, silyl enol ether 6.11 is acid sensitive, therefore 
excess Et3N was needed for the reaction to reach completion due to the by-product 
triethylammonium chloride which is mildly acidic under the reactions.  After the 
reaction was completed, an aqueous work-up was neccessary to remove triethyl 
ammonium hydrochloride salt (soluble in water) and majority of the non volatile and 
water soluble solvent (N,N-dimethyl formamide).  However, to guarantee maximum 
product transfer, a back extraction from the aqueous layer was needed for this work-up 
procedure.  One problem that was also recognized was that substantial amounts of 
starting material 1,4-cyclohexadione mono-ethylene ketal 6.10 was carried on to the last 
step while procedure was reproduced by a first year graduate student.  This required 
optimization of the reaction procedure with follow up by 1H NMR since the purity of 
product was not easily monitored by TLC due to facile desilylation of the TMS enol 
ether 6.11.  One of the contributors for the recovery of cyclohexanone 6.10 came from 
the original extensively acidic work-up procedure in order to remove excess 
triethylamine which had been used in the reaction.  Monitoring the work-up procedure 
by 1H NMR showed excessively acidic work-up condition (saturated ammonium 
chloride solution)  resulted in desilylation to the corresponding ketone.  However, the 
largest contributor came from the N,N-dimethyl formamide, a highly hydroscopic 
solvent, high concentrations of water in DMF resulted in incomplete reaction due to 
partial hydrolysis of TMSCl.  Therefore, a note was added to the procedure “it is 
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important to use very dry N,N-dimethylformamide (<150 ppm of H2O) to avoid 
hydrolysis of  TMSCl” to be certain of reproducibility of the procedure .  As a result, this 
work-up procedure guaranteed high product yield, purity and avoided column 
chromatography. 
 
Scheme 6.4. Synthesis of Silyl Enol Ether 6.11 
 
     
  6.2.2. 3-(2-(2-oxoethyl)-1,3-dioxolan-2-yl) Propanoic Acid  
  This step of the procedure was an ozonolysis of silyl enol ether 6.11 and 
subsequent reductive work-up using dimethyl sulfide or triphenyl phosphine to deliver 
aldehyde acid 6.12 (Scheme 6.5).  Original conditions for small scale ozonolysis 
employed dimethyl sulfide to reduce the ozonide.  Product aldehyde acid 6.12 was 
purified by column chromatography.  One hurdle that needed to be overcome was the 
purification procedure of aldehyde acid 6.12 had to avoid column chromatography.   
Since by-product was DMSO which was difficult to remove when performing on large 
scale reaction, and definitely could not remove by an extraction procedure due to 
DMSO’s presence both in the organic and aqueous layers.  Alternatively, the use of 
triphenylphosphine (PPh3) increased the product yield but isolation of aldehyde acid 
6.12 from the by-product triphenyl phosphine oxide was impossible via column 
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chromatography.   Normally, an acid base work-up procedure is applied to purify an acid 
substrate.  First, aldehyde acid 6.12 was converted to carboxylate salt with NaOH which 
was transferred to aqueous layer and triphenylphine oxide (PPh3O) remained in organic 
layer.  The aqueous layer was then acidified and aldehyde acid was back extracted into 
organic layer.   Unfortunately, dioxolane functionality was unstable to the strong acid 
conditions necessary for back extraction.  This resulted in dioxolane deprotection to the 
corresponding ketone.  Notably, aldehyde acid 6.12 is highly water soluble, taking 
advantage of this property, aldehyde acid 6.12 was first dissolved in aqueous layer, and 
then was back extracted with dichloromethane.  Multiple back extractions with 
dichloromethane helped recover most of aldehyde acid with high purity.  The partition 
constant (partition coefficient) of aldehyde acid 6.12 between water and an organic 
solvent was the key to an effective extraction.  First, aldehyde acid was dissolved in 
ether and most of the triphenyl phosphine precipitated which was then removed by 
filtration.  Aldehyde acid 6.12 was then brought to the aqueous layer.  This protocol 
worked well with this aldehyde acid whose ether has a low partition consant with.  
Dichloromethane on the other hand has high partition constant for 6.12 would ensure 
effective removal of product from water. It is also imperative that extractions of the 
aldehyde acid are done vigorously to guarantee efficient transfer of the aldehyde acid 
6.12 to the organic phase. 
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Scheme 6.5. Sythesis of Aldehyde Acid 6.12 Precusor for NCAL Reaction 
 
 
  6.2.3. Preparation of N-Methyl-2-Chloropyridinium Trifluoromethane Sulfonate  
 Mukaiyama reagent 6.8 was prepared using 2-chloropyridine 6.13 and methyl 
trifluoromethane sulfonate in dichloromethane (Scheme 6.6).  A detailed procedure with 
fully characterization data including IR, 1H NMR and 13C NMR spectra were provided 
along with the procedure. 
 
Scheme 6.6.  Preparation of Mukaiyama Reagent 6.8 
 
    
  6.2.4. Preparation of O-trimethylsilylquinidine (O-TMS QND)45 
 A modified procedure that is described in detail was built on the previously 
reported protocol by Calter and co-workers and applicable for large scale synthesis. O-
trimethylsilyl quinidine 6.9 was prepared by treating commercially available quinidine 
and trimethylchlorosilane in dichloromethane (Scheme 6.7).  Purification via column 
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chromatography was found unnecessary, in this organic syntheses procedure the 
preparation protocol for O-TMS QND 6.9 was modified from the original.   Since O-
TMS quinidine 6.9 is a mixture of two conformers at ambient temperature but low 
temperature 1HNMR allowed two set of data which was also submitted along with the 
procedure for clarity purposes.   
 
Scheme 6.7. Preparation of O-TMS Quinidine 6.9 
 
 
   6.2.5. Asymmetric Synthesis of the Bicyclic β-Lactone 
Finally, the procedure for the asymmetric NCAL reaction for the formation of the 
bicyclic β-lactone 6.4 in large scale (~15–17g) was developed and optimized.    Low 
reaction concentrations were originally used for NCAL reaction; however, for this 
procedure it was found that the reaction could be obtained in higher yield at 0.2–0.4 M 
as compared to 0.05 M, and complete consumption of starting aldehyde acid 6.12 even 
with shorter reaction times.  Due to the amount of by-product such as pyridone derived 
from Mukaiyama reagent, and side-product formed in the reaction, a recrystallization 
protocol for bicyclic β-lactone 6.4 was impossible to obtain.    Due to a high affinity of 
the product with SiO2, β-lactone 6.4 tends to be decomposed under extended exposure to 
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column chromatography and found too difficult to isolate in the pure form.  In this 
procedure, a short column was employed to remove most of by products.  The semi-
crude β-lactone 6.4 after column chromatography could be purified by recrystallization 
using 50% ethyl acetate and 50% hexanes.  Finally, to determine enaniomeric excess of 
β-lactone 6.4, ring opening of the β-lactone by (D)–(+)–α-methylbenzylamine gave two 
diastereomers and enantiomeric ratio of β-lactone could be determined indirectly by 
diasteromeric ratio of 1H NMR;  however, the outcome could have resulted from a 
kinetic resolution.   A direct method was developed by chiral HPLC in place of 
resolution method previously reported by chiral GC using a non-commercially available 
chiral column: 2,3-di-OAc-6-TBS ®-CD (Scheme 6.8) .   
 
Scheme 6.8. Synthesis of Optically Active β-Lactone  
 
 
6.3. Conclusion 
We successfully developed an Organic Syntheses procedure for the asymmetric 
synthesis of (1S,5R)-6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one via the 
nucleophile-catalyzed aldol-lactonization (NCAL).  The advantage of this procedure was 
that an optically active common intermediate (~ 5g, 90% ee) was obtained from achiral 
starting material 25g with a three step sequence (Scheme 6.9).  It was a great challenge 
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to complete the procedure.  The work accomplished resulted from a great team effort 
among a postdoctoral fellow, two graduate students and a summer intern student.  It took 
almost 4 years since the time the project has started until it actually got accepted.  
Although it took a lot of effort to finish this Organic Syntheses procedure, the reward 
was remarkable that the procedure we created would be handy and reliable if someone 
needed to synthesize the same intermediate.  The most important thing was the 
experience that I learned from this opportunity was phenomenal.  This experience gave 
me the idea of how process chemistry is performed in industry.   
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Scheme 6.9. Organic Syntheses Procedure for Optically Active Bicyclic β-Lactone 6.4 
via Asymmetric NCAL Reaction 
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CHAPTER VII 
CONCLUSIONS 
 
Natural products continue to be an important proving ground for synthetic 
chemists due to their diverse molecular architectures and interesting biological activities. 
The potential of human 20S proteasome inhibitors continues to be of interest for 
anticancer chemotherapy and the recent FDA approval of bortezomib (Velcade) 
validates the proteasome as a target for cancer chemotherapy.  Salino A is a unique 
bicyclo [3.2.0] β-lactone-containing natural product.  Salino A is a potent nanomolar 
inhibitor of the proteasome, and is currently in Phase I human clinical studies for 
multiple myeloma following the finding that salino A exhibited great potential in mouse 
models toward several cancers when administered intravenously despite the potentially 
labile β-lactone.   
 We developed a concise, 9-step racemic synthesis of salino A from O-benzyl 
serine, then extended to enantioselective to (–)-salino A.  Our strategy of (–)-salino A 
and derivatives made possible by the A1,3-strain of β-keto tertiary amides which enables 
retention of optical purity during a key bis-cyclization process that simultaneously forms 
the γ-lactam and fused β-lactone core.  In addtion, the key bis-cyclization of a β-
ketoamide, amenable to gram scale, constructs both the γ-lactam and the fused-β-lactone 
in one operation leading to the brevity of the synthesis. The flexibility of the described 
strategy derives from the versatility of the bicyclic core enabling attachment of various 
C4-sidechains, even in the presence of the β-lactone, and the ability to use alternative 
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ketene heterodimers to vary the C2 side chain. Several derivatives including (–)-
homosalino A were synthesized and their activity toward proteasome inhibition was 
evaluated. The ability of the described β-keto tertiary amide substrates to maintain 
stereochemical integrity by virtue of A1,3 strain raises interesting questions regarding 
how such integrity is maintained with β-keto secondary amides, known salino A 
precursors, or if a dynamic kinetic resolution is operative during related biosynthetic 
aldol-lactonizations. 
Finally, an Organic Syntheses procedure for the asymmetric synthesis of (1S,5R)-
6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one via the nucleophile-
catalyzed aldol-lactonization (NCAL) was successfully optimized with other colleagues. 
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APPENDIX A 
  EXPERIMENTAL PROCEDURES AND SELECTED SPECTRA 
 
General 
  
 All reactions were carried out under nitrogen atmosphere in flame-dried glassware. 
Dichloromethane, acetonitrile, methanol, tetrahydrofuran, and ethyl ether were purified by 
passage through activated molecular sieves. Hünig’s base and triethylamine were distilled from 
potassium hydroxide prior to use. All other commercially obtained reagents were used as 
received.  1H NMR chemical shifts are reported as δ values in ppm relative to CDCl3 (7.27 ppm), 
C6D6 (7.15 ppm), C2D6O (2.05 ppm) and coupling constants (J) are reported in Hertz (Hz). 
Unless indicated otherwise, deuterochloroform (CDCl3) served as an internal standard (77.23 
ppm), C6D6 (128.39 ppm), C2D6O (29.92 ppm) for all 13C spectra. Flash column chromatography 
was performed using 60Å Silica Gel (Silicycle, 230-400 mesh) as a stationary phase. Mass 
spectra were obtained at the Center for Chemical Characterization and Analysis (Texas A&M 
University). Thin layer chromatography (TLC) was performed using glass-backed silica gel 
60F254 (250 µm thickness). 
Procedure 
 
Representative Procedure for Ketene Dimerization1 as Described for Homodimer (±)-
2.13a: To a solution of 3-cyclohexyl propionyl chloride (17.5 g, 100 mmol) in Et2O (75 mL) was 
added triethylamine (16.0 mL, 110 mmol) at a rate sufficient to maintain gentle refluxing. 
                                                 
1
 (a) Duffy, R. J.; Morris, K. A.; Romo, D. J. Am. Chem. Soc., 2005, 127, 16754-16755.  (b) Purohit, V. C.; Richardson, R. D.; Smith, J. W.; 
Romo, D. J. Org. Chem. 2006, 71, 4549-4558. 
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During addition of triethylamine, a white solid precipitated. After complete addition of 
triethylamine, the reaction mixture was refluxed for an additional 1 h, cooled to ambient 
temperature, and filtered through a pad of Celite and SiO2. The filtrate was concentrated under 
reduced pressure and the residue was purified by flash chromatography (95:5 pentane:Et2O) to 
afford ketene dimer (±)-2.13a (8.25 g, 60 %) as a colorless oil. 
 
 
Homodimer (±)-2.13b:1 Prepared according to the representative procedure using octanoyl 
chloride (5.4 g, 33 mmol) in Et2O (25 mL) and triethylamine (5.2 mL, 37 mmol). Purification by 
flash chromatography on SiO2 (95:5 pentane:Et2O) gave ketene dimer (±)-2.13b (3.0 g, 65%) as 
a clear oil. Rf = 0.74 (20% EtOAc/hexanes); IR (neat) 1875, 1726cm-1cm-1; 1H NMR (500 MHz, 
C6D6) δ 4.36 (dt, J = 1.5, 7.5 Hz, 1H), 3.33 (dt, J = 1.0, 7.0 Hz, 1H), 2.01-2.15 (m, 2H), 1.02-
1.36 (m, 18H), 0.87 (t, J = 7.0 Hz, 3H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, C6D6) 
δ169.0, 146.5, 101.0, 54.0, 31.9, 31.7, 29.8, 29.10, 29.08, 27.6, 26.5, 25.0, 23.0, 22.8, 14.3, 14.2; 
LRMS (CI) Calcd. for C16H28O2 [M+H] 253, found 253. 
 
 
Homodimer (±)-2.13c:1 Prepared according to the representative procedure using 
hydrocinnamoyl chloride (5.0 g, 30 mmol) in diethyl ether (25 mL) and triethylamine (4.6 mL, 
33 mmol). Purification by flash chromatography on SiO2 (95:5 pentane:Et2O) gave ketene dimer 
(±)-2.13c (1.75 g, 46%) as a clear oil. 
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Homodimer (±)-2.13d: To a solution of 4-chlorobutyrylchloride (5.64 mL, 0.05 mol) in Et2O 
(50 mL) was added triethylamine (8.4 mL, 0.06 mol) via a syringe pump at 23 oC for a period of 
1 h. During addition of triethylamine, a salt precipitated as a white solid. After stirring for an 
additional 90 min, the reaction mixture was diluted with hexanes (75 mL), filtered through a pad 
of SiO2 via a fritted funnel, and then the pad of SiO2 was washed with 200 mL of 40% 
Et2O/hexanes.  The combined filtrates were concentrated under reduced pressure and the residue 
was purified by flash chromatography (95:5 pentane/Et2O) gave ketene dimer (±)-2.13d (2.25 g, 
43 %) as a colorless oil.  Rf = 0.29 (90% pentane/ether); IR (neat) 1874, 1726cm-1; 1H NMR (500 
MHz, C6D6) δ 4.20 (t, J = 7.0 Hz, 1H), 3.36 (t, J = 7.0 Hz, 1H), 2.98-3.01 (m, 2H), 2.92-2.96 (m, 
1H), 2.86-2.90 (m, 1H), 2.09-2.21 (m, 2H), 1.30-1.45 (m, 2H); 13C NMR (125 MHz, C6D6) δ 
167.7, 147.3, 98.2, 51.7, 44.1, 41.4, 30.4, 28.5; LRMS (EI) Calcd. for C8H10Cl2O2 [M] 208, 
found 208. Satisfactory HRMS could not be obtained for this compound by MALDI or ESI. 
 
 
Heterodimer (±)-2.11a: To a 2-neck 500 mL round bottom flask fitted with a condenser, acetyl 
chloride (11.0 mL, 0.156 mol), 4-chlorobutyrylchloride (14.7 mL, 0.130 mol), and  Et2O (200 
mL) was added, followed by triethylamine (43.9 mL, 0.312 mol) via a syringe pump at 23 oC for 
a period of 1 h. During addition of triethylamine, the triethylamine hydrochloride salt 
precipitated as a white solid. After stirring for an additional 1 h, the reaction mixture was diluted 
 107 
 
with hexanes (300 mL) and filtered through a pad of SiO2 via a fritted funnel. The pad of SiO2 
was then washed with 300 mL of 40% Et2O/hexanes.  The combined filtrates were concentrated 
under reduced pressure, and the residue was purified by flash chromatography (95/5 
pentane/Et2O) to afford ketene-dimer (±)-2.11a (2.3 g, 13 %) as a clear oil. Rf = 0.41 (9:1 
pentane/Et2O); IR (neat) 1860, 1694 cm-1; 1H NMR (300 MHz, benzene-d6) δ 4.41 (dd, J = 2.1, 
4.5 Hz, 1H), 3.80 (dd, J = 1.5, 4.5 1H), 3.35 (t, J = 7.8 Hz, 1H), 2.79-2.95 (m, 2H), 1.25-1.46 (m, 
2H); 13C NMR (125 MHz, benzene-d6) δ 167.4, 152.6, 85.7, 51.7, 40.9, 29.9; LRMS (CI) Calcd. 
for C6H8ClO2 [M+H] 147, found 147. 
 
 
Heterodimer (±)-2.11b: To a solution of acetyl chloride (7.5 mL, 0.105 mol) and 
valerylchloride (10.4 mL, 0.081mol) in Et2O (200 mL) was added triethylamine (29.6 mL, 0.211 
mol) via a syringe pump at 0 oC for a period of 1h. During addition of triethylamine, the 
triethylamine hydrochloride salt precipitated as a white solid. After stirring for an additional 10 
min at 0 oC, the reaction mixture was removed from the ice-bath and stirring was continued at 23 
oC for 45 min. The reaction mixture was diluted with hexanes (300 mL), filtered through a pad of 
SiO2 via a fritted funnel, and then the pad of SiO2 was washed with 300 mL of 40% 
Et2O/hexanes.  The combined filtrates were concentrated under reduced pressure and the residue 
was purified by flash chromatography (95:5 pentane/Et2O) to afford ketene dimer (±)-2.11b (1.3 
g, 10 %) as a clear oil. Rf = 0.51 (20% EtOAc/hexanes); IR (neat) 1860, 1694 cm-1; 1H NMR 
(500 MHz, benzene-d6) δ 4.43 (dd, J = 1.5, 4.5 Hz, 1H), 3.79 (dd, J = 1.5, 4.5 Hz, 1H), 2.98-3.01 
(m, 1H), 2.80-2.83 (m, 2H), 1.25-1.36 (m, 1H), 1.16-1.24 (m, 3H); 13C NMR (125 MHz, 
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benzene-d6) δ 168.2, 153.7, 85.6, 54.1, 44.1, 29.3, 24.8; LRMS (CI) Calcd. for C6H10ClO2 
[M+H] 161, found 161. 
 
 
Representative Procedure for Ring Opening of Ketene Dimers to Give β-Ketoamides as 
Described for β-Ketoamide (±)-2.20a: To a solution of (4-methoxy-benzylamino)-acetic acid 
benzyl ester (178 mg, 0.624 mmol) and 2-hydroxypyridine (59 mg, 0.624 mmol) in THF (2 mL) 
was added ketene dimer (±)-2.13a (259 mg, 0.936 mmol). The reaction mixture was stirred at 50 
°C for 24h (or treated at 60 °C for 3h with microwave irradiation) and the solvent was 
evaporated under reduced pressure. The residue was purified by flash chromatography (1:4 
EtOAc/hexanes) to afford keto ester (±)-2.20a (303 mg, 86%) as a colorless oil and as a 2.2:1 
ratio of rotamers: IR (neat) 1749, 1652 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.30-7-40 (m, 5 H), 
7.07-7.13 (m, 2 H), 6.81-6.89 (m, 2 H), 5.15 (s, 1.4 H), 5.14 (0.6 H), 4.73 (d, J = 16.5 Hz, 0.7H), 
4.68 (d, J = 15.3 Hz, 0.3H), 4.49 (d, J = 15.6 Hz, 0.3H), 4.43 (d, J = 16.5 Hz, 0.7H), 4.27 (d, J = 
17.1 Hz, 0.7H), 4.13 (d, J = 18.6 Hz, 0.3H), 3.94 (d, J = 17.4 Hz, 0.7H), 3.93 (d, J = 18.3 Hz, 
0.3H), 3.78-3.83 (m, 3.7 H) 3.55 (t, J = 9.0 Hz, 0.3H), 2.40-2.58 (m, 2H), 0.76-1.94 (m, 26H); 
13C NMR were complex due to the presence of rotamers and attempted VT NMR did not lead to 
coalescence so these are not included; LRMS (ESI Calcd. For C35H47NO5 [M+H] 561, found 
562. 
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β-Ketoamide (±)-2.20b: Prepared according to the representative procedure using (4-methoxy-
benzylamino)-acetic acid benzyl ester (910 mg, 3.02 mmol), 2-hydroxypyridine (304 mg, 3.02 
mmol) in THF (13 mL), and ketene dimer (±)-2.13b (800 mg, 3.02 mmol). Purification by flash 
chromatography on SiO2  (1:4 EtOAc/hexanes) gave keto ester (±)-2.20b (1.36 g, 82%) as a 
colorless oil and as a 2.2:1 ratio of rotamers: IR (neat) 1750, 1646 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 7.31 – 7.38 (m, 5H), 7.11 (d, J = 8.0 Hz, 0.6H), 7.08 (d, J = 8.5 Hz, 1.4H), 6.87 (d, J = 
8.5 Hz, 1.4H), 6.82 (d, J = 8.5 Hz, 0.6H), 5.09-5.17 (m, 2H), 4.72 (d, J = 16.5 Hz, 0.7H), 4.64 (d, 
J = 15.0 Hz, 0.3H), 4.53 (d, J = 15.0 Hz, 0.3H), 4.43 (d, J = 16.5 Hz, 0.7H), 4.25 (d, J = 17.5 Hz, 
0.7H), 4.13 (d, J = 19.0 Hz, 0.3H), 3.93 (d, J = 18.5 Hz, 0.3H), 3.92 (d, J = 17.5 Hz, 0.7H), 3.80 
(s, 2.1H), 3.78 (s, 0.9H), 3.65 (t, J = 7.0 Hz, 0.7H), 3.40 (t, J = 7.0 Hz, 0.3H), 2.42-2.57 (m, 2H), 
1.94-2.01 (m, 1H), 1.79-1.86 (m, 1H), 1.47-1.55 (m, 2H), 1.17-1.31 (m, 16H), 0.86-0.90 (m, 
6H); 13C NMR were complex due to the presence of rotamers and attempted VT NMR did not 
lead to coalescence so these are not included; LRMS (ESI) Calcd. for C33H47NO5 [M+Li] 544, 
found 544. 
 
 
β-Ketoamide (±)-2.20c: Prepared according to the representative procedure using (4-methoxy-
benzylamino)-acetic acid benzyl ester (636 mg, 2.23 mmol), 2-hydroxypyridine (212 mg, 2.23 
mmol) in THF (22 mL), and ketene dimer (±)-2.13c (588 mg, 2.22 mmol). Purification by flash 
chromatography on SiO2  (1:4 EtOAc/hexanes) gave keto ester (±)-2.20c (1.04 g, 85%) as a 
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colorless oil. 2.2:1 ratio of rotamers: IR (neat) 1745, 1642 cm-1; 1H NMR (500 MHz, CDCl3) δ 
7.08-7.38 (m, 15H), 6.98 (d, J = 8.5 Hz, 0.6H), 6.78 (d, J = 9.0 Hz, 0.6H), 6.72 (d, J = 8.5 Hz, 
1.4H), 6.69 (d, J = 9.0 Hz, 1.4H), 5.14 (s, 1.4H), 5.05 (s, 0.6H), 4.77 (d, J = 14.5 Hz, 0.3H), 4.56 
(d, J = 16.5 Hz, 0.7H), 4.31 (d, J = 17.5 Hz, 0.7H), 4.28 (d, J = 12.5 Hz, 0.3H), 4.18 (d, J = 16.5 
Hz, 0.7H), 3.96 (d, J = 8.5 Hz, 0.3H), 3.95 (d, J = 9.0 Hz, 0.3H), 3.79 (s, 0.9H), 3.78 (s, 2.1H), 
3.64-3.72 (m, 1.7H), 3.29 (dd, J = 9.0, 14.0 Hz, 0.7H), 3.16-3.24 (m, 0.6H), 3.12 (dd, J = 5.5, 
13.5 Hz, 0.7H), 2.77-2.96 (m, 4H); 13C NMR were complex due to the presence of rotamers and 
attempted VT NMR did not lead to coalescence so these are not included; LRMS (ESI) Calcd. 
for C35H35NO5 [M+Li] 556, found 556. 
 
N
PMB
O O
BnO2C
 
β-Ketoamide (±)-2.20e:  Prepared according to the representative procedure using (4-methoxy-
benzylamino)-acetic acid benzyl ester (910 mg, 3.19 mmol), 2-hydroxypyridine (304 mg, 3.20 
mmol) in THF (25 mL), and commercially available ketene dimer 2.13e (1.0 mL, 16 mmol). 
Purification by flash chromatography on SiO2 (1:4 EtOAc/hexanes) gave keto ester 2.20e (930 
mg, 78%) as a colorless oil.  Due to the presence of enol tautomers and amide rotamers, the 
NMR spectra of this compound is extremely complex and so line listing is not provided. 
 
 
Representative Procedure for Preparation of Ketoacid Intermediate from Benzyl Ester as 
Described for β-Ketoacid (±)-2.21a: A racemic mixture of ketoamide benzyl ester (±)-2.20a 
 111 
 
(270 mg, 0.481 mmol), and 10 wt% palladium on carbon (27 mg) in THF (10 mL) was stirred at 
ambient temperature for 3 h under H2 atmosphere.  The reaction mixture was filtered through a 
pad of Celite, and concentrated to afford keto acid (±)-2.21a (222 mg, 98%) as a white solid and 
as a 2.2:1 ratio of two rotamers: IR (neat) 1729, 1652 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.13 
(d, J = 8.5 Hz, 0.6H), 7.09 (d, J = 8.5 Hz, 1.4H), 6.89 (d, J = 9.0 Hz, 1.4H), 6.84 (d, J = 9.0 Hz, 
0.6H), 4.71 (d, J = 16.5 Hz, 0.7H), 4.68 (d, J = 13.5 Hz, 0.3H), 4.47 (d, J = 15.0 Hz, 0.3H), 4.42 
(d, J = 16.5 Hz, 0.7H), 4.25 (d, J = 17.5 Hz, 0.7H), 4.13 (d, J = 19.0 Hz, 0.3H), 3.94 (d, J = 18.0 
Hz, 0.3H), 3.90 (d, J = 17.0 Hz, 0.7H), 3.81 (s, 3H), 3.79 (dd, J = 1.5, 4.5 Hz, 0.7H), 3.57 (t, J = 
7.0 Hz, 0.3H), 2.44-2.56 (m, 2H), 1.88-1.94 (m, 1H), 1.54-1.74 (m, 11H), 1.35-1.43 (m, 2H), 
1.07-1.20 (m, 8H), 0.78-0.92 (m, 4H); LRMS (APCI) Calcd. for C28H41NO5 [M–H] 470, found 
470. 
 
 β-Ketoacid (±)-2.21b: Prepared according to the representative procedure for preparation of 
ketoacid intermediate from benzyl ester (±)-2.20b (415 mg, 0.772 mmol), 10 wt% palladium on 
carbon (40 mg) in THF (10 mL) afford keto acid (±)-2.21b (340 mg, 98%) as a colorless oil and 
as a 3:1 ratio of rotamers: IR (neat) 1721, 1649, 1614 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.13 
(d, J = 8.5 Hz, 0.5H), 7.09 (d, J = 8.5 Hz, 1.5H), 6.89 (d, J = 9.0 Hz, 1.5H), 6.84 (d, J = 8.5 Hz, 
0.5H), 4.71 (d, J = 16.5 Hz, 0.75H), 4.65 (d, J = 14.5 Hz, 0.25H), 4.51 (d, J = 14.5 Hz, 0.25H), 
4.42 (d, J = 16.5 Hz, 0.75H), 4.23 (d, J = 17.5 Hz, 0.75H), 4.12 (d, J = 19.0 Hz, 0.25H), 3.94 (d, 
J = 19.0 Hz, 0.25H), 3.89 (d, J = 17.5 Hz, 0.75H), 3.81 (s, 2.25H), 3.79 (s, 0.75H), 3.66 (dd, J = 
6.0, 8.0 Hz, 0.75H), 3.43 (t, J = 7.0 Hz, 0.25H), 2.45-2.55 (m, 2H), 1.95-2.04 (m, 1H), 1.79-1.87 
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(m, 1H), 1.48-1.55 (m, 2H), 1.16-1.34 (m, 16H), 0.85-0.88 (m, 6H); LRMS (ESI) Calcd. for 
C26H41NO5 [M-H] 446, found 446. 
 
 
β-Ketoacid (±)-2.21c: Prepared according to the representative procedure for preparation of 
ketoacid intermediate from benzyl ester (±)-2.20c (985 mg, 1.79mmol), 10 wt% palladium on 
carbon (99 mg) in a mixture of solvent THF (20 mL) and MeOH (4 mL) afforded ketoacid (±)-
2.21c (0.70g, 85%) as a white solid and as a 2.2:1 ratio of rotamers: IR (neat) 1722, 1634, 1612 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.10-7.28 (m, 10H), 6.98 (d, J = 8.5 Hz, 0.6H), 6.79 (d, J = 
9.0 Hz, 0.6H), 6.73 (d, J = 9.0 Hz, 1.4H), 6.69 (d, J = 9.0 Hz, 1.4H), 4.81(d, J = 15.0 Hz, 0.3H), 
4.50 (d, J = 16.5 Hz, 0.7H), 4.22 (d, J = 14.5 Hz, 0.3H), 4.21 (d, J = 17.0 Hz, 0.7H), 4.14 (d, J = 
16.5 Hz, 0.7H), 3.96 (d, J = 9.0 Hz, 0.3H), 3.95 (d, J = 9.0 Hz, 0.3H), 3.78 (s, 0.9H), 3.77 (s, 
2.1H), 3.69 (d, J = 17.5 Hz, 0.7H), 3.30 (dd, J = 9.0, 13.0 Hz, 0.7H), 3.24 (dd, J = 9.0, 13.0 Hz, 
0.3H), 3.18 (dd, J = 5.0, 13.5 Hz, 0.3H), 3.12 (dd, J = 5.0, 13.5 Hz, 0.7H), 2.76-2.97 (m, 5H); 
LRMS (ESI) Calcd. for C28H29NO5 [M-H] 458, found 458. 
 
 
β-Ketoacid 2.21e: Prepared according to the representative procedure for preparation of 
ketoacid intermediate from benzyl ester 2.20e (0.320 mg, 0.866 mmol), 10 wt% palladium on 
carbon (35 mg) in THF (10 mL) afford ketoacid 2.21e (250 mg, 99%) as a colorless oil.  IR 
(neat) 1723, 1612 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.0 
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Hz, 2H), 4.51 (s, 2H), 4.05 (s, 2H), 3.81 (s, 3H), 3.68 (s, 2H), 2.30 (s, 3H) (only major peaks 
were assigned); LRMS (ESI) Calcd. for C14H17NO5 [M–H] 278, found 278. 
 
 
Representative Procedure for Preparation of β-Lactone via Bis-Cyclization as Described 
for β-Lactone, (±)-2.23a: To a suspension of N-propyl-2-bromo pyridinium triflate (95 mg, 0.27 
mmol) and 4-pyrrolidinopyridine (40 mg, 0.27 mmol) in CH2Cl2 (4 mL) was added Hünig’s base 
(63 µL, 0.36 mmol) at 0 °C. After stirring for 10 min, a solution of ketoacid (±)-2.21a (85 mg, 
0.18 mmol) in CH2Cl2 (3 mL) was added via syringe pump over 1 h at 0 °C. The resulting 
suspension was stirred for 2 h at 0 °C. The crude reaction mixture was diluted with Et2O (50 mL) 
and washed with aqueous NH4Cl solution and brine (each 30 mL). The organic layer were dried 
over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (1:10 
EtOAc/hexanes) to give a mixture of two diastereomeric β-lactones (76 mg, 93%, dr 2.2:1) as a 
colorless oil. (±)-2.23a (major): Rf = 0.76 (40% EtOAc/hexanes); IR (neat) 1825, 1709 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 7.20 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.03 (d, J = 14.5 
Hz, 1H), 4.34 (s, 1H), 4.04 (d, J = 14.5 Hz, 1H), 3.81 (s, 3H), 2.70 (dd, J = 6.0, 7.5 Hz, 1H), 
1.86-1.97 (m, 2H), 1.60-1.81 (m, 11H), 1.08-1.32 (m, 10H), 0.80-1.00 (m, 5H); 13C NMR (75 
MHz, CDCl3) δ 174.7, 166.2, 159.5, 130.0, 126.8, 114.3, 83.1, 68.2, 53.3, 45.2, 43.8, 37.3, 34.8, 
33.6, 33.4, 33.2, 32.9, 32.6, 32.5, 31.2, 26.5, 26.4, 26.2, 26.1, 26.0 (2); LRMS (ESI) Calcd. for 
C28H39NO4 [M+Li] 460, found 460. 
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β-Lactone (±)-2.23b: Prepared according to the representative procedure for preparation of β-
lactone via bis-cyclization using N-propyl-2-bromo pyridinium triflate (141 mg, 0.402 mmol), 4-
pyrrolidinopyridine (60 mg, 0.40 mmol), Hünig’s base (93 µL, 0.54 mmol), and ketoacid  (±)-
2.21b (120 mg, 0.268 mmol) in CH2Cl2  (11 mL). Purification by flash chromatography on SiO2  
(1:10 EtOAc/hexanes) gave a mixture of two diastereomeric β-lactones (104 mg, 90%, dr = 
2.2:1). (±)-2.23b (major): IR (neat) 1836, 1705 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.20 (d, J = 
8.5 Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 5.04 (d, J = 15.0 Hz, 1H), 4.36 (s, 1H), 4.05 (d, J = 15.0 
Hz, 1H), 3.80 (s, 3H), 2.55 (dd, J = 5.5, 9.0 Hz, 1H), 1.85-2.00 (m, 3H), 1.69-1.77 (m, 1H), 1.47-
1.58 (m, 2H), 1.18-1.39 (m, 16H), 0.89 (t, J = 6.8 Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 174.5, 166.3, 159.7, 130.2, 127.0, 114.5, 83.0, 68.5, 55.4, 47.4, 45.4, 35.6, 
31.74, 31.68, 29.5, 29.4, 29.1, 28.0, 26.3, 24.0, 22.8, 22.7, 14.24, 14.19; LRMS (ESI) Calcd. for 
C26H39NO4 [M+H] 430, found 430. 
 
 
β-Lactone (±)-2.23c: Prepared according to the representative procedure for preparation of β-
lactone via biscyclization using N-propyl-2-bromo pyridinium triflate (84.6 mg, 0.245 mmol), 4-
pyrrolidinopyridine (36.2 mg, 0.245 mmol), Hünig’s base (57 µL, 0.33 mmol), and ketoacid  (±)-
2.21c (75 mg, 0.16 mmol) in CH2Cl2  (6.5 mL). Purification by flash chromatography on SiO2 
(1:4 EtOAc/hexanes) gave two diastereomeric β-lactones (61 mg, 85%, dr = 2.5:1). (±)-2.23c 
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(major): Rf = 0.29 (20% EtOAc/hexanes); IR (neat) 1830, 1702, 1612 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 6.83-7.34 (m, 14H), 4.99 (d, J = 15.0 Hz, 1H), 4.12 (s, 1H), 4.07 (d, J = 14.0 Hz, 1H), 
3.83 (s, 3H), 3.38 (dd, J = 3.0, 13.0 Hz, 1H), 2.98 (dd, J = 11.5, 13.0 Hz, 1H), 2.92  (dd, J = 3.5, 
11.5 Hz, 1H), 2.34-2.43 (m, 2H), 1.63-1.79 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 172.8, 166.1, 
159.7, 139.3, 138.6, 130.4, 129.4, 128.9, 128.8, 128.1, 127.0, 126.7, 126.6, 114.5, 82.5, 68.8, 
55.5, 49.7, 45.6, 36.2, 31.6, 30.1; LRMS (ESI) Calcd. for C28H27NO4 [M+H] 442, found 442. 
 
 
β-Lactone (±)-2.23d: To a suspension of N-propyl-2-bromo pyridinium triflate (130 mg, 0.371 
mmol) and 4-pyrrolidinopyridine (53 mg, 0.371 mmol) in CH2Cl2 (6 mL) was added Hünig’s 
base (63 µL, 0.494 mmol) at 0 °C. After stirring for 10 min, a solution of the crude ketoacid 
2.21d from hydrogenolysis (100 mg, 0.247mmol) in CH2Cl2 (4 mL) was added via syringe pump 
over 1 h at 0 °C. The resulting suspension was stirred for 2 h at 0 °C. The crude reaction mixture 
was diluted with Et2O (70 mL) and washed with aqueous NH4Cl solution and brine (30 mL of 
each). The organic layer was dried over MgSO4, filtered, and concentrated. The residue was 
purified by flash chromatography (1:10 EtOAc/hexanes) to give a mixture of two diastereomeric 
β-lactones (67 mg, 70%, dr 4:1) as a colorless oil. (±)-2.23d (major): Rf = 0.66 (40% 
EtOAc/hexanes); IR (neat) 1832, 1702 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.22 (d, J = 14.5 Hz, 
2H), 6.90 (d, J = 14.5 Hz, 2H), 5.05 (d, J = 24.5 Hz, 1H), 4.45 (s, 1H), 4.02-4.10 (m, 1H), 4.06 
(d, J = 24.5 Hz, 1H), 3.82 (s, 3H), 3.73-3.81 (m, 1H), 3.49-3.62 (m, 2H), 2.98 (t, J = 12 Hz, 1H), 
2.26-2.40 (m, 1H), 2.05-2.24 (m, 3H), 1.84-1.93 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 173.1, 
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165.1, 159.6, 130.1(2C), 126.3, 114.4(2C), 81.4, 68.9, 53.3, 45.3, 43.8, 43.7, 42.4, 32.4, 29.0, 
26.6; LRMS (ESI) Calcd. for C18H22Cl2NO4 [M+H] 386, found 386. 
 
 
β-Lactone (±)-2.23e: Prepared according to the representative procedure for preparation of β-
lactone via biscyclization using N-propyl-2-bromo pyridinium triflate (188 mg, 0.537 mmol), 4-
pyrrolidinopyridine (79.6 mg, 0.577 mmol), Hünig’s base (125 µL, 0.716 mmol), and ketoacid 
2.21e (100 mg, 0.358 mmol) in CH2Cl2  (14 mL). Purification by flash chromatography on SiO2 
(2:3 EtOAc/hexanes) gave β-lactone (±)-2.23e (23 mg, 25%). Rf = 0.14 (33% EtOAc/hexanes); 
IR (neat) 1836, 1702 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.24 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 
8.4 Hz, 2H), 5.06 (d, J = 14.7 Hz, 1H), 4.41 (s, 1H), 4.07 (d, J = 14.7 Hz, 1H), 3.82 (s, 3H), 3.05 
(d, J = 18.9 Hz, 1H), 2.70 (d, J = 18.6 Hz, 1H), 1.70 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
171.4, 165.8, 159.8, 130.4, 126.7, 114.5, 77.9, 71.7, 55.5, 45.5, 41.6, 22.2; LRMS (APCI) Calcd. 
for C14H15NO4 [M+Li] 268, found 268. 
 
 
PMB-Deprotection of β-lactone, (±)-2.24a: To a solution of (±)-2.23a (20 mg, 0.044 mmol) in 
CH3CN (1 mL) was added an aqueous solution of CAN (123 mg, 0.225 mmol) in H2O (0.4 mL) 
at 0 °C dropwise. After stirring at ambient temperature for 1 h, the reaction mixture was diluted 
with saturated NaHCO3 (2 mL) and extracted with EtOAc (20 mL x 3). The combined organic 
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layer was washed with brine, dried over MgSO4, filtered and concentrated. The residue was 
purified by flash chromatography (1:6 to 1:1 EtOAc/hexanes) to give the desired product (±)-
2.24a (13 mg, 89%) as a white solid. A crystal suitable for X-ray analysis was obtained by slow 
evaporation from Et2O with ~5% CH2Cl2.  Rf = 0.55 (40% EtOAc/hexanes); IR (neat) 1832, 
1709 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.48 (s, 1H), 4.61 (s, 1H), 2.62 (dd, J = 6.5, 8.5 Hz, 
1H), 1.98-2.02 (m, 2H), 1.51-1.81 (m, 13H), 1.12-1.35 (m, 9H), 0.87-0.98 (m, 4H); 13C NMR 
(125 MHz, CDCl3) δ 178.4, 166.7, 85.6, 65.2, 42.8, 37.5, 34.7, 33.7, 33.2, 33.1, 32.9, 32.7, 32.5, 
31.4, 26.44, 26.37, 26.12, 26.09, 26.08, 26.0; LRMS (ESI) Calcd. for C20H31NO3 [M+H] 334, 
found 334. 
 
Procedure for Racemic Synthesis of (±)-Salinosporamide A 
 
(S)-O-Benzyl Serine Allyl Ester 2.34: To the suspension of (S)-O-benzyl serine 2.10 (3.85 g, 
19.6 mmol) and p-anisaldehyde (3.21 g, 23.5 mmol) in MeOH (40 mL) was added triethylamine 
(3.28 mL, 23.5 mmol) at ambient temperature. The resulting suspension was stirred at ambient 
temperature for 1 h. The resulting solution was diluted with additional MeOH (40 mL) and 
NaBH4 (1.11 g, 29.4 mmol) was added at 0 °C portionwise. After stirring at ambient temperature 
for 2 h, all volatiles were removed under reduced pressure. The remained solid was dissolved in 
water (50 mL) and acidified to pH 2 with 1 N HCl. The precipitate white solid was filtered, 
washed with water (2 X 30 mL) and Et2O (2 X 30 mL), and dried under vacuum to give O-
benzyl-N-PMB serine (5.21g, 84%) as a white solid. 
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The suspension of O-benzyl-N-PMB serine (12.8 g, 40.6 mmol) and p-TsOH (9.65 g, 
50.8 mmol) in allyl alcohol (30 mL) and benzene (100 mL) was stirred at reflux with a Dean-
Stark apparatus until the calculated amount of water had been collected. The resulting solution 
was concentrated in vacuo, re-suspended in 5% aqueous NaHCO3 (100 mL), the pH was adjusted 
to 9.0 with 1 M NaOH, and the product was extracted with Et2O:EtOAc (1:1, 100 mL x 3). The 
organic layer was washed with brine, dried over Na2SO4, and concentrated. The residue was 
purified by flash chromatography (1:6 EtOAc/hexanes) to give the desired allyl ester 2.34 (12.7 
g, 88%) as a yellow oil. Rf = 0.61 (33% EtOAc/hexanes); IR (neat) 1738, 1612 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.25-7.35 (m, 7 H), 6.90 (d, J = 8.5 Hz, 2H), 5.87-5.95 (m, 1 H), 5.22-5.35 
(m, 2 H), 4.69 (dt, J = 1.2, 5.7 Hz, 2H), 4.58 (d, J = 12.3 Hz, 1H), 4.53 (d, J = 12.0 Hz, 1H), 3.89 
(d, J = 12.6 Hz, 1H), 3.82 (s, 3H), 3.70-3.82 (m, 2H), 3.71 (d, J = 13.2 Hz, 1H), 3.57 (t, J = 4.8 
Hz, 1H), 2.28 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 173.1, 158.9, 138.1, 132.2, 131.9, 129.8 
(2C), 128.6 (2C), 127.9, 127.8(2C), 118.7, 114.0 (2C), 73.4, 71.3, 65.7, 60.6, 55.5, 51.6; LRMS 
(ESI) Calcd. for C21H26NO4 [M+H] 356, found 356. 
 
 
β-Ketoamide 2.35a/2.35b:  Prepared according to the representative procedure for ring opening 
of hetero-ketene dimers using allyl ester 2.34 (1.92 g, 5.40 mmol), 2-hydroxypyridine (642 mg, 
6.75 mmol) in THF (14 mL), and ketene dimer (±)-2.11a (990 mg, 6.75 mmol).  The reaction 
mixture was stirred at 60 °C for 36 h and purification by flash chromatography on SiO2  (1:4 
 119 
 
EtOAc:Hexanes) gave a mixture of two diastereomers 2.35a/2.35b (2.17 g, 80%, dr 1:1) as a 
colorless oil.  
2.35a: Rf = 0.58 (40% EtOAc/Hexanes); 1H NMR (500 MHz, CDCl3) δ 7.18-7.36 (m, 7H), 6.87 
(d, J = 8.0 Hz, 2H), 5.85-5.93 (m, 1H), 5.24-5.33 (m, 2H), 4.82 (d, J = 16.5 Hz, 1H), 4.66 (d, J = 
17.0 Hz, 1H), 4.59-4.61 (m, 2H), 4.50 (dd, J = 4.0, 8.5 Hz, 1H), 4.47 (d, J = 11.5 Hz, 1H), 4.44 
(d, J = 11.5 Hz, 1H), 4.08 (dd, J = 8.5, 10.0 Hz, 1H), 4.01 (dd, J = 3.5, 10.0 Hz, 1H), 3.93 (dd, J 
= 5.5, 8.5 Hz, 1H), 3.81 (s, 3H), 3.46-3.58 (m, 2H), 2.34-2.43 (m,1H), 2.17-2.24 (m, 1H), 2.11 
(s, 3H); LRMS (APCI) Calcd. for C27H32ClNO6 [M+H] 502, found 502.  2.35b: Rf = 0.50 (40% 
EtOAc/Hexanes); IR (neat) 1738, 1642, 1613 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.25-7.36 (m, 
7H), 6.89 (d, J = 8.5 Hz, 2H), 5.86-5.94 (m, 1H), 5.24-5.33 (m, 2H), 4.88 (d, J = 16.5 Hz, 1H), 
4.69 (d, J = 17.0 Hz, 1H), 4.57-4.66 (m, 3H), 4.50 (d, J = 11.5 Hz, 1H), 4.45 (d, J = 11.5 Hz, 
1H), 4.03-4.06 (m, 2H), 3.92 (t, J = 7.0 Hz, 1H), 3.82 (s, 3H), 3.57 (t, J = 6.0 Hz, 2H), 2.34-2.41 
(m, 1H), 2.15-2.21 (m, 1H), 1.97 (s, 3H); 13C (125 MHz, CDCl3) δ 202.5, 170.9, 168.5, 159.5, 
137.8, 131.8, 128.8, 128.7, 128.6, 128.0, 127.9, 119.1, 114.4, 73.6, 68.5, 66.3, 60.3, 55.5, 53.7, 
52.7, 43.3, 31.9, 28.7; LRMS (APCI) Calcd. for C27H32ClNO6 [M+H] 502, found 502.   
 
CO2allyl
PMBN O
O
BnO
2.35a/b
Cl
CO2H
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O
BnO
2.36a/b
Cl
 
β-Keto Acid 2.36a/b: To a solution of allyl ester 2.35a/b (1.24 g, 2.47 mmol) in THF (20 mL) 
was added morpholine (646 mg, 7.41 mmol) and Pd(PPh3)4 (29 mg, 0.025 mmol) at ambient 
temperature. The reaction mixture was stirred at ambient temperature for 3 h and diluted with 
Et2O (200 mL). The organic layer was washed with 0.2 N HCl and brine, dried over MgSO4 and 
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concentrated.  The residue was purified by flash chromatography on SiO2 (15:85 
acetone/dichloromethane) to give acid 2.36a/b (620 mg, 75%). Data for 2.36a: IR (neat) 
1721, 1639cm-1; 1H NMR (300 MHz, CDCl3) δ 7.20-7.40 (m, 7H), 6.89 (d, J = 8.7 Hz, 2H), 4.82 
(d, J = 16.5 Hz, 1H), 4.70 (d, J = 16.5 Hz, 1H), 4.48 (s, 2H), 4.41-4.45 (m, 1H), 4.00-4.10 (m, 
3H), 3.84 (s, 3H), 3.50-3.65 (m, 2H), 2.20-2.50 (m, 2H), 2.13 (s, 3H); LRMS (ESI) Calcd. for 
C24H28ClNO6 [M–H] 460, found 460. 
 
 
Benzyloxy-β-Lactone (±)-2.37: Prepared according to the representative procedure for bis-
cyclization process using N-propyl-2-bromo pyridinium triflate (273 mg, 0.789 mmol), 4-
pyrrolidinopyridine (223 mg, 1.56 mmol), Hünig’s base (70 µL, 0.39 mmol), and ketoacid 
2.36a/b (180 mg, 0.390 mmol) in CH2Cl2 (15 mL).  Purification by flash chromatography (SiO2, 
10% EtOAc/hexanes) gave a mixture of two diastereomeric β-lactones 2.37a and 2.37b (59 mg, 
34 %, dr = 2:1, 500 MHz 1H NMR). Data for (±)-2.37a: Rf = 0.32 (20% EtOAc/hexanes); IR 
(neat) 1830, 1703 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32-7.36 (m, 3H), 7.13-7.15 (m, 4H), 
6.80 (d, J = 8.5 Hz, 2H), 4.73 (d, J = 15.5 Hz, 1H), 4.31 (d, J = 15.5 Hz, 1H), 4.17 (d, J = 12.0 
Hz, 1H), 4.13 (d, J = 11.5 Hz, 1H), 4.01 (ddd, J = 5.0, 7.5, 12.5 Hz, 1H), 3.77-3.81 (m, 1H), 3.77 
(s, 3H), 3.73 (d, J = 11.5 Hz, 1H), 3.57 (d, J = 11.5 Hz, 1H), 2.91 (t, J = 7.5 Hz, 1H), 2.31-2.38 
(m, 1H), 2.10-2.16 (m, 1H), 1.72 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.8, 166.1, 159.2, 
136.4, 129.2, 128.6, 128.5, 128.2, 128.0, 113.9, 83.4, 79.3, 73.5, 61.6, 55.2, 45.0, 44.3, 42.5, 
28.4, 19.2; LRMS (ESI) Calcd. for C24H26ClNO5 [M+H] 444, found 444. 
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Hydroxy-β-Lactone (±)-2.38:
 
Prepared according to the representative procedure for 
debenzylation using the mixture of β-lactones (38 mg, 0.13 mmol, dr 6:1) and 10 wt% palladium 
on carbon (10 mg) in THF (5 mL) at ambient temperature for 5 h under H2 atmosphere. 
Purification by flash chromatography (1:40 EtOAc/CH2Cl2) gave the desired alcohol (±)-2.38 
along with the minor diastereomer (29.9 mg, 98%, dr 6:1) as a waxy solid.  Further purification 
allowed enrichment to ~10-19:1 dr (500 MHz 1H NMR). (±)-2.38: Rf = 0.29 (4.8% 
EtOAc/CH2Cl2); IR (neat) 3449, 1831, 1687 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 8.5 
Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.13 (d, J = 15.0 Hz, 1H), 4.06 (d, J = 15.5 Hz, 1H), 4.03 (ddd, 
J = 5.5, 7.5, 12.5 Hz, 1H), 3.92 (dd, J = 9.0, 13.5 Hz, 1H), 3.85 (dd, J = 4.5, 13.5 Hz, 1H), 3.80 
(s, 3H), 3.78-3.82 (m, 1H), 2.94 (t, J = 7.0 Hz, 1H), 2.32-2.38 (m, 1H), 2.01-2.18 (m, 1H), 1.77 
(s, 3H), 0.86 (dd, J = 5.0, 9.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 174.2, 166.7, 159.6, 
129.0, 128.7, 114.7, 83.6, 80.2, 55.3, 55.1, 44.9, 44.1, 42.4, 28.4, 19.1; LRMS (ESI) Calcd. for 
C17H20ClNO5 [M+H] 354, found 354. 
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N-PMB-Salinosporamide A (±)-2.39: To a solution of diastereomeric alcohols, (±)-2.38 plus 
minor diastereomer (29 mg, 0.082 mmol, dr >10:1), in DMSO/toluene (0.8 mL/0.8 mL) was 
added EDCI (79 mg, 0.41 mmol), followed by dichloroacetic acid (14 µL, 0.16 mmol) at 
ambient temperature. The reaction mixture was stirred at ambient temperature for 2 h and diluted 
with EtOAc (50 mL). The organic layer was washed with 0.1 N HCl, and brine, dried over 
MgSO4, filtered, and concentrated. The residue was used for the next step without further 
purification due to some instability of resulting aldehyde to column chromatography. 
A solution of tri-n-butyl-2-cyclohexenyltin (140 mg, 0.377 mmol) in THF (0.7 mL) was 
treated with n-BuLi (2.5 M in hexanes, 133 µL, 0.333 mmol) at –78 °C. After 30 min, ZnCl2 (0.5 
M in THF, 0.77 mL, 0.39 mmol) was added and following an additional 30 min, a solution of the 
crude aldehyde in THF (1.3 mL) was slowly added to the freshly prepared zinc reagent 2.8. The 
resulting mixture was stirred at –78 °C for 2.5 h, quenched with water and diluted with EtOAc 
(50 mL).  The organic layer was washed with saturated NH4Cl and brine, dried over Na2SO4, 
filtered, and concentrated. The residue was purified by flash chromatography (1:6 
EtOAc/hexanes) to give a mixture of predominantly two diastereomers  (12 mg, 33%, dr 3.5:1 + 
trace minor diasts., 500 MHz 1H NMR) as a colorless oil which was carried directly to the next 
step without further characterization.  The major diastereomer 2.39 was confirmed to possess the 
correct relative stereochemistry following subsequent conversion to salinosporamide A (below):  
Rf = 0.64 (40% EtOAc/Hexanes); IR (neat) 3467, 1828, 1692 cm-1; LRMS (ESI) Calcd. for 
C23H28ClNO5 [M+Li] 440, found 440. 
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Rac-Salinosporamide A ((±)-1.1a): To a mixture of diastereomer (±)-2.39 (10 mg, 0.023 mmol, 
dr 3.5:1) in CH3CN (0.1 mL) was added an aqueous solution of CAN (63 mg, 0.12 mmol) in 
H2O (25 µL) at 0 °C. After stirring at 0 °C for 2 h, the reaction mixture was diluted with EtOAc 
(25 mL) and washed with brine. The organic layer was dried over anhydrous MgSO4, filtered, 
and concentrated. The residue was purified by flash chromatography (1:10 to 1:4 
EtOAc/CH2Cl2) providing diastereomerically pure salinosporamide A (±)-1.1a (3.5 mg, 49%) as 
a white solid (dr >19:1, 500 MHz 1H NMR).  A crystal suitable for X-ray analysis was obtained 
by slow evaporation from CH2Cl2 with ~5% CH3CN:  Rf = 0.09 (5% EtOAc/CH2Cl2); IR (neat) 
3413, 1821, 1700 cm-1; 1H NMR (500 MHz, pyridine-d5) δ 10.63 (s, 1H), 6.42 (d, J = 10.5 Hz, 
1H), 5.86-5.90 (m, 1H), 4.26 (t, J = 9.0 Hz, 1H), 4.13 (dt, J = 7.5, 10.5 Hz, 1H), 4.02 (dt, J = 7.0, 
10.5 Hz, 1H), 3.18 (t, J = 7.0 Hz, 1H), 2.82-2.89 (m, 1H), 2.45-2.52 (m, 1H), 2.27-2.36 (m, 2H), 
2.07 (s, 3H), 1.89-1.95 (m, 2H), 1.66-1.72 (m, 1H), 1.35-1.40 (m, 1H) 1H was overlapped with 
H2O; 13C NMR (125 MHz, pyridine-d5) δ 176.9, 169.4, 129.1, 128.7, 86.3, 80.4, 71.0, 46.2, 43.3, 
39.3, 29.0, 26.5, 25.4, 21.7, 20.0; LRMS (ESI) Calcd. for C15H20ClNO4 [M+Li] 314, found 314. 
 
Procedure for Asymmetric Synthesis of (–)-Salinosporamide A 
 
(R)-O-Benzyl Serine Allyl Ester (R)-2.34: To a suspension of (R)-O-benzyl-serine 3.3 (4.35 g, 
22.3 mmol) in distilled MeOH (80 mL) was added triethylamine (3.76 mL, 26.8 mmol) and p-
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anisaldehyde (4.55 g, 33.4 mmol) at 23 oC. The resulting suspension was stirred until the 
solution became homogeneous (~ 30 min). The solution was then cooled to 0 oC, followed by 
addition of anhydrous MgSO4 (13.4 g, 112 mmol). After 7 h, the MgSO4 was filtered via fritted 
funnel and washed with MeOH (80 mL).  The combined filtrate was cooled to 0 oC for 15 min 
and then NaBH4 (1.11 g, 29.4 mmol) was added portionwise. After stirring at 0 oC for 2 h, the 
solidified reaction mixture was left in a freezer (~ –10 oC) for 12 h.  All volatiles were removed 
under reduced pressure and the remaining solid was resuspended in water (50 mL) and acidified 
to pH 3 with 2 N HCl. The precipitated white solid was filtered via a Büchner funnel, washed 
with ice-cold water (2 x 30 mL) and ice-cold Et2O (2 x 30 mL), and dried under vacuum to give 
O-benzyl-N-PMB serine (6.80 g, 97 %) as a white solid.  
To O-benzyl-N-PMB serine (6.80 g, 21.6 mmol) and p-TsOH (4.93 g, 25.9 mmol) was 
added allyl alcohol (20 mL) and benzene (40 mL).  The solution was stirred at reflux (~ 100 oC) 
with a Dean-Stark apparatus until the calculated amount of water had been collected (~8 h). The 
resulting solution was concentrated, resuspended in 5% aqueous NaHCO3 (120 mL), and 
extracted with EtOAc (500 mL).  The pH was adjusted to 10.0 (until pH of aqueous solution 
maintained at 10 after extraction) with 2 M NaOH solution. The organic layer was washed with 
brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by 
flash chromatography (1:6 EtOAc/hexanes) to give the desired allyl ester (R)-2.34 (6.30 g, 82%) 
as a yellow oil. Rf = 0.61 (33% EtOAc/hexanes); [α]23D = + 20.6 (c = 1.8, CHCl3); IR (neat) 
1738, 1612 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.25-7.35 (m, 7 H), 6.90 (d, J = 8.5 Hz, 2H), 
5.87-5.95 (m, 1 H), 5.22-5.35 (m, 2 H), 4.69 (dt, J = 1.2, 5.7 Hz, 2H), 4.58 (d, J = 12.3 Hz, 1H), 
4.53 (d, J = 12.0 Hz, 1H), 3.89 (d, J = 12.6 Hz, 1H), 3.82 (s, 3H), 3.70-3.82 (m, 2H), 3.71 (d, J = 
13.2 Hz, 1H), 3.57 (t, J = 4.8 Hz, 1H), 2.28 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 172.9, 158.9, 
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138.1, 132.2, 131.9, 129.8 (2C), 128.6 (2C), 127.9, 127.8(2C), 118.7, 114.0 (2C), 73.4, 71.3, 
65.7, 60.6, 55.5, 51.6; HRMS (ESI) Calcd. for C21H26NO4 [M+H] 356.1862, found 356.1858.  
Enantiomeric excess was determined to be 98% by chiral HPLC (CHIRALPAK IA, 250 x 4.6 
mm (L x I.D.), solvent (isocratic) 95:5 hexanes/2-propanol, flow rate 1.0 mL/min, λ = 230 nm).  
Retention times: (S)-serine derivative 15.97 min; (R)-serine derivative 22.34 min. 
 
β-Ketoamides, 3.6a/3.6b. To a 10 mL microwave vessel containing (R)-O-benzyl serine allyl 
ester (R)-2.34 (356 mg, 1.00 mmol) was added ketene-dimer (±)-2.11a (191 mg, 1.30 mmol), 2-
hydroxypyridine (124 mg, 1.30 mmol) and dichloroethane (3.5 mL). The reaction mixture was 
stirred at 23 oC until the solution turned transparent.  The reaction vessel was heated to 50 oC and 
irradiated in the microwave at 100 W for 2 h (same scale reaction was repeated for 5 times).  The 
combined reaction mixtures were removed by means of a rotary evaporator, and the residue was 
purified by a short column (1:4 EtOAc/hexanes) to afford a 1:1 mixture of diastereomeric keto 
amides (2R,4R)-3.6a/(2S,4R)-3.6b  (2.26 g, 90%) as a colorless oil. (2R,4R)-3.6a: Rf = 0.57 and 
(2S,4R)-3.6b: Rf = 0.51 (5:95 EtOAc/CH2Cl2); the first MPLC separation (5:95 EtOAc/CH2Cl2) 
gave 850 mg of (2R,4R)-3.6a (30:1 dr, 38%), second MPLC separation gave additional 0.16 g 
(28:1 dr, 7%).  Data for (2R,4R)-3.6a diastereomer (45:1 dr, 98% ee): [α]23D = + 66.1 (c = 1.0, 
CHCl3); IR (neat) 1739, 1645 cm-1; 1H NMR (500 MHz, CDCl3) for major rotamer δ 7.22-7.36 
(m, 7H), 6.87 (d, J = 9 Hz, 2 H), 5.85-5.93 (m, 1H), 4.82 (d, J = 16.5 Hz, 1H), 4.66 (d, J = 16.5 
Hz, 1H), 4.59-4.61 (m, 2H), 4.50 (dd, J = 4.0, 8.5 Hz, 1H), 4.47 (d, J = 12 Hz, 1H), 4.44 (d, J = 
12 Hz, 1H), 4.08 (dd, J = 8.5, 10.0 Hz, 1H), 4.01 (dd, J = 3.5, 10.0 Hz, 1H), 3.93 (dd, J = 5.5, 8.5 
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Hz, 1H), 3.81 (s, 3H), 3.46-3.58 (m, 2H), 2.34-2.43 (m,1H), 2.17-2.24 (m, 1H), 2.11 (s, 3H); 13C 
NMR (125 MHz, CDCl3) for major rotamer δ 203.3, 169.9, 168.5, 164.9, 159.5, 137.8, 131.8, 
128.9, 128.6, 128.0, 127.9, 119.1, 114.3, 73.9, 68.6, 66.3, 60.1, 55.5, 54.8, 52.6, 42.9, 32.1, 28.0; 
HRMS (ESI) Calcd. for C27H32ClNO6Li [M+Li] 508.2078, found 508.2073.  Enantiomeric 
excess was determined by chiral HPLC (Chiralpak IA, 250 x 4.6 mm (L x I.D.), solvent 
(isocratic) 90:10 hexanes/2-propanol, flow rate 1.0 mL/min, wavelength λ = 230 nm).  Retention 
times: (2R, 4R)-3.6a 19.34 min; ent-3.6a(2S, 4S): 21.09 min. 
β-Ketoamide (2R,4R)-3.6a/(2S,4R)-3.6b (gram-scale synthesis).  To an 80 mL microwave vessel 
containing (R)-O-benzyl serine allyl ester (R)-2.34 (3.56 g, 0.01 mol) was added ketene dimer 
(±)-2.11a (1.61 g, 0.011 mmol), 2-hydroxypyridine (1.05 g, 0.011 mmol) and dichloroethane (35 
mL). The reaction mixture was stirred at 23 oC until the solution turned transparent.  The reaction 
vessel was heated to 48 oC and irradiated in the microwave at 100 W for 2 h (same scale reaction 
was repeated one more time).  The reaction mixture was concentrated under reduced pressure, 
and the residue was purified by a short SiO2 column (95:5 DCM/EtOAc) to afford a 1:1 mixture 
of diastereomeric keto amides (2R,4R)-3.6a/(2S,4R)-3.6b (8.02 g, 80%) as a colorless oil.  Two 
sequential separations by MPLC (SiO2, 5:95 EtOAc/CH2Cl2) gave 2.30 g of (2R,4R)-3.6a (32:1 
dr).  Data for (2R,4R)-3.6a (45:1 dr, 98% ee): [α]23D = + 66.1 (c = 1.0, CHCl3); IR (neat) 1739, 
1645 cm-1; 1H NMR (500 MHz, CDCl3) for major rotamer δ 7.22-7.36 (m, 7H), 6.87 (d, J = 9 
Hz, 2 H), 5.85-5.93 (m, 1H), 5.24-5.33 (m, 2H), 4.82 (d, J = 16.5 Hz, 1H), 4.66 (d, J = 16.5 Hz, 
1H), 4.59-4.61 (m, 2H), 4.50 (dd, J = 4.0, 8.5 Hz, 1H), 4.47 (d, J = 12 Hz, 1H), 4.44 (d, J = 12 
Hz, 1H), 4.08 (dd, J = 8.5, 10.0 Hz, 1H), 4.01 (dd, J = 3.5, 10.0 Hz, 1H), 3.93 (dd, J = 5.5, 8.5 
Hz, 1H), 3.81 (s, 3H), 3.46-3.58 (m, 2H), 2.34-2.43 (m,1H), 2.17-2.24 (m, 1H), 2.11 (s, 3H); 13C 
NMR (125 MHz, CDCl3) for major rotamer δ 203.3, 169.9, 168.5, 164.9, 159.5, 137.8, 131.8, 
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128.9 (2C), 128.6 (2C), 128.0, 127.9 (2C), 119.1, 114.3 (2C), 73.9, 68.6, 66.3, 60.1, 55.5, 54.8, 
52.6, 42.9, 32.1, 28.0; HRMS (ESI) Calcd. for C27H32ClNO6Li [M+Li] 508.2078, found 
508.2073.  Enantiomeric excess was determined by chiral HPLC (Chiralpak IA, 250 x 4.6 mm (L 
x I.D.), solvent (isocratic) 90:10 hexanes/2-propanol, flow rate 1.0 mL/min, λ = 230 nm).  
Retention times: (2R, 4R)-3.6a 19.34 min; ent-3.6a(2S, 4S): 21.09 min. 
 
Epimerization of β-ketoamide 3.6b.  To a solution of ketoamide (2S,4R)-3.6b (0.30 g, 0.598 
mmol, ~ 20:1 dr) in 10 mL of EtOAc/MeOH (4:1) was added TsOH (137 mg, 0.718 mmol) and 
the solution was heated to 45 oC for 48 h.  After cooling to room temperature, the reaction 
mixture was diluted with Et2O (150 mL), H2O (100 mL) was added and the pH of the aqueous 
layer was adjusted to ~10 using a 0.1 M NaOH solution.  After extraction, the layers were 
separated and the organic layer was washed with brine (100 mL), dried over MgSO4, filtered, 
and concentrated under reduced pressure to deliver 0.295 g (98 %) of a 1:1 mixture of 
ketoamides 3.6a /3.6b which could be repurified by MPLC to increase material throughput of the 
desired diastereomer 3.6a.  HPLC analysis of (2R,4R)-ketoamide 3.6a verified that epimerization 
only occurred at the β-ketoamide and not the α-amino acid position under these conditions.   
 
 
β-Ketoacid (2R,4R)-3.4a. To a solution of ketoamide (2R,4R)-3.6a (0.85 g, 1.69 mmol, dr ~ 
30:1 ) in THF (34.0 mL) at -5 oC (ice and saturated NaCl solution) was added Pd(PPh3)4 (195 
 128 
 
mg, 0.169 mmol), and which was immediately followed by morpholine (0.177 ml, 2.03 mmol). 
The reaction mixture was stirred at -5 oC for 1 h and diluted with ice cold Et2O (500 mL). The 
organic layer was acidified to pH 3 with 0.025 N HCl.  The organic layer was washed with brine, 
dried over MgSO4 and concentrated.  The crude ketoacid (2R,4R)-3.4a (29:1 dr according to 500 
MHz 1H NMR) was used in the subsequent step without further purification.  (Note: longer 
reaction leads to epimerization). Data for (2R,4R)-3.4a: 1H NMR (500 MHz, CDCl3) for major 
rotamer δ 7.25-7.36 (m, 7H), 6.88 (d, J = 9 Hz, 2 H), 4.80 (d, J = 16.5 Hz, 1H), 4.66 (d, J = 16.5 
Hz, 1H), 4.48 (d, J = 12 Hz, 1H), 4.45 (d, J = 12 Hz, 1H), 4.43 (dd, J = 5, 7.5 Hz, 1H), 4.03 (ddd, 
J = 5, 7.5,10 Hz, 2H), 3.97 (dd, J = 5.5, 8.5 Hz, 1H), 3.81 (s, 3H), 3.75-3.78 (m, 2H), 3.54-3.59 
(m, 1H), 3.48 (ddd, J = 5, 8.5, 11.5 Hz, 1H), , 2.39-2.46 (m,1H), 2.19-2.26 (m, 1H), 2.12 (s, 3H). 
β-Ketoacid (2R,4R)-3.4a (gram-scale synthesis). To a solution of ketoamide (R,R)- 3.6a  (2.30 
g, 4.55 mmol, ~ 32:1 dr) in THF (91.0 mL) at -5 oC (ice and saturated NaCl solution) was added 
Pd(PPh3)4 (526 mg, 0.455 mmol), followed by immediate addition of morpholine (0.475 ml, 5.46 
mmol). The reaction mixture was stirred at -5 oC for 70 min and diluted with ice cold Et2O (800 
mL).  A 0.02 N HCl solution was added until the pH was measured to be ~3.  The layers were 
separated and the organic layer was washed with brine (400 mL), dried over MgSO4 and 
concentrated.  The crude ketoacid (R,R)-3.4a  (~ 32:1 dr according to 500 MHz 1H NMR) was 
used in the subsequent step without further purification.  (Note: longer reaction time led to 
epimerization).  
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Benzyloxy-β-lactone (–)-2.37a/2.37b.  To a solution of 4-pyrrolidinopyridine (1.21g, 8.45 
mmol) in toluene (46 mL) at –10 oC was added MsCl (0.20 mL, 2.54 mmol). Immediately, a 
solution of freshly synthesized ketoacid (R,R)-3.4a (1.69 mmol) in toluene
 
(12 mL) was added to 
the resulting suspension via syringe pump over 30 min. After 50 min, the reaction mixture was 
diluted with ice-cold Et2O (400 mL) and washed with 20 % CuSO4 solution (2 x 200 mL) to 
remove excess 4-pyrrolidinopyridine and then washed with water (2 x 200 mL). The organic 
layer was dried over MgSO4, filtered, and concentrated. Immediately, the residue was purified by 
flash chromatography (1:9 → 3:7 EtOAc/hexanes) to give a mixture of two co-eluting, 
inseparable β-lactones (–)-2.37a/2.37b (260 mg, 35%, 7:1 dr, 500 MHz 1H NMR) as a colorless 
oil and recovered ketoacid (36%, 2:1 dr). Rf = 0.36 (20% EtOAc/hexanes).  Data for (–)-2.37a: 
IR (neat) 1830, 1703 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.32-7.36 (m, 3H), 7.13-7.15 (m, 4H), 
6.80 (d, J = 8.5 Hz, 2H), 4.73 (d, J = 15.5 Hz, 1H), 4.31 (d, J = 15.5 Hz, 1H), 4.17 (d, J = 12.0 
Hz, 1H), 4.13 (d, J = 11.5 Hz, 1H), 4.01 (ddd, J = 5.0, 7.5, 12.5 Hz, 1H), 3.77-3.81 (m, 1H), 3.77 
(s, 3H), 3.73 (d, J = 11.5 Hz, 1H), 3.57 (d, J = 11.5 Hz, 1H), 2.91 (t, J = 7.5 Hz, 1H), 2.31-2.38 
(m, 1H), 2.10-2.16 (m, 1H), 1.72 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.8, 166.1, 159.2, 
136.4, 129.2 (2C), 128.6, 128.5 (2C), 128.2, 128.0 (2C), 113.9 (2C), 83.4, 79.3, 73.5, 61.6, 55.2, 
45.0, 44.3, 42.5, 28.4, 19.2; LRMS (ESI) Calcd. for C24H27ClNO5 [M+H] 444, found 444.  
Enantiomeric excess of (-)-32 was determined to be 92% by chiral HPLC (CHIRALPAK IA, 250 
x 4.6 mm (L x I.D.), solvent (isocratic) 87:13 hexanes/2-propanol, flow rate 1.0 mL/min, λ = 230 
nm).  Retention times: (–)-2.37a: 13.68 min; (+)-2.37a: 16.12 min.  
 
Benzyloxy-β-lactone (–)-2.37a/2.37b (gram-scale synthesis). To a solution of 4-
pyrrolidinopyridine (2.60 g, 18.2 mmol, 4.0 equiv) in toluene (84 mL) at -5 oC (ice and saturated 
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NaCl solution) was added MsCl (0.53 mL, 6.83 mmol, 1.5 equiv). Immediately, a solution of 
freshly prepared ketoacid (R,R)-3.4a (4.55 mmol) in toluene
 
(25 mL) was added to the resulting 
suspension via syringe pump over 45 min and 5 mL of additional toluene were used to ensure 
complete transfer. After 3 h, the reaction mixture was diluted with ice cold Et2O (700 mL) and 
washed with 20% CuSO4 solution (500 mL) to remove most of the 4-pyrrolidinopyridine, 
saturated NH4Cl (500 mL), and then washed with water (2 x 500 mL). The organic layer was 
dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography 
(1:9 → 3:7 EtOAc/hexanes) to give a mixture of two inseparable β-lactones (–)-2.37a/2.37b 
(1.05 g, 52%, 5:1 dr, 500 MHz 1H NMR) as a yellow oil and recovered ketoacid (10 %, 4:1 dr). 
Rf = 0.36 (20% EtOAc/hexanes).  Enantiomeric excess of (–)-2.37a was determined to be 90%.  
The diastereomeric β-lactones were carried directly forward to the deprotection at which point 
they could be separated. 
 
 
Representative Procedure for Debenzylation as Described for Hydroxy-β-Lactone (–)-
2.38a/2.38b. To a mixture of β-lactones (–)-2.37a and 2.37b (260 mg, 0.586 mmol, dr 7:1) in 
THF was added palladium on carbon (52 mg, 20 wt%).  After evacuating twice by aspirator 
vacuum, and refilling with H2, a balloon of H2 was attached to the flask and the heterogenous 
solution was stirred vigorously at 23 oC for 12 h. The reaction mixture was then diluted with 
Et2O, and dried over MgSO4. The organics were filtered through a pad of Celite, concentrated, 
and purified by MPLC (SiO2, 5:95 EtOAc/CH2Cl2) to give the desired alcohol (–)-2.38a in 75% 
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yield (155 mg, dr >19:1, 92% ee) as a waxy solid. Data for (–)-2.38a: Rf = 0.29 (5:95 
EtOAc/CH2Cl2); [α]23D = – 67.0 (c = 0.95, CHCl3). IR (neat) 3449, 1831, 1687 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 7.30 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 5.13 (d, J = 15.0 Hz, 
1H), 4.06 (d, J = 15.5 Hz, 1H), 4.03 (ddd, J = 5.5, 7.5, 12.5 Hz, 1H), 3.92 (dd, J = 9.0, 13.5 Hz, 
1H), 3.85 (dd, J = 4.5, 13.5 Hz, 1H), 3.80 (s, 3H), 3.78-3.82 (m, 1H), 2.94 (t, J = 7.0 Hz, 1H), 
2.32-2.38 (m, 1H), 2.01-2.18 (m, 1H), 1.77 (s, 3H), 0.86 (dd, J = 5.0, 9.5 Hz, 1H); 13C NMR 
(125 MHz, CDCl3) δ 174.2, 166.7, 159.6, 129.0(2C), 128.7, 114.7(2C), 83.6, 80.2, 55.3, 55.1, 
44.9, 44.1, 42.4, 28.4, 19.1; LRMS (ESI) Calcd. for C17H21ClNO5 [M+H] 354, found 354. 
 
Procedure A for Zincate Addition: 
 
N-PMB-salinosporamide A (–)-2.39.  To a solution of alcohol (–)-2.38a (155 mg, 0.440 mmol, 
dr >19:1) in DMSO/toluene (2.2 mL/2.2 mL) was added EDCI (424 mg, 2.20 mmol), and 
dichloroacetic acid (18 µL, 0.22 mmol) at 23 oC. The reaction mixture was stirred for 5 h, and 
diluted with EtOAc (150 mL). The reaction mixture was acidified using 0.1 N HCl to pH 3.  The 
organic layer was then washed with brine (100 mL), dried over MgSO4, filtered, and 
concentrated. The residue was used for the next step without further purification due to some 
instability of the resulting aldehyde to column chromatography. For characterization purpose, 
aldehyde (–)-4.22 was isolated via flash column chromatography (5:95 EtOAc/CH2Cl2) as a clear 
oil. Data for (–)-4.22: Rf = 0.35 (5:95 EtOAc/CH2Cl2); IR (neat) 1839, 1712 (br) cm-1; 1H NMR 
(500 MHz, CDCl3) δ 8.73 (s, 1H), 7.28 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 5.13 (d, J = 
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14.5 Hz, 1H), 4.12 (d, J = 14.5 Hz, 1H), 4.03 (ddd, J = 4.5, 7.5, 11.5 Hz, 1H), 3.81 (s, 3H), 3.74-
3.80 (m, 1H), 3.08 (t, J = 7.0 Hz, 1H), 2.34-2.41 (m, 1H), 2.11-2.18 (m, 1H), 1.61 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 190.5, 174.2, 162.3, 160.4, 131.4(2C), 126.2, 114.9(2C), 84.7, 82.8, 
55.5, 46.1, 45.1, 42.3, 28.6, 20.1; MS could not be obtained for this compound due to instability 
of β-lactone. 
A solution of tri-n-butyl-2-cyclohexenyltin (490 mg, 1.32 mmol) in THF (2.0 mL) was 
treated with n-BuLi (2.5 M in hexanes, 512 µL, 1.28 mmol) at –78 °C. After 30 min, ZnCl2 (0.5 
M in THF, 2.62 mL, 1.41 mmol) was added and after an additional 30 min, a solution of the 
crude aldehyde in THF (1.5 mL) was slowly added to the freshly prepared zinc reagent 2.8. The 
resulting mixture was stirred at –78 °C for 4 h, quenched with water and diluted with Et2O (150 
mL). Saturated NH4Cl was added until a pH of 7 was achieved.  The layers were separated and 
then the organic layer was washed with brine (100 mL).  The filtrate was dried over MgSO4, 
filtered, and concentrated. The residue was purified by flash chromatography (95:5 → 85:5 
EtOAc/hexanes) to give a mixture of four inseparable diastereomers (100 mg, 62 %, dr = 
11:3:1:1 according to 500 MHz 1H NMR) as a colorless oil, which was carried directly to the 
next step without further purification.  The major diastereomer (–)-2.39 was confirmed to 
possess the correct relative stereochemistry following subsequent conversion to salinosporamide 
A. 
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Representative Procedure for PMB-Deprotection as Described for (–)-salinosporamide A 
((–)-1.1a): To a methanolic solution (1.2 mL) containing the mixture of alcohol (–)-2.39 (100 
mg, 0.23 mmol) and other diastereomers from the previous step, was added an aqueous solution 
of CAN (1.26 g, 2.3 mmol) in H2O (0.6 mL) at 0 °C dropwise. After stirring at 0 °C for 6 h, the 
reaction mixture was diluted with EtOAc (100 mL), washed with saturated solution of NaHCO3, 
and brine. The organic layer was dried over MgSO4, filtered, and concentrated. The residue was 
purified by flash chromatography (5:95 → 15:85 EtOAc/CH2Cl2) to give salinosporamide A (–)-
1.1a (31 mg, 43 %) as a white solid (dr ~ 15:1, 500 MHz 1H NMR).  Further purification was 
accomplished by recrystallization involving slow evaporation from 95:5 CH2Cl2/acetone to 
provide (–)-1.1a (28 mg, 90 %, dr > 19:1):  Rf = 0.50 (33 % EtOAc/hexanes); m.p. 152-156 oC, 
lit. 169-171 oC; [α]23D = – 71.3 (c = 0.39, MeOH); lit. [α]25D = – 72.9 (c = 0.55, MeOH);   IR 
(neat) 3346, 1820, 1698 cm-1; 1H NMR (500 MHz, pyridine-d5) δ 10.69 (s, 1H), 7.63 (d, J = 9.0 
Hz, 1H), 6.45 (d, J = 10.0 Hz, 1H), 5.89-5.93 (m, 1H), 4.28 (t, J = 9.0 Hz, 1H), 4.16 (dt, J = 7.0, 
11.0 Hz, 1H), 4.05 (dt, J = 7.0, 11.0 Hz, 1H), 3.21 (t, J = 7.0 Hz, 1H), 2.84-2.91 (m, 1H), 2.48-
2.55 (m, 1H), 2.30-2.39 (m, 2H), 2.10 (s, 3H), 1.91-1.98 (m, 2H), 1.70-1.73 (m, 2H), 1.35-1.42 
(m, 1H); 13C NMR (125 MHz, pyridine-d5) δ 176.9, 169.4, 129.1, 128.7, 86.3, 80.4, 71.0, 46.2, 
43.3, 39.3, 29.0, 26.5, 25.4, 21.7, 20.0; HRMS (ESI) Calcd. for C15H21ClNO4 [M+H] 314.1161, 
found 314.1162. 
 
Cyclopropyl Ketoamide 3.7: Rf = 0.29 (95% DCM/EtOAc); IR (neat) 1759, 1697 cm-1; (500 
MHz, CDCl3) δ 7.30-7.38 (m, 3H), 7.24-7.26 (m, 2H), 7.15 (d, J = 9Hz, 2H), 6.83 (d, J = 9Hz, 
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2H), 5.18 (d, J = 14.5 Hz, 1H), 4.46 (d, J = 12 Hz, 1H), 4.37 (d, J = 12 Hz, 1H), 4.08 (d, J = 14.5 
Hz, 1H), 3.87 (t, J = 3.0 Hz, 1H), 3.79 (s, 3H), 3.74 (dd, J = 10, 3 Hz, 1H), 3.70 (dd, J = 10, 3 
Hz, 1H), 1.76 (d, J = 9.5 Hz, 1H), 1.73 (d, J = 9.5 Hz, 1H), 1.64 (dd, J = 9.5, 5 Hz, 1H), 1.56(dd, 
J = 9.5, 5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 208.0, 172.8, 159.5, 137.7, 129.9 (2C), 128.7 
(2C), 128.2 (2C), 127.9 (2C), 114.4(2C), 73.5, 66.8, 65.2, 55.6, 44.0, 32.0, 21.7, 20.8; HRMS 
(ESI) Calcd. for C22H23NO4Li [M+Li] 372.1787, found 372.1786. 
 
 
Decomposition of β-lactones 2.37a/2.37b.  To a mixture of β-lactones (16 mg, 0.036 mmol, dr 
5:1) in 1.5 mL CH2Cl2 was added 4-pyrrolidinopyridine (18 mg, 0.126 mmol) at 23 oC.  After 8 
h, the reaction mixture was diluted with ether (25 mL) and washed with 20 % CuSO4 solution 
(20 mL) to remove the majority of the 4-pyrrolidinopyridine and this was followed by washing 
with saturated NH4Cl (20 mL), and then water (2 x 20 mL). The organic layer was dried over 
MgSO4, filtered, and concentrated. The residue was purified by flash chromatography (1:9 → 3:7 
EtOAc/hexanes) to give a mixture of recovered β-lactones 2.37a/2.37b (7.5 mg, 47%, 9:1 dr) and 
unsaturated γ-lactam 4.13 (4.5 mg, 31%): Rf = 0.26 (95% DCM/EtOAc); IR (neat) 1682, 1513 
cm-1; 1H NMR (500 MHz, CDCl3) δ 7.35-7.38 (m, 2H), 7.31-7.33 (m, 1H), 7.26-7.28 (m, 2H), 
7.10 (d, J = 9Hz, 2H), 6.80 (d, J = 9Hz, 2H), 5.03 (d, J = 15 Hz, 1H), 4.45 (d, J = 12 Hz, 1H), 
4.41 (d, J = 12 Hz, 1H), 4.17 (d, J = 15 Hz, 1H), 3.85 (t, J = 4.5, 1H), 3.73-3.81 (m, 2H), 3.78 (s, 
3H), 3.66 (dd, J = 10, 4 Hz, 1H), 3.53 (dd, J = 10, 5 Hz, 1H), 2.75-2.78 (m, 2H), 1.93 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 171.7, 159.1, 151.2, 137.8, 130.2, 129.9, 129.6 (2C), 128.7 (2C), 
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128.2, 128.0 (2C), 114.2(2C), 73.6, 68.7, 63.0, 55.5, 44.1, 43.4, 27.9, 12.9; HRMS (ESI) Calcd. 
for C23H27ClNO3 [M+H] 400.1679, found 400.1683. 
 
Salino Ester 2.40. IR (neat) 1833, 1712cm-1; (500 MHz, CDCl3) δ 7.95 (d, J = 11Hz, 2H), 6.95 
(d, J = 11Hz, 2H), 6.47 (s, 1H), 5.91-5.94 (m, 1H), 5.60-5.62 (m, 1H), 5.48 (d, J = 5.5 Hz, 1H), 
3.94 (ddd, J = 7.5, 6.0, 5.5 Hz, 1H), 3.88 (s, 3H), 3.76 (ddd, J = 7.0, 6.0, 5.0 Hz, 1H), 2.79 (t, J = 
7 Hz, 1H), 2.74-2.78 (m, 1H), 2.26-2.32 (m, 1H), 2.08-2.15 (m, 1H), 2.01-2.05 (m, 2H), 1.88-
1.94 (m, 1H), 1.77-1.84 (m, 1H), 1.76 (s, 3H), 1.65-1.72 (m, 1H), 1.57-1.63 (m, 1H); 13C NMR 
(125 MHz, CDCl3) δ 175.9, 166.7, 165.6, 164.6, 132.4 (2C), 132.1, 124.5, 121.2, 114.5 (2C), 
84.5, 70.5, 56.0, 44.7, 42.5, 37.5, 30.1, 28.5, 26.7, 25.1, 21.3, 20.2; HRMS (ESI) Calcd. for 
C23H26ClNO6 [M+H] 448.1527, found 448.1429. 
 
 
Salino Oxazolidine 4.25. IR (neat) 1830, 1723cm-1; (500 MHz, CDCl3) δ 7.26-7.33 (m, 2H), 
6.92-6.94 (m, 2H), 5.93 (s, 1H), 5.91 (d, J = 13.5 Hz ,1H), 5.84-5.88 (m, 1H), 4.18 (d, J = 10.0 
Hz, 1H), 3.88 (ddd, J = 11.5, 6.5, 5.0 Hz, 1H), 3.83 (s, 3H), 3.68 (ddd, J = 11.5, 6.5, 5.0 Hz, 1H), 
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2.95 (t, J = 6.5 Hz, 1H), 2.88-2.93 (m, 1H), 2.14-2.27 (m, 2H), 2.03-2.08 (m, 2H), 1.80-1.86 (m, 
2H), 1.82 (s, 3H), 1.60-1.66 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 172.0, 168.2, 161.2, 130.1, 
129.3(2C), 125.4, 114.3 (2C), 89.5, 85.2, 83.0, 80.3, 55.6, 50.3, 42.4, 36.8, 30.1, 29.5, 26.5, 25.3, 
21.3, 21.2; HRMS (ESI) Calcd. for C23H26ClNO5Li [M+Li] 438.0910, found 438.1861. 
 
Procedure B for Zincate Addition: 
 
Procedure for Modified Moffatt Oxidation and Zincate Formation/Addition as Described 
for N-PMB-salinosporamide A (–)-2.39/4.24. To a solution of alcohol (–)-2.38a (42 mg, 
0.119mmol, dr >19:1) in DMSO/toluene (0.9mL/0.9mL) was added EDCI (0.114mg, 
0.595mmol), anddichloroacetic acid (5 mL, 0.060 mmol) at 23 oC. The reaction mixture was 
stirred for 6 h, and diluted with EtOAc (100 mL). The reaction mixture was acidified using 0.1 N 
HCl to pH 3. The organic layer was then washed with brine (60 mL), dried over MgSO4, 
filtered, and concentrated. The crude aldehyde was used for the next step without further 
purification due to some instability of the aldehyde (–)-4.22 observed upon flash column 
chromatography.   
Preparation of stock solution of zincate 4.23: Zinc dust (1.64 g, 25.0 mmol, Baker, 20 
mesh) was activated by the addition of an HCl solution (5 mL, 1.0 M) in a 25 mL round-
bottomed flask. After stirring vigorously for 15 min at 23 ºC, the acid solution was decanted and 
the zinc was repeatedly washed with dry THF (3 X 5 mL). the zinc was then dried under high 
vacuum for 2 h. Addition of dry THF (5 mL) was followed by slow addition of 3-bromo-
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cyclohexene (0.806g, 5.0 mmol, Acros) over 15 min. The resulting mixture was stirred at 23 ºC 
for 18 h, and then transferred via syringe to a dry centrifuge tube to remove the excess zinc 
suspension (10 min, 80 rpm). The resulting clear solution was then utilized directly, following 
titration as described below, being careful not to disturb the pellet at the bottom during transfers. 
The concentration of the zincate 4.23 solution was determined as follows: A stock solution of 
iodine in THF was prepared by addition of iodine (254 mg, 1.0 mmol) in 10 mL of THF leading 
to a 100 mM solution. A portion (500 µL) of this iodine solution was placed into a dry 5 mL 
round-bottomed flask equipped with a magnetic stir bar. The zincate solution, after being 
centrifuged, was added dropwise into the iodine stock solution until the red color disappeared. 
Using this procedure, the prepared zincate solution was determined to be ~200 µM and was used 
(in excess) directly in the following reaction. 
To a solution of the crude aldehyde (~0.119 mmol) in THF (1.0 mL) at –78 °C was added 
~1.2 mL (0.238 mmol, ~200 µM in THF, ~2.0 equiv) of zincate 4.23 via syringe pump over 30 
min. The resulting mixture was slowly warmed up to – 20 ºC for 1 h, quenched with water and 
diluted with Et2O (120 mL). Saturated NH4Cl was added until a pH of 7 was achieved. The 
layers were separated and then the organic layer was washed with brine (80 mL). The filtrate was 
dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography 
(95:5 → 85:5 EtOAc/hexanes) to give a mixture of two inseparable diastereomers (–)-2.39/(–)-
4.24 (38 mg, 74%, dr = 4:1 according to 500 MHz 1H NMR) as a colorless oil, which was carried 
directly to the next step without further purification. 
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Salinosporamide A (–)-1.1a, and C5, C6-Bis-Epi-Salinosporamide A (–)-4.26: To a 
methanolic solution (0.8 mL) containing the mixture of alcohols (–)-2.39a/4.24 (38 mg, 0.088 
mmol) was added an aqueous solution of CAN (0.240 g, 0.44 mmol) in H2O (0.2 mL) at 0 °C 
dropwise. After stirring at 0 °C for 6 h, the reaction mixture was diluted with EtOAc (100 mL), 
washed with saturated solution of NaHCO3, and brine. The organic layer was dried over MgSO4, 
filtered, and concentrated. The residue was purified by flash chromatography (5:95 → 15:85 
EtOAc/CH2Cl2) to give salinosporamide A (–)-1.1a (14 mg, 51 %, dr > 19:1, 500 MHz 1H 
NMR) as a white solid in addition to a novel diastereomeric salinosporamide A 4.26 (3.3 mg, 
12%, dr > 19:1, 500 MHz 1H NMR). 
Data for minor diastereomer 4.26: Rf = 0.56 (33 % EtOAc/CH2Cl2); IR (neat) 2931, 1830, 1702 
cm-1; 1H NMR (500 MHz, CDCl3) δ 6.28 (s, 1H), 6.10 – 6.14 (m, 1H), 5.85 – 5.88 (m, 1H), 3.99 
(ddd, J = 5.0, 7.5, 12.5 Hz, 1H), 3.83 (dd, J = 7.5, 9.0 Hz, 1H), 3.78 (ddd, J = 5.0, 7.5, 12.5 Hz, 
1H), 2.83 (t, J = 7.5 Hz, 1H), 2.48-2.50 (m, 1H), 2.27-2.34 (m, 1H), 2.11 – 2.18 (m, 1H), 2.06-
2.08 (m, 2H), 1.98 (d, J = 9 Hz, 1H), 1.80 – 1.91 (m, 2H), 1.87 (s, 3H), 1.60 – 1.67 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 175.8, 165.0, 135.2, 123.5, 85.4, 78.7, 71.8, 44.9, 42.7, 38.4, 28.5 
26.6, 25.2, 21.8, 19.4; HRMS (MALDI) Calcd. for C15H20ClNO4Na [M+Na] 336.0973, found 
336.0957. 
 
Procedure for Asymmetric Synthesis of (–)-Homosalinosporamide A 
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β-Ketoamide (-)-5.5: To a 10 mL microwave vessel containing (R)-O-benzyl serine allyl ester 
(R)-2.34 (356 mg, 1.00 mmol) was added ketene-dimer (±)-2.11b (177 mg, 1.1 mmol), 2-
hydroxypyridine (105 mg, 1.1 mmol) and dichloroethane (3.5 mL). The reaction mixture was 
stirred at 23 oC until the solution turned transparent.  The reaction vessel was heated to 53 oC and 
irradiated in the microwave at 100 W for 2 h (same scale reaction was repeated for 3 times).  The 
combined reaction mixtures were removed by means of a rotary evaporator, and the residue was 
purified by a short column (95:5 DCM/EtOAc) to afford a 1:1 mixture of diastereomeric keto 
amides 5.5a/5.5b (1.21g, 80%) as a colorless oil. MPLC separation (5:95 EtOAc/CH2Cl2) gave 
350 mg of (2R,4R)-5.5a (25:1 dr, 29%).  Enantiomeric excess was determined to be 94% ee by 
chiral HPLC (Chiralpak IA, 250 x 4.6 mm (L x I.D.), solvent (isocratic) 87:13 hexanes/2-
propanol, flow rate 1.0 mL/min, wavelength λ = 230 nm).  Retention times: (R, R)-5.5a 12.92 
min; (S, S)-5.5a 16.52 min. 
(2R,4R)-5.5a: Rf = 0.74 (5:95 EtOAc/DCM); IR (neat) 1738, 1646, 1613 cm-1; 1H NMR (500 
MHz, CDCl3) for major rotamer δ 7.21-7.35 (m, 7H), 6.87 (d, J = 8.0 Hz, 2H), 5.85-5.93 (m, 
1H), 5.24-5.33 (m, 2H), 4.82 (d, J = 17.0 Hz, 1H), 4.66 (d, J = 17.0 Hz, 1H), 4.59-4.61 (m, 3H), 
4.44 (d, J = 12.0 Hz, 1H), 4.41 (d, J = 12.0 Hz, 1H), 4.05 (dd, J = 8.0, 10.0 Hz, 1H), 3.98 (dd, J 
= 3.5, 10.0 Hz, 1H), 3.81 (s, 3H), 3.53 (dd, J = 3.5, 8.0 Hz, 1H), 3.36-3.44 (m, 2H), , 2.15 (s, 
3H), 2.04-2.11 (m, 1H), 1.84-1.91 (m, 1H), 1.67-1.76 (m,1H), 1.53-1.59 (m, 1H); 13C NMR (125 
MHz, CDCl3) for major rotamer δ 204.5, 170.2, 168.5, 164.9, 159.4, 137.8, 131.8, 128.6, 128.2, 
128.0, 127.8, 119.1, 114.4, 73.6, 68.5, 66.3, 60.1, 57.9, 55.5, 52.0, 44.5, 30.4, 27.3, 26.9; LRMS 
(ESI) Calcd. for C28H35ClNO6 [M+H] 516, found 516.   
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β-Ketoacid (-)-(2R,4R)-5.6a: 
To a solution of ketoamides (-)-(R,R)5.5a (350 mg, 0.678 mmol, 25:1 dr) in THF (13.6 mL) at -5 
oC (ice and saturated NaCl solution), was added Pd(PPh3)4 (78 mg, 0.068 mmol), and 
immediately followed by morpholine (0.071 mL, 0.814 mmol). The reaction mixture was stirred 
at -5 oC for 1 h and diluted with ice-cold Et2O (500 mL). The organic layer was washed with 
0.05 N HCl to pH 3 and brine, dried over MgSO4, filtered and concentrated.  The crude ketoacid 
(R,R)-5.6a (24:1 dr according to 500 MHz 1H NMR) was used in the subsequent step without 
further purification. 
 
 
Benzyloxy-β-lactone (-)-5.7a/(-)-5.7b: to a solution of 4-pyrrolidinopyridine (386 mg, 2.71 
mmol) and (194 mg, 1.02 mmol) TsCl in toluene (16 mL) at -5 oC (ice and saturated NaCl 
solution), freshly synthesized ketoacid 5.6a in toluene (7 mL) was added via syringe pump for a 
period of 30 min.  The resulting suspension was stirred for 3.5 h. The reaction mixture was 
diluted with ice-cold Et2O (400 mL) and washed with 20 % CuSO4 solution (150 mL x 2) to 
remove excess 4-pyrrolidinopyridine and then washed with water (150 mL x 2). The organic 
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layer was dried over MgSO4, filtered, and concentrated. The residue was purified by flash 
chromatography (20% EtOAc/hexanes), which gave a mixture of two diastereomeric β-lactones 
(-)-5.7a/5.7b (186 mg, 60 % for 2 steps, dr = 3.5:1 based on 500 MHz 1H NMR).   
(-)-5.7a (major): Rf = 0.35 (30% EtOAc/hexanes); IR (neat) 1827, 1700 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.32-7.62 (m, 3H), 7.13-7.16 (m, 4H), 6.79-6.81 (m, 2H), 4.72 (d, J = 15.5 Hz, 
1H), 4.33 (d, J = 15.5 Hz, 1H), 4.14 (s, 3H), 3.77 (s, 3H), 3.74 (d, J = 11.0 Hz, 1H), 3.59 (d, J = 
11.0 Hz, 1H), 3.58-3.64 (m, 2H), 2.54 (t, J = 7.0 Hz, 1H), 2.16-2.24 (m, 1H), 1.97-2.11 (m, 1H), 
1.87-1.94(m, 2H), 1.72 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 174.2, 166.4, 159.3, 136.7, 
129.5, 128.9, 128.7, 128.4, 128.2, 114.1, 83.8, 79.3, 73.7, 61.8, 55.5, 47.9, 44.8, 44.5, 30.6, 23.0, 
19.9; HRMS (ESI) Calcd. for C25H28ClNO5Na [M+Na] 480.1554, found 480.1559. 
 
 
Hydroxy-β-Lactone (-)-5.8a: prepared according to the representative procedure for 
debenzylation using the mixture of β-lactones 5.7a/5.7b (186 mg, 0.407 mmol, dr 3.5:1) and 20 
wt% palladium on carbon (38 mg) in THF (10 mL) at 23 oC for 12 h under H2 atmosphere. 
Purification by flash chromatography (5:95 EtOAc/CH2Cl2) gave the desired alcohol (-)-5.8a (93 
mg, 62 %) along with the minor diastereomer as a white solid.  Enantiomeric excess was 
determined to be 82 % ee by chiral HPLC (Chiralcel OD, 250 x 4.6 mm (L x I.D.), solvent 
(isocratic) 87:13 hexanes/2-propanol, flow rate 1.0 mL/min, wavelength λ = 230 nm).  Retention 
times: (-)-5.8a 19.72 min; (+)-5.8a 28.76 min.  Enantiomeric excess of the desired alcohol was 
enriched by recrystallization with DCM/ether with mother liquor of 89 %ee. 
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(-)-5.8a: Rf = 0.26 (5% EtOAc/CH2Cl2); 1H NMR (500 MHz, CDCl3) δ 7.31 (d, J = 8.5 Hz, 2H), 
6.89 (d, J = 8.5 Hz, 2H), 5.13 (d, J = 15.5 Hz, 1H), 4.07 (d, J = 15.5 Hz, 1H), 3.92 (dd, J = 9.0, 
14.0 Hz, 1H), 3.86 (dd, J = 4.5, 13.5 Hz, 1H), 3.81 (s, 3H), 3.61-3.64 (m, 2H), 2.56 (t, J = 7.0 
Hz, 1H), 2.17-2.26 (m, 1H), 1.98-2.12 (m, 2H), 1.89-1.96 (m, 1H), 1.77 (s, 3H), 0.86 (dd, J = 
4.5, 9.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 174.5, 167.0, 159.7, 129.2, 129.1, 114.9, 84.0, 
80.3, 55.5, 55.3, 47.9, 44.7, 44.3, 30.5, 23.0, 19.8; LRMS (ESI) Calcd. for C17H20ClNO5 [M+H] 
368, found 368.   
 
 
OH-β-Lactone (-)-5.9: to the alcohol (-)-5.8a (77 mg, 0.210 mmol), and EDCI (403 mg, 2.10 
mmol), was added DMSO/toluene (1.5 mL/1.5 mL), followed by dichloroacetic acid (9 µL, 
0.105 mmol). The reaction mixture was stirred at 23 oC for 6h and diluted with Et2O (150 mL). 
The organic layer was acidified to pH 3 with 0.1 N HCl, and washed with brine.  The organic 
was then dried over MgSO4, filtered, and concentrated. The residue was used for the next step 
without further purification due to some instability of resulting aldehyde to SiO2.  
A solution of tri-n-butyl-2-cyclohexenyltin (234 mg, 0.630 mmol) in THF (1.5 mL) was treated 
with n-BuLi (2.05M in hexanes, 297 µL, 0.609 mmol) at –78 °C. After 30 min, ZnCl2 (0.5 M in 
THF, 1.34 mL, 0.672 mmol) was added and after an additional 30 min, a solution of the crude 
aldehyde in THF (1.0 mL) was slowly added to the freshly prepared zinc reagent 2.8. The 
resulting mixture was stirred at –78 °C for 5 h, quenched with water and diluted with EtOAc 
(150 mL).  The organic layer was washed with saturated NH4Cl until pH 7 and brine (100 mL).  
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The filtrate was dried over MgSO4, filtered, and concentrated. The residue was purified by flash 
chromatography (95:5 → 85:5 EtOAc/hexanes) to give a mixture of four diastereomers (58 mg, 
61%, dr = 8:2:1:1 according to 500 MHz 1H NMR) as a colorless oil, which was carried directly 
to the next step without further purification.   
 
 
Homosalinosporamide A (-)-5.1: to a solution of alcohol (-)-5.9 (58 mg, 0.127 mmol), along 
with other diastereomers from the previous step, in MeOH (0.9 mL) was added an aqueous 
solution of CAN (694 mg, 1.27 mmol) in H2O (0.3 mL) at -10 °C dropwise. After stirring at -10 
°C for 6 h, the reaction mixture was diluted with EtOAc (100 mL), washed with saturated 
solution of NaHCO3, and brine. The organic layer was dried over MgSO4, filtered, and 
concentrated. The residue was purified by flash chromatography (5:95 to 15:85 EtOAc/CH2Cl2) 
to give homosalinosporamide A (-)-5.1 (17 mg, 41%) as a white solid (dr >19:1, 500 MHz 1H 
NMR):  Rf = 0.36 (40% EtOAc/hexanes); [α]23D = - 63.2 (c = 0.15, MeOH); IR (neat) 3360, 
1821, 1697 cm-1; 1H NMR (500 MHz, pyridine-d5) δ 10.58 (s, 1H), 6.46 (d, J = 10.0 Hz, 1H), 
5.89-5.93 (m, 1H), 4.28 (d, J = 9.0 Hz, 1H), 3.63 (dt, J = 2.0, 6.5 Hz, 2H), 2.93 (t, J = 7.0, 1H), 
2.86-2.90 (m, 1H), 2.28-2.37 (m, 2H), 2.12-2.25 (m, 1H), 2.07 (s, 3H), 1.93-1.97 (m, 2H), 1.68-
1.75 (m, 2H), 1.35-1.41 (m, 3H); 13C NMR (125 MHz, C3D6O) δ 176.7, 169.1, 129.4, 128.8, 
86.7, 79.8, 71.2, 48.2, 45.8, 39.4, 31.4, 26.6, 25.8, 23.3, 22.1, 20.4; LRMS (ESI) Calcd. for 
C16H23ClNO4 [M+1] 328.132, found 328.134. 
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PMB-salino A derivative, (±)-19a/19b. Aldehyde was prepared according to the 
representative modified Moffatt oxidation using the alcohol (±)-5.18 (80 mg, 0.218 mmol), in 
DMSO/toluene (1.2 mL/1.2 mL), and addition of EDCI (208 mg, 1.09 mmol), followed by 
dichloroacetic acid (10 µL, 0.109 mmol) at 23 oC for 5 h.  The crude aldehyde was used in the 
subsequent step without further purification. 
To a solution of aldehyde (0.109 mmol) in THF at -78 oC, Grignard reagent 22 (0.164 mmol) in 
THF was added slowly down the side of the flask. The reaction mixture was warmed to 0 oC for 
10 min, quenched with NH4Cl saturated solution, and diluted with ether (100 mL).  The organic 
layer was then washed with brine, dried over MgSO4 and concentrated.  The residue was purified 
by flash chromatography (95:5 → 85:15 EtOAc/hexanes) to provide mixture of (±)-19a/19b 
(22.5 mg, 48 %, dr = 3:1 according to 500 MHz 1H NMR) as a colorless oil which was carried 
directly to the next step without further purification.  
 
 
Salino A derivative (±)-20a.  Prepared according to the representative procedure for PMB 
deprotection using a mixture of alcohol (±)-19a/19b (22.5 mg, 0.052 mmol, dr = 3:1) in i-PrOH 
(0.3 mL) was added an aqueous solution of CAN (285 mg, 0.52 mmol) in H2O (0.1 mL) at 0 °C 
dropwise. The residue was purified by flash chromatography (5:95 to 15:85 EtOAc/CH2Cl2) to 
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give (±)-20a (7.2 mg, 45 %, dr >19:1) as a white solid:  Rf = 0.48 (5:95 EtOAc/CH2Cl2 ); IR 
(neat) 3354, 1829, 1705 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.41-7.51 (m, 5H), 5.81 (s, 1H), 
5.32 (d, J = 4.5 Hz, 1H), 3.98 (ddd, J = 5.0, 7.5, 11.0 Hz, 1H), 3.78 (ddd, J = 4.5, 7.5, 11.0 Hz, 
1H), 2.92 (t, J = 7.0 Hz, 1H), 2.26-2.33 (m, 1H), 2.24 (d, J = 4.5 Hz, 1H), 2.09-2.16 (m, 1H), 
1.93 (s, 3H); 13C NMR (125 MHz, CDCl3 and C3D6O) δ 175.3, 167.3, 137.2, 128.8, 128.7, 
126.4, 85.7, 77.8, 68.1, 45.1, 42.3, 28.0, 19.6; HRMS (ESI) Calcd. for C15H17ClNO4 [M+H] 
310.0848, found 310.0858. 
 
 
PMB-Salino A Derivative (±)-5.21a/b: To a solution of aldehyde (0.109 mmol) in THF at -78 
oC, Grignard reagent 23 (0.164 mmol) in THF was added slowly down the side of the flask. The 
reaction mixture was then warmed up to 0 oC for 10 min, quenched with NH4Cl saturated 
solution, and diluted with ether (100 mL).  The organic layer was then washed with brine, dried 
over MgSO4 and concentrated.  The residue was purified by flash chromatography (95:5 → 
85:15 EtOAc/hexanes) to provide mixture of (±)-5.21a/b (22.0 mg, 44 %, dr = 3:1 according to 
500 MHz 1H NMR) as a colorless oil, which was carried directly to the next step without further 
purification. 
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Salino A Derivative (±)-5.22a/b: Prepared according to the representative procedure PMB 
deprotection using a mixture of alcohol (±)-5.21a/b (22.0 mg, 0.048 mmol, dr = 3:1) in i-PrOH 
(0.3 mL) was added an aqueous solution of CAN (263 mg, 0.48 mmol) in H2O (0.1 mL) at 0 °C 
dropwise. The residue was purified by flash chromatography (5:95 → 15:85 EtOAc/CH2Cl2) to 
give (±)-5.22a (6.9 mg, 43 %, dr >19:1) as a white solid: Rf = 0.55 (4:6 EtOAc/Hexanes); IR 
(neat) 3350, 1825, 1702 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 7.5, 1H), 7.21-7-28 (m, 
2H), 5.44 (s, 1H), 5.24 (d, J = 4.5 Hz, 1H), 3.98 (ddd, J = 5.0, 7.0, 11.5 Hz, 1H), 3.78 (ddd, J = 
5.0, 8.0, 11.0 Hz, 1H), 2.91 (t, J = 7.0 Hz, 1H), 2.33 (s, 3H), 2.26-2.32 (m, 1H), 2.27 (s, 3H), 
2.14-2.21 (m, 1H), 2.16 (d, J = 4.5 Hz, 1H), 2.0 (s, 3H); 13C NMR (125 MHz, CDCl3 and 
C3D6O) δ 174.9, 167.6, 138.0, 135.9, 134.7, 131.3, 127.2, 124.8, 84.5, 78.8, 67.6, 45.3, 42.3, 
28.2, 21.0, 19.1, 15.2; LRMS (ESI) Calcd. for C17H20ClNO4Na [M+Na] 360, found 360. 
 
 
Azido salino A (–)-5.12: to the salino A (–)-1.1a (11 mg, 0.035 mmol), NaI (105 mg, 0.70 
mmol), and NaN3 (403 mg, 2.10 mmol), was added DMSO (1.0 mL). The reaction mixture was 
stirred at 23 oC for 48h and diluted with EtOAc (30 mL).  The reaction mixture was washed with 
H2O (15 mL) and the aqueous layer was back extracted with EtOAc (15 mL).  The combined 
extracts were washed with brine (15 mL), dried over anhydrous MgSO4, filtered via fritted 
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funnel, and concentrated down under reduced pressure.  The residue was purified by flash 
chromatography (5:95 → 15:85 EtOAc/CH2Cl2) to give (-)-5.12(2.6 mg, 23 %, dr >19:1) as a 
white solid: Rf = 0.35 (15:85 EtOAc/CH2Cl2) and recovered salino A 1.1a (4.4 mg, 40%); Data 
for 5.12: IR (neat) 2096, 1821, 1699 cm-1; 1H NMR (500 MHz, C3D6O) δ 8.08 (s, 1H), 5.93–5.96 
(m, 1H), 5.77–7.81(m, 1H), 4.52 (d, J = 8.5 Hz, 1H), 3.89 (t, J =8.5 Hz, 1H), 3.71 (t, J =7 Hz, 
2H), 2.63 (dd, J = 7.0, 8.0 Hz, 1H), 2.44-2.50 (m, 2H), 1.92-2.01 (m, 1H), 1.87(s, 3H), 1.75–1.82 
(m, 2H), 1.46–1.53 (m, 2H), 1.36–1.45 (m, 2H). 
 
Organic Syntheses Procedure: Asymmetric Nucleophile-Catalyzed Aldol-Lactonization 
with Aldehyde Acids 
A. (1,4-dioxaspiro[4.5]dec-7-en-8-yloxy)trimethylsilane (6.11). An oven dried 500 mL, 
two-necked, round-bottomed flask is equipped with a large stir bar (Note 2) and one neck is 
fitted with a 50-mL pressure-equalizing addition funnel fitted with a nitrogen inlet and the 
second neck is sealed with a rubber septum.  The reaction flask is charged with solid 1,4-
cyclohexanedione mono-ethylene ketal (25 g, 160 mmol, 1 equiv) and then N,N-
dimethylformamide (Note 3) (100 mL) is added to dissolve the solid.  Triethylamine (52.0 mL, 
368 mmol, 2.3 equiv) is added via syringe to the reaction vessel.  Freshly distilled trimethylsilyl 
chloride (26.7 mL, 208 mmol, 1.3 equiv) is added to the addition funnel and then dispensed 
dropwise into the reaction vessel over a period of ~15 minutes.  After the addition is complete, 
the addition funnel is replaced with a condenser and the reaction mixture is then heated in an oil 
bath at 80 oC (external temperature) for 12 h (Note 4).  On cooling to ambient temperature (23 
oC), the reaction mixture is quenched by addition of cold H2O (150 mL, cooled in an ice bath for 
15 min), the mixture is diluted with hexanes (300 mL), and the mixture is transferred to a 1000 
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mL separatory funnel.  The aqueous layer is removed and back-extracted with hexanes (2 x 100 
mL).  The combined hexane extracts iswashed with saturated NaHCO3 solution (1 x 100 mL), 
saturated NH4Cl (2 x 150 mL), and then brine (1 x 150 mL).  The organic layer is dried over 
anhydrous MgSO4 (25 g) for 15 min and then concentrated on a rotary evaporator (25 mm Hg, 
30 oC). Further concentration under reduced pressure (0.5 mm Hg, ambient temperature, 23 oC) 
delivers 31-33 g (85-90 %) of the silyl enol ether 6.11 (Note 5) as a dark yellow oil, which is of 
sufficient purity for use in the subsequent step without further purification. 
 
B. 3-(2-(2-oxoethyl)-1,3-dioxolan-2-yl) propanoic acid (6.12). To a 1000 mL one-neck, 
round-bottomed flask containing the crude silyl enol ether (32 g, 140 mmol, 1.0 equiv) is added 
500 mL of CH2Cl2.  The reaction mixture is then cooled to –78 oC (acetone/dry ice bath) with 
stirring for 15 min.  Stirring is stopped and ozone is bubbled through the solution with a large 
gas sparge tube (40-60 micrometer) for ~1-2 h until the blue color persists (Note 6).  A stream of 
nitrogen is then bubbled through the solution mixture until the blue color disappears (~ 1 h).   
Solid triphenylphosphine (37.1 g, 141 mmol, 1.01 equiv) is added with stirring, and the reaction 
is allowed to warm gradually to ambient temperature (23 oC) and stirred for ~18 h until the 
ozonide test provides a negative result (Note 7).  The solvent is removed by means of a rotary 
evaporator (25 mm Hg, 30 oC).  Residual CH2Cl2 is removed under reduced pressure at 0.5 mm 
Hg for 12 h to give a yellow slurry (Note 8).  Diethyl ether (80 mL) is added and the solid/liquid 
mixture is stirred vigorously for 30 min and the solid is then filtered off by vacuum filtration 
using a Buchner funnel fitted with filter paper (Whatmann #1, 70 mm).  The solid is rinsed with 
ice cold ether (2 x15 mL).  The ether filtrates are combined and transferred to a separatory funnel 
(250 mL) and extracted vigorously with water (4 x 80 mL) (Note 9).    To a 500 mL Erlenmeyer 
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flask containing the combined aqueous extracts (~250 mL), solid NaCl (70 g) is then added with 
stirring and additional NaCl was added until the solution is saturated.  The aqueous solution is 
transferred to a 500 mL separatory funnel and extracted with hexanes (2 x 100 mL) to remove 
unreacted cyclohexane dione monoketal from step A (Note 4).  The aqueous solution is then 
transferred to a clean 1000 mL separatory funnel and extracted vigorously with CH2Cl2 (3 x 150 
mL).  The aqueous solution is saturated again with additional sodium chloride (5 g) and extracted 
vigorously again with CH2Cl2 (3 x 150 mL).  The combined CH2Cl2 extracts are dried over 
anhydrous MgSO4 (50 g) for 15 min, filtered using a Buchner funnel equipped with filter paper 
(Whatman #1, 70 mm), and concentrated by rotary evaporation (25 mm Hg, 30 oC) to deliver a 
light yellow oil.  Further concentration under high vacuum (0.5 mm Hg, 23 oC) provides 15-17 g 
(57-65%) of the aldehyde acid as a light yellow solid, which is of sufficient purity for use in the 
subsequent step without further purification (Notes 10 and 11).  
 
 
 
C. Preparation of N-methyl-2-chloropyridinium trifluoromethane sulfonate (6.8):  
A 1000 mL round-bottomed flask, equipped with a magnetic stirring bar and a rubber septum, is 
flame dried under a stream of nitrogen, and cooled to ambient temperature.  Following addition 
of 250 mL of CH2Cl2 and then 2-chloropyridine (13.1 mL, 139 mmol, 1 equiv) the flask is 
cooled in a dry ice/acetone bath (-78 oC) under nitrogen.  Methyl trifluoromethane sulfonate (25 
g, 153 mmol, 1.1 equiv) is then added slowly via syringe over 10 minutes through the septum 
down the side of the flask to allow cooling prior to mixing with the bulk solvent.  The cold bath 
is removed and the reaction mixture is allowed to warm slowly to ambient temperature (23 oC) 
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and stirred an additional 12 h leading to a white precipitate.  The reaction mixture is concentrated 
by rotary evaporation (25 mm Hg, 30 oC) to deliver a white solid.  Toluene (120 mL) is added to 
further induce precipitation, and after swirling under nitrogen for ~10 minutes, the 
toluene/CH2Cl2 mixture is removed from the solids via cannula under N2 pressure.  The white 
solid is dried under reduced pressure at 0.5 mmHg for 12 h at 23 oC to afford 37.6-38.4 g (91-
93%) of N-methyl-2-chloropyridinium trifluoromethane sulfonate 6.8 as a white solid (mp. 147-
148º C) (Note 12).  
D. Preparation of O-trimethylsilylquinidine (6.9, O-TMS QND):  A one-neck, 250 mL 
round-bottomed flask, equipped with a mechanical stirrer, is flame dried with a stream of 
nitrogen and left to cool down to ambient temperature for 10 min.  Quinidine (4.0 g, 12.4 mmol, 
1 equiv) is added to 100 mL CH2Cl2 and then distilled trimethylsilyl chloride (1.9 mL, 15 mmol, 
1.2 equiv) is added slowly via syringe pump over 15 min.  The resulting solution is stirred at 
ambient temperature for 24 h and then partioned between 100 mL CH2Cl2 and 100 mL NaHCO3 
in a separatory funnel.  The layers are separated, and the aqueous layer is extracted with two 50 
mL portions of CH2Cl2.  The combined organic extracts are dried over MgSO4, filtered, and 
concentrated by rotary evaporation ((25 mm Hg, 30 oC).  The residue is then left to dry under 
reduced pressure at 0.5 mmHg for 12 h at 23 oC to afford 3.80-3.95 g (77-80% yield) of O-
trimethylsilylquinidine (6.9) as a clear oil which was of sufficient purity for use without 
purification (Note 13).    
 E. (1R, 5S)-6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one (6.4). N-methyl-
2-chloropyridinium trifluoromethane sulfonate (6.8) (Note 12) (33.2 g, 119.6 mmol, 1.5 equiv) is 
weighed out in a one-neck, oven-dried 1000 mL round-bottomed flask.   A stir bar is added and 
the flask is purged with nitrogen and then charged with 240 mL dry acetonitrile.  The catalyst O-
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TMS QND (6.9) (3.16 g, 7.97 mmol, 0.1 equiv) (Note 13) is dissolved in 100 mL dry acetonitrile 
at 23 oC and transferred to the reaction flask via cannula with nitrogen pressure which is 
followed by addition of freshly distilled Hünig’s base via syringe (35.4 mL, 199.3 mmol, 2.5 
equiv).  The reaction mixture is stirred for 10 min and then a solution of 3-(2-(2-oxoethyl)-1,3-
dioxolan-2-yl) propanoic acid (6.12) (15 g, 79.7 mmol, 1.0 equiv) in 60 mL of dry CH3CN is 
added via syringe pump over ~1 h (30 mL syringe, ~1 mL/min, syringe loaded twice).  The 
reaction mixture changes from yellow to a dark red color during the addition of aldehyde acid.  
The reaction mixture is stirred for an additional 18 h at ambient temperature and reaction 
progress is monitored by disappearance of aldehyde acid 6.12 and formation of β-lactone 6.4 by 
TLC analysis (Rf 0.29 and 0.52, respectively in 60 % EtOAc/hexanes, KMnO4 stain). When 
judged complete, the reaction mixture is concentrated by rotary evaporation and then by high 
vacuum (0.5 mm Hg, 30 oC) for 3 h to provide a dark brown, viscous oil (~ 75 g).  The reaction 
mixture is diluted with 25 mL of CH2Cl2 and loaded onto a silica gel plug (188 g, 2.5 g silica gel 
per gram of crude product, 10 cm diameter flash column) pre-eluted with 50% EtOAc:hexanes 
using a long stem funnel to carefully deliver the crude mixture onto the silica gel surface 
(washing with 5 mL CH2Cl2 and then 10 mL 50% EtOAc:hexanes).  The product is quickly 
eluted with 50% EtOAc:hexanes (2000 mL).  Forty fractions (~45 mL in 50 mL test tubes) are 
collected and fractions 7–35 contained the majority of the β-lactone (Rf = 0.52 (50% 
EtOAc:hexanes; KMnO4).  The fractions are combined and concentrated by rotary evaporation 
(25 mm Hg, 30 oC) and then under high vacuum (0.5 mm Hg at 23 oC) to deliver 7.5-7.8 g of 
semi-crude β-lactone.  Recrystallization (Note 14) from EtOAc:hexanes gives a total of 4.6–4.8 g 
(34 - 35%) of bicyclic-β-lactone  (Note 15).   Enantiomeric excess is deteremined by chiral 
HPLC analysis (Note 16). 
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2. Notes 
1. 1,4-Cyclohexanedione mono-ethylene ketal (Aldrich, 97%), PPh3 (Acros, 99%), 2-
chloropyridine (Aldrich, 99%), methyl trifluoromethanesulfonate (Acros, 96%), quinidine 
(Acros, 99%), NEt3 (Acros, 99%), TMSCl (Acros, 98%), N,N-dimethylformamide (Aldrich, 
99.9%), acetonitrile (Aldrich, 99.8%), N, N-diisopropylethyl amine base (Hünig’s base, Acros, 
98%), MgSO4 (EMD, powder 98%), sodium bicarbonate (EMD, Powder), dichloromethane 
(EMD, 99.8%), NaCl (EMD, crystals, 99%), ammonium chloride (EMD, 99.5%), hexanes 
(Fisher, 98.5%), diethylether (EMD, 99%), silica gel (Silicycle, 230-400 mesh), KI (EM, 99%).  
Triethylamine, trimethylsilyl chloride, and Hünig’s base were freshly distilled over CaH2 prior to 
use.  N,N-Dimethylformamide, dichloromethane and acetonitrile were dried through activated 
alumina using a converted MBraun System.   
2.  A football-shaped stir bar is ideal since copious amounts of Et3N•HCl formed during the 
course of the reaction makes stirring difficult. 
3. It is important to use very dry N,N-dimethylformamide (<150 ppm of H2O) to avoid 
hydrolysis of TMSCl. 
4. While it is best to have all starting material converted to the silyl enol ether, reaction progress 
is monitored by aliquot NMR not by TLC due to facile desilylation of the TMS enol ether 6.11. 
Generally, ensuring high quality and dryness of reagents/solvents and using specified reaction 
times ensured complete reaction.  Any residual cyclohexanone is not deleterious to the 
subsequent ozonolysis and can be removed in the next step during extraction. 
5. Data for silyl enol ether 6.11: Rf  = 0.65 (20% EtOAc/hexanes); IR (neat) 1673 cm-1; 1H NMR 
(500 MHz, CDCl3) δ 0.15 (s, 9 H), 1.76 (t, J = 6.5 Hz, 2 H), 2.18-2.20 (m, 4 H), 3.93-3.97 (m, 4 
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H), 4.68-4.71 (m, 1 H); 13C (125 MHz, CDCl3) δ 149.9, 107.8, 100.8, 64.5, 34.1, 31.3, 28.7, 
0.44; MS (EI) m/z calc. for C11H20O3 (M+1): 228.12. Found: 228.12. 
6.  The time required for excess ozone to be added is of course dependent on the O2 pressure and 
ozone generation efficiency.  We used a Welsbash Ozonizer (total pressure: 7-10 psi; O2/ozone 
pressure: 3.0-4.5 psi). 
7. The ozonide test is performed by adding 0.1 g of potassium iodide to 1.0 mL of glacial acetic 
acid and ~1.0 mL of the ozonolysis reaction mixture in a 5 mL round-bottomed flask.  A brown 
mixture indicates the presence of ozonide. Blanks must always be prepared; 0.1 g of KI added to 
1.0 mL CH2Cl2 and 1.0 mL of glacial acetic acid.  The test solution has a very short shelf life and 
will naturally result in high blank values if stored for any length of time.  Caution: Care must be 
excercised in transferring and manipulating the ozonide reaction mixture due to the known 
instability of ozonides.  It is preferable to perform the quenching step in the same fume hood and 
avoid transferring the reaction mixture.  A yellow solution is a negative result and suggests it is 
safe to proceed to work up.  
8. The majority of the CH2Cl2 must be removed at this step to minimize retention of aldehyde 
acid in the organic layer during the first stage of the extraction procedure. 
9.  It is imperative that extractions of the aldehyde acid are done very vigorously to ensure 
efficient transfer of the aldehyde acid to the aqueous phase.  However, patience is then required 
to allow for separation of the layers due to emulsion formation.  A copper wire loop was used to 
assist in breakdown of the emulsion. 
10. It is best to use the aldehyde acid soon after drying otherwise it should be stored in the 
freezer (-5 oC) under N2 to avoid oxidation to the diacid.  Data for aldehyde acid: Rf = 0.29 (60% 
EtOAc:hexanes); IR (thin film) 1791, 1731 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.11 (t, J = 7.5, 
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2 H), 2.45 (t, J = 7.5 Hz, 2 H), 2.69 (d, J = 3 Hz, 2 H), 4.03 (s, 4 H), 9.73 (t, J = 3 Hz, 1 H), 13C 
(75 MHz, CDCl3) δ 200.0, 179.0, 108.3, 65.2, 50.6, 32.9, 28.2;  MS (EI) m/z calc. for C8H11O5 
(M-H): 187.1. Found: 187.1. 
11. A minor product formed during the ozonolysis was identified to be the corresponding diacid 
formed by over oxidation and this is mostly removed during the extraction procedure. 
12. The pyridinium salt is somewhat hygroscopic and moisture sensitive and thus should be 
weighed out and transferred rapidly.  IR (solid) 3092, 1616, 1252 cm-1; 1H NMR (500 MHz, 
CD3CN) δ 4.40 (s, 3H), 8.05 (dt, J = 8.0, 1.5, 1H), 8.23 (dd, J = 8.0, 1.5 Hz, 1 H), 8.79 (dt, J = 
8.0, 1.5 Hz, 1 H), 8.92 (dd, J = 8.0, 1.5 Hz, 1 H); 13C NMR (125 MHz, CD3CN) δ 149.0, 148.9, 
148.3, 130.9, 127.3, 122.0 (q, J = 319 Hz), 48.6. 
13. Characterization data: IR (thin film) 3076, 2945, 1622, 1510 cm-1); This compound is a 
mixture of two conformers at ambient temperature but low temperature 1H NMR at -40 oC 
allowed assignment of one major conformer (500 MHz, -40 oC, CDCl3) δ 0.06 (S, 9 H), 0.76-
0.82 (m, 1 H), 1.31-1.53 (m, 2 H), 1.68 (br s, 1 H), 2.12 (t, 1 H), 2.21 (m, 1H), 2.76-2.99 (m, 
4H), 3.39 (dd, J = 12.0, 8.0 Hz, 1H), 3.94 (s, 3H), 5.04 (d, J = 9.0 Hz, 1H), 5.06 (d, J = 17.5 Hz, 
1H), 5.66 (br s, 1H), 6.10 (apparent quint, J = 9.0 Hz, 1H), 7.08(br s, 1H), 7.38 (dd, J = 2.5 and 
9.0 Hz, 1H), 7.56 (d, J = 4.5 Hz, 1H), 8.02 (d, J = 9.0 Hz, 1H), 8.75 (d, J = 4.5, 1H); 13C NMR 
was taken at ambient temperature.  13C NMR (75 MHz, CDCl3) δ 157.3, 147.5, 147.3, 144.1, 
140.7, 131.7, 126.0, 121.5, 118.5, 114.3, 100.3, 73.2, 60.1, 55.6, 50.3, 49.6, 40.1, 28.2, 26.3, 
19.6, 0.03. 
14.  Recrystallization is performed in a 50 mL Erlenmeyer flask by addition of 20 mL hot EtOAc 
to the dried, semi-crude β-lactone.  A stir bar is added to the flask and then heated with stirring to 
~50 oC on a hot plate to dissolve the solid.  Hexanes are added to the hot solution (~16 mL) with 
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continued heating until the solution turns cloudy.  On cooling to ambient temperature for ~1 h, 
crystals form and the flask is then placed in an ice-bath for an additional 30 min.  The crystals 
are collected by rapid vacuum filtration and washed quickly with an ice-cold mixture of 50 % 
EtOAc:hexanes (~ 10 mL) to give 4.0-4.2 g (30 – 31 %) of the bicyclic-β-lactone as light yellow 
crystals.  A second crop is collected by removal of ~1/3 of the mother liquor and placing the 
solution in a freezer (-10 oC) overnight to provide an additional 0.5 -0.6 g (4–5 %) as darker 
yellow crystals. 
15. Higher yields of β-lactone could be achieved by using aldehyde acid purified by flash 
chromatrography, however loss on the column led to further reduction of the overall yield. 
Characterization data for (1R,5S)-6-oxaspiro[bicyclo[3.2.0]heptane-3,2'-[1,3]dioxolan]-7-one 
(6.4): Rf = 0.52 (60% EtOAc/hexanes);  m.p. 103-104 ºC; [α]D25 + 62.5 (c 0.95, CHCl3); IR (thin 
film) 1821 cm-1; 1H NMR (500 MHz, CDCl3) δ 2.03 (dd, J = 8.5, 14 Hz, 1 H), 2.08 (dd, J = 5.0, 
15.5 Hz, 1 H), 2.32 (ddd, J = 0.5, 1.0, 14 Hz, 1 H), 2.38 (dd, J = 1.5, 15.5 Hz, 1 H), 3.88 – 3.94 
(m, 2 H), 3.99 – 4.09 (m, 3 H), 5.00 (t, J = 5 Hz, 1 H) ; 13C NMR (75 MHz, CDCl3) Anal. Calcd. 
For C18H10O4: C, 56.47; H, 5.92.  Found: C, 56.67; H, 5.91.  
16. Enantiomeric excess was determined to be 86-88% by chiral HPLC.  Conditions: Chiralcel 
OD, 250 x 4.6 mm (L x I.D.), solvent (isocratic) 85% hexanes, 15% 2-propanol, flow rate 1.0 
mL/min, wavelength λ = 220 nm.  Retention times were: (1R, 5S)-β-lactone, 18.06 min; (1S, 
5R)-β-lactone 22.96 min. An alternative method was developed previously using chiral GC with 
a non-commercially available chiral column: 2,3-di-OAc-6-TBS-CD and showed 92% ee with 
O-Ac quinidine as chiral promoter. 
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Waste Disposal Information and Hazards 
All toxic materials were disposed of in accordance with "Prudent Practices in the 
Laboratory"; National Academy Press; Washington, DC, 1995. 
Caution: Care must be excercised in transferring and manipulating the ozonide reaction 
mixture due to the known instability of ozonides.  It is best to perform the ozonide reduction step 
in the same fume hood and avoid transferring and manipulation of the reaction mixture.  A 
yellow solution following is a negative result and suggests it is safe to proceed to work up. 
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1H NMR of homodimer (±)-2.13d (500 MHz, C6D6) 
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13C NMR of homodimer (±)-2.13d (500 MHz, C6D6) 
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   1H NMR of heterodimer (±)-2.11a (500 MHz, C6D6) 
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13C NMR of heterodimer (±)-2.11a (500 MHz, C6D6) 
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1H NMR of heterodimer (±)-2.11b (500 MHz, C6D6) 
 
O
O
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13C NMR of heterodimer (±)-2.11b (500 MHz, C6D6) 
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1H NMR of ketoamide (±)-2.20a (500 MHz, CDCl3) 
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13C NMR of ketoamide (±)-2.20a (500 MHz, CDCl3) 
O
O
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1H NMR of ketoamide (±)-2.20b (500 MHz, CDCl3)
O
O
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13C NMR of ketoamide (±)-2.20b (500 MHz, CDCl3)
O
O
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1H NMR of ketoamide (±)-2.20c (500 MHz, CDCl3)
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13C NMR of ketoamide (±)-2.20c (500 MHz, CDCl3)
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1H NMR of ketoacid (±)-2.22a (500 MHz, CDCl3)
O
O
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13C NMR of ketoacid (±)-2.22a (500 MHz, CDCl3)
O
O
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1H NMR of ketoacid (±)-2.22b (500 MHz, CDCl3)
O
O
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13C NMR of ketoacid (±)-2.22b (500 MHz, CDCl3)
O
O
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1H NMR of ketoacid (±)-2.22c (500 MHz, CDCl3) 
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13C NMR of ketoacid (±)-2.22c (500 MHz, CDCl3)
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1H NMR of PMB-β-lactone (±)-2.23a (500 MHz, CDCl3)
O
O O
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13C NMR of PMB-β-lactone (±)-23a (500 MHz, CDCl3) 
O
O O
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1H NMR of PMB-β-lactone (±)-2.23b (500 MHz, CDCl3)
O
O O
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13C NMR of PMB-β-lactone (±)-2.23b (500 MHz, CDCl3)
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1H NMR of PMB-β-lactone, (±)-2.23c (500 MHz, CDCl3)
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13C NMR of PMB-β-lactone (±)-2.23c (500 MHz, CDCl3) 
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 182 
 
1H NMR of PMB-β-lactone (±)-23e (500 MHz, CDCl3)
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13C NMR of β-lactone, (±)-2.23e (500 MHz, CDCl3) 
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1H NMR of PMB-β-lactone, (±)-2.23d (500 MHz, CDCl3)  
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13C NMR of PMB-β-lactone, (±)-2.23d (500 MHz, CDCl3) 
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1H NMR of β-lactone, (±)-2.24a (500 MHz, CDCl3) 
O
O O
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13C NMR of β-lactone, (±)-2.24a (500 MHz, CDCl3)  
O
O O
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1H NMR of (R)-O-benzyl serine allyl ester 2.34 (500 MHz, CDCl3) 
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13C NMR of (R)-O-benzyl serine allyl ester 2.34 (500 MHz, CDCl3) 
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1H NMR of ketoamide (2R,4R)-3.6a (500 MHz, CDCl3) 
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13C NMR of ketoamide (2R,4R)-3.6a (500 MHz, CDCl3) 
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1H NMR of OBn-β-lactone (–)-2.37a (500 MHz, CDCl3) 
 
 193 
 
 
 
13C NMR of OBn-β-lactone (–)-2.37a (500 MHz, CDCl3) 
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1H NMR of OH-β-lactone (–)-2.38a (500 MHz, CDCl3) 
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13C NMR of OH-β-lactone (–)-2.38a (500 MHz, CDCl3) 
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1H NMR of aldehyde (–)-4.22 (500 MHz, CDCl3) 
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13C NMR of aldehyde (–)-2.44 (500 MHz, CDCl3) 
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1H NMR of (–)-salinosporamide A (–)-1.1a (500 MHz, C5D5N) 
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13C NMR of (–)-salinosporamide A (–)-1.1a (500 MHz, C5D5N)  
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O O
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1H NMR of (C5, C6-bis-epi-salino A) 4.26 (500 MHz, CDCl3)  
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13C NMR of (C5, C6-bis-epi-salino A) 4.26 (500 MHz, CDCl3 
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1H NMR of oxazolidine by-product 4.25 (500 MHz, CDCl3) 
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13C NMR of oxazolidine by-product 4.25 (500 MHz, CDCl3) 
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1H NMR of salino ester by-product 2.40 (500 MHz, CDCl3) 
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13C NMR of salino ester by-product 2.40 (500 MHz, CDCl3) 
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1H NMR of cyclopropane by-product 3.7 (500 MHz, CDCl3) 
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13C NMR of cyclopropane by-product 3.7 (500 MHz, CDCl3) 
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1H NMR of unsaturated lactam 4.13 (500 MHz, CDCl3) 
 
Cl
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13C NMR of unsaturated lactam 4.13 (500 MHz, CDCl3) 
Cl
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1H NMR of OBn-β-lactone 5.7a (500 MHz, CDCl3) 
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13C NMR of OBn-β-lactone 5.7a (500 MHz, CDCl3) 
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1H NMR of OH-β-lactone 5.8a (500 MHz, CDCl3) 
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13C NMR of OH-β-lactone 5.8a (500 MHz, CDCl3) 
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1H NMR of (–)-homosalinosporamide A (–)-5.1 (500 MHz, C5D5N) 
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13C NMR of (–)-homosalinosporamide A (–)-5.1 (500 MHz, C5D5N) 
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1H NMR of (±)-salino A derivative (±)-20 (500 MHz, CDCl3) 
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13C NMR of (±)-salino A derivative, (±)-20 (125 MHz, CDCl3 and C3D6O) 
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1H NMR of (±)-salino A derivative, (±)-22 (500 MHz, CDCl3) 
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13C NMR of (±)-salino A derivative, (±)-22 (500 MHz, CDCl3) 
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 1H NMR of (±)-azido-salino A derivative, (±)-5.12 (500 MHz, C3D6O) 
 221 
 
Determination of Optical Purity of (D)-Serine by HPLC (CHIRALPAK IA) 
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Determination of Optical Purity of (2R,4R)-β-Ketoamide by HPLC (CHIRALPAK IA) 
 
 
 
(2R,4R)-3.6a 
(S,S)-3.6a + (S,R) 
(2R,4R)-3.6a 
(S,S)-3.6a 
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Determination of Optical Purity of Bicyclic-β-Lactone by HPLC (CHIRALPAK IA) 
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Determination of Optical Purity of (R,R)-β-Ketoamide  by HPLC (CHIRALPAK IA) 
 
 
 
 
 
(R,R)-5.5a (S,S)-5.5a 
(R,R)-5.5a 
(S,S)-5.5a 
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Determination of Optical Purity of Bicyclic-β-Lactone by HPLC (CHIRALCEL OD) 
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1H NMR of silyl enol ether 6.11 (500 MHz, CDCl3) 
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13C NMR of silyl enol ether 6.11 (500 MHz, CDCl3) 
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1H NMR of aldehyde acid 6.12 (500 MHz, CDCl3) 
 229 
 
1H NMR o Mukaiyama salt 6.8 (500 MHz, CD3CN) 
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1H NMR of Mukaiyama salt 6.8 (500 MHz, CD3CN) 
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1H NMR of β-lactone 6.4 (500 MHz, CDCl3) 
 Optically Active β-lactone 6.4 
   
β-lactone 6.4: er  93:7, 86% ee.  
 
Racemic 
 
Mixed ~1:1; Racemic and Optically Active 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
β-lactone 5 
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APPENDIX B   
SINGLE CRYSTAL X-RAY DATA FOR β-LACTONE 5.20 
Table 1.  Crystal data and structure refinement for dr69. 
Identification code  dr69 
Empirical formula  C15 H16 Cl N O4 
Formula weight  309.74 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 15.516(3) Å α = 90°. 
 b = 11.0290(13) Å β = 91.007(10)°. 
 c = 16.725(2) Å γ = 90°. 
Volume 2861.5(7) Å3 
Z 8 
Density (calculated) 1.438 Mg/m3 
Absorption coefficient 2.513 mm-1 
F(000) 1296 
Crystal size 0.16 x 0.06 x 0.02 mm3 
Theta range for data collection 3.85 to 59.98°. 
Index ranges -17<=h<=16, -12<=k<=12, -18<=l<=18 
Reflections collected 48543 
Independent reflections 4192 [R(int) = 0.1021] 
Completeness to theta = 59.98° 98.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9515 and 0.6893 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4192 / 0 / 397 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0425, wR2 = 0.0962 
R indices (all data) R1 = 0.0707, wR2 = 0.1038 
Largest diff. peak and hole 0.300 and -0.349 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for dr69.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
__  
 x y z U(eq) 
______________________________________________________________________________
__   
Cl(1A) 1106(1) -5828(1) 10834(1) 45(1) 
O(1A) -243(1) -2015(2) 12379(1) 24(1) 
N(1A) -1298(1) -4188(2) 12846(1) 19(1) 
C(1A) -1418(2) -3011(2) 12475(1) 18(1) 
O(2A) -927(1) -1427(2) 13507(1) 26(1) 
C(2A) -690(2) -2935(2) 11850(2) 19(1) 
O(3A) -346(1) -5786(2) 12859(1) 25(1) 
C(3A) -212(2) -4152(2) 11878(2) 20(1) 
O(4A) -2519(1) -3622(2) 11610(1) 33(1) 
C(4A) -608(2) -4813(2) 12581(1) 19(1) 
C(5A) -894(2) -2022(2) 12911(2) 22(1) 
C(6A) -857(2) -2407(2) 11043(2) 27(1) 
C(7A) 769(2) -4051(2) 11930(2) 24(1) 
C(8A) 1243(2) -5237(2) 11830(2) 30(1) 
C(9A) -2345(2) -2739(2) 12212(2) 22(1) 
C(10A) -2968(2) -2775(2) 12901(2) 23(1) 
C(11A) -3015(2) -1791(3) 13416(2) 34(1) 
C(12A) -3586(2) -1818(3) 14053(2) 47(1) 
C(13A) -4109(2) -2809(4) 14154(2) 52(1) 
C(14A) -4075(2) -3777(3) 13640(2) 48(1) 
C(15A) -3496(2) -3773(3) 13019(2) 32(1) 
Cl(1B) 8752(1) 755(1) 8654(1) 36(1) 
Cl(1') 8964(11) -462(13) 9328(8) 36(5) 
O(1B) 5641(1) -1435(2) 8968(1) 23(1) 
N(1B) 6059(2) -1655(2) 10728(1) 18(1) 
C(1B) 5627(2) -2324(2) 10102(1) 17(1) 
O(2B) 4380(1) -1002(2) 9605(1) 26(1) 
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C(2B) 6259(2) -2285(2) 9386(2) 19(1) 
O(3B) 7255(1) -451(2) 10926(1) 22(1) 
C(3B) 7058(2) -1618(2) 9692(1) 21(1) 
O(4B) 5976(1) -4138(2) 10743(1) 24(1) 
C(4B) 6816(2) -1149(2) 10508(2) 20(1) 
C(5B) 5060(2) -1502(2) 9574(2) 20(1) 
C(6B) 6414(2) -3383(2) 8882(2) 25(1) 
C(7B) 7394(2) -632(2) 9127(2) 28(1) 
C(8B) 8297(3) -249(3) 9371(2) 41(1) 
C(9B) 5258(2) -3535(2) 10372(2) 19(1) 
C(10B) 4488(2) -3395(2) 10902(2) 21(1) 
C(11B) 3668(2) -3258(2) 10553(2) 26(1) 
C(12B) 2958(2) -3072(2) 11029(2) 33(1) 
C(13B) 3057(2) -3041(3) 11852(2) 34(1) 
C(14B) 3859(2) -3208(2) 12201(2) 31(1) 
C(15B) 4575(2) -3379(2) 11725(2) 28(1) 
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APPENDIX C 
  SINGLE CRYSTAL X-RAY DATA FOR ΗΟΜΟSALINOSPORAMIDE 5.1 
Table 1.  Crystal data and structure refinement for dr72. 
Identification code  dr72 
Empirical formula  C64 H87 Cl4 N4 O16 
Formula weight  1310.18 
Temperature  383(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 9.694(3) Å α = 90°. 
 b = 25.624(9) Å β = 93.571(13)°. 
 c = 13.118(4) Å  γ= 90°. 
Volume 3252.2(18) Å3 
Z 2 
Density (calculated) 1.338 Mg/m3 
Absorption coefficient 2.234 mm-1 
F(000) 1390 
Crystal size 0.06 x 0.01 x 0.01 mm3 
Theta range for data collection 3.38 to 59.99°. 
Index ranges -10<=h<=10, -28<=k<=28, -14<=l<=14 
Reflections collected 24861 
Independent reflections 9114 [R(int) = 0.2299] 
Completeness to theta = 59.99° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9780 and 0.8776 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9114 / 649 / 832 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0821, wR2 = 0.1159 
R indices (all data) R1 = 0.1842, wR2 = 0.1448 
Absolute structure parameter 0.06(3) 
Largest diff. peak and hole 0.284 and -0.296 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for dr72.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
__  
 x y z U(eq) 
______________________________________________________________________________
__   
Cl(1A) 3360(3) 10437(1) 5607(2) 55(1) 
O(1A) 2006(6) 8479(3) 4120(5) 32(2) 
O(2A) 884(6) 7690(3) 4039(5) 33(2) 
O(3A) 4478(7) 8279(3) 6756(5) 34(2) 
O(4A) 5595(6) 7654(3) 3488(5) 35(2) 
N(1A) 3965(7) 7801(4) 5327(5) 26(2) 
C(1A) 4240(10) 8696(4) 5055(7) 31(2) 
C(2A) 3562(10) 8467(4) 4073(7) 31(2) 
C(3A) 3487(10) 7860(4) 4255(7) 28(2) 
C(4A) 4258(10) 8244(5) 5858(7) 29(2) 
C(5A) 3544(10) 9202(4) 5440(8) 35(2) 
C(6A) 4519(10) 9494(4) 6162(8) 38(2) 
C(7A) 3856(11) 9977(4) 6611(7) 42(3) 
C(8A) 3968(10) 8690(4) 3092(7) 38(3) 
C(9A) 1876(11) 7948(4) 4110(7) 31(2) 
C(10A) 4187(9) 7501(4) 3531(8) 31(2) 
C(11A) 4141(10) 6907(5) 3862(8) 36(2) 
C(12A) 2729(10) 6721(4) 4148(8) 41(2) 
C(13A) 2740(12) 6138(4) 4342(8) 43(2) 
C(14A) 2980(11) 5854(5) 3286(8) 46(2) 
C(15A) 4086(11) 6120(5) 2722(8) 44(2) 
C(16A) 4611(11) 6579(4) 3001(8) 39(2) 
Cl(1B) 3309(3) 4719(1) 7335(2) 50(1) 
O(1B) 1962(7) 6670(3) 8818(5) 36(2) 
O(2B) 836(7) 7460(3) 8795(5) 41(2) 
O(3B) 4565(6) 6863(3) 6501(5) 31(2) 
O(4B) 5578(6) 7446(3) 9919(4) 30(2) 
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N(1B) 4003(8) 7346(4) 7878(5) 30(2) 
C(1B) 4223(10) 6445(4) 8136(7) 32(2) 
C(2B) 3522(10) 6665(5) 9045(8) 34(2) 
C(3B) 3479(10) 7287(4) 8909(7) 32(2) 
C(4B) 4306(10) 6903(5) 7378(8) 30(2) 
C(5B) 3584(11) 5949(4) 7667(8) 35(2) 
C(6B) 4657(11) 5664(4) 7099(8) 42(2) 
C(7B) 4084(11) 5172(5) 6496(8) 47(3) 
C(8B) 3860(10) 6439(4) 10089(7) 36(3) 
C(9B) 1882(11) 7204(4) 8861(8) 33(2) 
C(10B) 4209(10) 7615(4) 9697(7) 32(2) 
C(11B) 4273(10) 8199(4) 9422(7) 35(2) 
C(12B) 2855(11) 8426(4) 9040(8) 41(2) 
C(13B) 3030(12) 9030(5) 8899(8) 47(2) 
C(14B) 3465(11) 9303(5) 9907(8) 47(2) 
C(15B) 4486(11) 9010(5) 10527(8) 44(2) 
C(16B) 4859(10) 8532(5) 10314(8) 40(2) 
Cl(1C) -1744(3) 5091(1) 7955(3) 68(1) 
O(1C) 324(6) 7028(3) 6236(5) 33(2) 
O(2C) 1526(6) 7769(3) 6612(5) 34(2) 
O(3C) -2716(7) 7141(3) 8461(5) 40(2) 
O(4C) -3046(6) 7981(3) 5323(5) 36(2) 
N(1C) -1726(7) 7671(4) 7303(6) 30(2) 
C(1C) -1999(10) 6777(4) 6828(7) 33(2) 
C(2C) -1183(10) 7046(5) 6022(7) 31(2) 
C(3C) -1104(10) 7657(5) 6350(7) 31(2) 
C(4C) -2233(11) 7215(5) 7638(8) 33(2) 
C(5C) -1309(11) 6312(4) 7355(8) 38(2) 
C(6C) -1058(11) 5875(4) 6657(8) 45(2) 
C(7C) -478(11) 5358(5) 7208(8) 51(3) 
C(8C) -1560(10) 6906(4) 4897(7) 36(3) 
C(9C) 485(10) 7539(4) 6456(7) 30(2) 
C(10C) -1608(9) 8087(4) 5591(7) 33(2) 
C(11C) -1540(10) 8640(5) 6026(8) 37(2) 
C(12C) -171(10) 8786(4) 6585(8) 42(2) 
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C(13C) -216(12) 9378(5) 6832(8) 50(2) 
C(14C) -307(11) 9687(5) 5869(8) 51(2) 
C(15C) -1300(11) 9478(5) 5118(8) 42(2) 
C(16C) -1847(3) 9002(1) 5173(2) 39(2) 
Cl(1D) -2943(3) 10079(1) 8771(2) 67(2) 
Cl(1') -3541(3) 10078(1) 8951(2) 78(4) 
O(1D) 714(3) 8300(1) 11716(2) 38(2) 
O(2D) 1752(3) 7529(1) 11395(2) 40(2) 
O(3D) -1689(3) 8423(1) 8945(2) 36(2) 
O(4D) -2968(3) 7395(1) 11761(2) 32(2) 
N(1D) -1219(3) 7783(1) 10144(2) 30(2) 
C(1D) -1370(11) 8644(4) 10729(8) 37(2) 
C(2D) -838(10) 8302(5) 11638(8) 34(2) 
C(3D) -816(10) 7731(4) 11228(7) 30(2) 
C(4D) -1428(10) 8292(4) 9810(8) 32(2) 
C(5D) -545(12) 9154(5) 10621(9) 51(2) 
C(6D) -1087(13) 9513(5) 9869(10) 67(3) 
C(7D) -2470(13) 9606(5) 9677(10) 78(3) 
C(8D) -1418(10) 8440(4) 12649(7) 41(3) 
C(9D) 754(10) 7788(5) 11419(7) 34(2) 
C(10D) -1535(11) 7303(4) 11762(8) 35(2) 
C(11D) -1154(13) 6768(5) 11398(9) 49(2) 
C(12D) -1200(20) 6370(8) 12368(14) 51(2) 
C(13D) -1010(20) 5816(8) 12094(15) 54(2) 
C(14D) -2020(20) 5638(8) 11098(15) 54(2) 
C(15D) -2320(20) 6040(8) 10416(15) 53(3) 
C(16D) -1745(19) 6546(6) 10560(15) 50(2) 
C(12') -2060(30) 6365(11) 11910(20) 52(3) 
C(13') -1820(30) 5783(11) 11780(20) 54(3) 
C(14') -610(30) 5640(10) 11180(20) 54(3) 
C(15') -270(30) 6033(10) 10460(20) 51(3) 
C(16') -150(30) 6542(9) 10780(20) 49(3) 
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APPENDIX D  
SINGLE CRYSTAL X-RAY DATA FOR C5, C6-BIS-EPI-SALINOSPORAMIDE A 
Table 1.  Crystal data and structure refinement for 
DRB_HN_100927_G_SALINO_A_MINOR. 
 
Identification code  twin5 
Empirical formula  C15 H20 Cl N O4 
Formula weight  313.77 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
Unit cell dimensions a = 10.6099(7) Å α = 90°. 
 b = 10.7142(7) Å β = 105.557(4)°. 
 c = 13.7817(8) Å γ = 90°. 
Volume 1509.26(17) Å3 
Z 4 
Density (calculated) 1.381 Mg/m3 
Absorption coefficient 2.383 mm-1 
F(000) 664 
Crystal size 0.12 x 0.05 x 0.02 mm3 
Theta range for data collection 3.33 to 59.98°. 
Index ranges -11<=h<=11, -11<=k<=11, -15<=l<=15 
Reflections collected 9026 
Independent reflections 9031 [R(int) = 0.0000] 
Completeness to theta = 59.98° 98.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9539 and 0.7630 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9031 / 1 / 384 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0537, wR2 = 0.1120 
R indices (all data) R1 = 0.0844, wR2 = 0.1229 
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Absolute structure parameter 0.020(15) 
Largest diff. peak and hole 0.291 and -0.311 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) 
for DRB_HN_100927_G_SALINO_A_MINOR.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
______________________________________________________________________________
__  
 x y z U(eq) 
______________________________________________________________________________
__   
Cl(1) 3978(1) 9644(1) 3791(1) 40(1) 
Cl(2) -168(1) 5544(1) 10015(1) 61(1) 
C(1) 3584(3) 7049(3) 6308(3) 26(1) 
C(2) 4235(3) 8087(3) 5862(2) 28(1) 
C(3) 5180(4) 8684(3) 6773(3) 27(1) 
C(4) 4859(3) 8116(3) 7725(2) 24(1) 
C(5) 5435(4) 10060(3) 6728(3) 36(1) 
C(6) 6239(4) 7564(3) 7944(3) 28(1) 
C(7) 4796(4) 7613(3) 5018(3) 34(1) 
C(8) 5267(4) 8595(3) 4411(3) 34(1) 
C(9) 4501(3) 8967(3) 8496(2) 22(1) 
C(10) 3934(3) 8335(3) 9279(2) 25(1) 
C(11) 4940(4) 7508(3) 9954(3) 30(1) 
C(12) 5137(4) 7461(4) 10945(3) 36(1) 
C(13) 4355(4) 8166(4) 11513(3) 39(1) 
C(14) 3128(4) 8698(4) 10804(3) 39(1) 
C(15) 3435(4) 9296(3) 9905(3) 31(1) 
C(16) 1818(4) 4741(4) 7907(3) 30(1) 
C(17) 865(3) 4060(3) 8375(3) 28(1) 
C(18) 419(3) 2960(3) 7688(2) 26(1) 
C(19) 901(3) 3176(3) 6723(3) 26(1) 
C(20) -949(3) 2492(4) 7608(3) 36(1) 
C(21) 1781(4) 2034(3) 7110(3) 29(1) 
C(22) 1387(4) 3769(3) 9492(3) 30(1) 
C(23) 1441(3) 4905(4) 10171(3) 37(1) 
C(24) -51(3) 3124(3) 5695(3) 29(1) 
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C(25) 505(4) 3430(3) 4788(3) 35(1) 
C(26) 1247(4) 2328(4) 4507(3) 47(1) 
C(27) 1114(4) 1959(4) 3573(3) 46(1) 
C(28) 296(4) 2637(4) 2667(3) 42(1) 
C(29) -122(5) 3900(4) 2939(3) 53(1) 
C(30) -579(4) 3827(4) 3886(3) 39(1) 
N(1) 3887(3) 7156(2) 7310(2) 24(1) 
N(2) 1670(3) 4318(2) 6958(2) 29(1) 
O(1) 2862(2) 6226(2) 5817(2) 31(1) 
O(2) 6462(2) 8004(2) 7064(2) 32(1) 
O(3) 6968(2) 6931(2) 8555(2) 35(1) 
O(4) 5681(2) 9616(2) 8947(2) 28(1) 
O(5) 2580(2) 5570(2) 8319(2) 34(1) 
O(6) 1383(2) 1895(2) 7965(2) 30(1) 
O(7) 2596(2) 1437(2) 6871(2) 37(1) 
O(8) -553(2) 1873(2) 5626(2) 36(1) 
______________________________________________________________________________
__ 
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